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Clostridium difficile is a gram positive, anaerobic bacterium that is the 
leading cause of antibiotic-associated pseudomembranous colitis worldwide.  C. 
difficile is an extremely infectious bacterium that produces spores that are highly 
resistant to standard disinfectant agents and can survive on surfaces for long 
periods of time.  Both the resistance of the spores combined with multiple 
patients with low-immune systems has lead to an increase in hospital-acquired C. 
difficile infection, which has had a severe economic impact on the healthcare 
system.  Due to the emerging antibiotic resistance problems and the common 
occurrence of patient relapse using the current drugs of choice, alternative 
therapeutic avenues are being explored.  C.difficile produces two potent 
exotoxins; Toxin A and Toxin B that are the causative agents of infection.  These 
toxins have multi-modular domain organisations, with each domain playing a role 
in cytotoxicity.  Some of these domains have been characterised structurally 
using X-ray crystallography.  In this thesis, the low resolution SAXS structure of 
Toxin A will be presented along with the advances made towards determining the 
X-ray crystallographic structure of the full-length Toxin A.  
 
In addition to Toxins A and B, some strains of C. difficile produce a binary 
toxin, CDT, which is made up of two individually produced components, CDTa 
and CDTb.  The CDTa component is the enzymatically active component, 
whereas CDTb is the transport component, directly involved in translocating 
CDTa into target cells.  The precise role of CDT in pathogenesis is unclear, 
however there is evidence that CDT ADP-ribosylates monomeric actin in target 
cells, but the detailed mechanism by which this reaction takes place is unknown.  
Here site directed mutagenesis of key residues of the active site of CDTa was 
performed and the effect of these mutations on the enzyme’s cytotoxicity tested.  
By separately mutating three active site residues, the cytotoxic effect of CDTa 
can be completely eradicated, details of which will be discussed in this thesis.  
Additionally, the progress made towards determining the X-ray crystallographic 
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ADPRT   Adenosine Diphosphate Ribosyl Transferase 
ARTT    Adenosine Diphosphate Ribosyl Turn-Turn 
β-OG    Beta-Octyl-Glucoside 
β-TAD Beta-Methylene-Thiazole-4-carboxamide adenine 
dinucleotide 
CD    Circular Dichroism 
CDAD    Clostridium difficile Associated Disease 
CDI    Clostridium difficile Infection 
DLS    Dynamic Light Scattering 
Dmax    Maximum Particle Diameter 
DO    Dissolved Oxygen 
dRI    Refractive Index 
GAP    GTPase Activating Protein 
GDI    Guanine-Nucleotide Dissociation Inhibitor 
GDP    Guanosine Diphosphate 
GEF    Guanine-Nucleotide Exchange Factor 
GF    Gel Filtration  
GTP    Guanosine Triphosphate 
HPLC    High Pressure Liquid Chromatography 
InsP6    Inositol Hexakisphosphate 
LB    Luria-Bertani 
LCT    Large Clostridial Toxins 
L-CPL    Left-handed Circularly Polarized Light 
LS    Light Scattering 
LSR    Lipolysis-Stimulated Lipoprotein Receptor 
MBP    Maltose-Binding Protein 
NSD    Normalized Spacial Discrepancy 
OD    Optical Density 
PCT    Pre-Crystallisation Test 
PDB    Protein Data Bank 
PDI    Polydispersity Index 
PEG    Polyethylene Glycol 
PHE    Public Health England 
!PID    Proportional-Integral-Derivative 
PMC    Pseudomembranous Colitis 
P(r)    Radial Patterson Function 
PSD    Particle Size Distribution 
R-CPL    Right-handed Circularly Polarized Light 
Rg    Radius of Gyration 
SAXS    Small-Angle X-ray Scattering 
SDS-PAGE Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis 
SEC-MALS Size-Exclusion Chromatography Multi-Angle Light 
Scattering 
TB    Terrific Broth 
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1.1 Introduction to Clostridium difficile  
1.1.1 Clostridium difficile 
Clostridium difficile Infection 
 
Clostridium difficile is an anaerobic Gram-positive spore-forming 
bacterium that was first described in 1935 (Hall and O’Toole, 1935).  C. difficile is 
named so because it grew slowly in culture and was difficult to isolate (Kelly and 
LaMont, 1998).  It is one of the most common causes of antibiotic-associated 
diarrhoea in the world (Carroll and Bartlett, 2011; Kyne, 2010).  Initially C. difficile 
was not considered to be a particularly harmful pathogen until a rise in the 
number of cases of PMC (pseudomembranous colitis) in the 1970s.  It is known 
to cause a number of intestinal diseases known as C. difficile associated disease 
(CDAD) or C. difficile infections (CDI) (Kyne, 2010).  These diseases range from 
mild diarrhoea to severe toxic megacolon, which can be fatal.  Infection with C. 
difficile accounts for 90–100 % of antibiotic-associated PMC, with a 6–30 % 
mortality rate (McMaster-Baxter and Musher, 2007).  CDI is associated with a 
broad range of symptoms including fever, abdominal pain, and leukocytosis, but 
patients with CDI are diagnosed by the presence of C. difficile toxins in faecal 
samples.  Patients with PMC are treated with broad-spectrum antibiotics such as 
metronidazole and vancomycin, which can be very effective.  Metronidazole and 
vancomycin have similar efficacy in mild disease, however there is growing 
concern regarding treatment failure with the use of metronidazole in severe 
disease where vancomycin has been shown to be superior (Ananthakrishnan, 
2011; Aslam et al., 2005; Musher et al., 2005).  However metronidazole is 
commonly the drug of choice as it is a lower cost drug than vancomycin.  The use 
of broad-spectrum antibiotics to treat other diseases can suppress the intestinal 
bacterial flora causing a disturbance in the normal balance in the gut, resulting in 
host susceptibility to colonization or overgrowth of C. difficile (Bartlett, 2002; 
Carroll and Bartlett, 2011; Kelly and LaMont, 1998; Lyerly et al., 1988; Shen, 
2012; Voth and Ballard, 2005).  Patients with mild cases of CDI are usually 
advised to discontinue taking any antibiotics to prevent suppression of the natural 
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gut flora, whereas for patients with extreme cases of CDI that lead to PMC, 
metronidazole and vancomycin are the suggested treatments (Cecil, 2012).  
Relapse is a common problem associated with antibiotic treatment (occurring in 
up to 25% of cases), in which case patients are required to continue with 
prolonged courses of these drugs (Bartlett, 2002).  As treatment with antibiotics 
commonly leads to relapse, an alternative treatment of faecal transplantation is 
sometimes used whereby fresh donor faeces are introduced into the cecum 
(Mattila et al., 2012).  This helps to re-establish the normal composition of 
intestinal flora preventing C. difficile from colonizing the gut.        
C. difficile is an extremely infectious bacterium and can produce highly 
resistant spores.  These spores can survive on surfaces for long periods of times 
and are resistant to standard disinfectants (Cecil, 2012).  Bleach can kill C. 
difficile spores but their resistance and ability to survive for long periods are 
particularly difficult to control in hospital environments which means the majority 
of infections are contracted nosocomially (Davies et al., 2011; He et al., 2013).  
Thus CDIs cause significant problems in the healthcare system, with studies 
showing that CDI infections cost hospitals in the US an estimated $1-3 billion 
annually (McGlone et al., 2012).  
 
Clostridium difficile Virulence Factors 
 
C. difficile has a number of virulence factors that contribute to its 
pathogenicity, such as its flagella, capsule and putative Type IV pilus.  In addition 
C. difficile produces a variety of proteins for adhesion and evasion including 
collagen and fibronectin-binding proteins, von Willebrand Factor binding proteins, 
sortases, cysteine proteases and adhesins (Vedantam et al., 2012).   The 
pathogenic strains of C. difficile produce two potent exotoxins, Toxin A and Toxin 
B (often called TcdA and TcdB), which induce mucosal inflammation and 
diarrhoea (Borriello, 1998; Kelly and LaMont, 1998; Voth and Ballard, 2005).  In 
addition to these exotoxins, some of the more virulent C. difficile strains produce 
an ADP- ribosylating binary toxin (CDT), however, the role of this toxin in disease 
is unclear (Perelle et al., 1997; Popoff et al., 1988).  Details of both Toxin A, 
Toxin B and CDT will be discussed in terms of biology and structural features in 
Chapter 1.2.   
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1.2 Introduction to C. difficile Toxins 
1.2.1 Large Clostridial Toxins A and B 
Biology of LCTs 
 
Bacteria from the genus Clostridium produce a wide range of toxins, the 
most well known being the clostridial neurotoxins such as the Clostridium 
botulinum neurotoxins (BoNTs), which can cause flaccid muscular paralysis 
known as botulism.  Additionally there is the well known Clostridium tetani 
neurotoxin (TeNT) which causes spastic paralysis (Pellizzari et al., 1999).  
Clostridium difficile produces two large exotoxins: Toxins A and B, which are part 
of the large clostridial toxin (LCT) group, owing to their high molecular mass: 
Toxin A is 308 kDa and Toxin B is 269.6 kDa (Jank and Aktories, 2008).  Other 
key members of the LCT family include, lethal toxins from Clostridium sordellii 
and α-toxin from Clostridium novyi.  All members of the LCT family are 
monoglycosyltransferases that inactivate small GTPases in target cells (Busch 
and Aktories, 2000; Just and Gerhard, 2004).   
Toxins A and B are encoded by the genes tcdA and tcdB, which are 
located in a 19.6 kb locus, known as the PaLoc (pathogenicity locus) (Aubry et 
al., 2012; Govind and Dupuy, 2012; Vedantam et al., 2012; Voth and Ballard, 
2005).  There are two other genes in the PaLoc that encode positive and 
negative regulators of the production of these toxins, TcdR and TcdC 
(Matamouros et al., 2007).  In addition there is a gene encoding a holin-like 
protein which is thought to allow secretion of the toxins, TcdE (Govind and 
Dupuy, 2012; Rupnik et al., 1998; Tan et al., 2001).  C. difficile strains are 
grouped on the basis of the variations in the structure of the PaLoc (Rupnik, 
2005; Rupnik et al., 1998).   
Toxins A and B share 47% sequence identity and have multi-modular 
domain organisations described by Jank and Aktories as the ABCD model (Jank 
and Aktories, 2008).  The ‘A’ domain is the biologically active N-terminal domain, 
the ‘B’ domain is the C-terminal binding domain, the ‘C’ domain is the cysteine 
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protease domain, located next to the ‘A’ domain, and the ‘D’ domain is the 
hydrophobic pore forming domain, located between the ‘C’ and ‘B’ domains (for a 
schematic diagram see Figure 1.2.1a).  The C-terminal binding ‘B’ domain, which 
consists of polypeptide repeats, is involved in receptor binding to specific cell-
surface carbohydrate receptors, but other domains may also play a direct or 

















The precise mechanism by which Toxins A and B enter target cells is 
unclear, however there is a theory based on multiple findings that can be 
explained in four key steps, which are summarised in Figure 1.2.1b.  
Figure 1.2.1a- Schematic representation of domain organisation of Clostridium 
difficile toxins.  A: Domain organisation of Toxin A and Toxin B from the LCT 
family of toxins.  B: Domain organisation of the two components of the binary 
toxin, CDT. 
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Step 1: The binding ‘B’ domain interacts with highly specific carbohydrate 
receptors on the cell surface, which stimulates receptor-mediated endocytosis of 
the toxin into the endosomal compartment. 
Step 2:  The pH of the endosome decreases causing conformational 
changes within the toxin, allowing potential pore formation of the ‘D’ domain and 
insertion into the endosomal membrane (Barth et al., 2001; Qa’Dan et al., 2000).  
The ‘A’ domain and ‘C’ domain are translocated into the cytosol which has been 
shown by the use of 86Rb ions (Barth et al., 2001; Qa’Dan et al., 2000).  
 
 
Figure 1.2.1b- Diagram illustrating the predicted mechanism of LCT uptake into 




Step 3: It is thought that the cysteine protease domain ‘C’ is involved in 
autoprocessing of the toxins, and requires InsP6 (Egerer et al., 2007; Giesemann 
et al., 2008; Pruitt et al., 2009).  This autoproteolysis allows the release of the 
enzymatic ‘A’ domain into the cytosol.   
Step 4: The LCTs target Rho proteins for glucosylation by the biologically 
active ‘A’ domain in the cytosol.  Toxins A and B specifically target Rho GTPases 
(Rho, Ras and Cdc42), which are molecular switches involved in numerous 
signalling processes, in particular the regulation of the actin cytoskeleton (Figure 
1.2.1b). The ‘A’ domains of Toxins A and B catalyse the addition of UDP-Glc 
(UDP-glucose) to Thr-37 (monoglucosylation) in Rho GTPase leading to 
depolymerisation of actin filaments, disruption of the cytoskeleton and eventually 
cell rounding and cell death (Jank et al., 2007a; Just et al., 1995a, 1995b).  
 
There is on-going speculation as to which of the two toxins are essential 
for virulence, with contradicting reports.  There are a number of reports that 
suggest Toxin B is essential for pathogenicity, whereas the role of Toxin A is less 
clear.  This is reflected in the reported outbreaks of C. difficile strains that are 
Toxin A negative/Toxin B positive.  Universal gene knock-out systems developed 
for the genus Clostridium (Heap et al., 2007; O’Connor et al., 2006) were used in 
studies that indicate Toxin A is not essential for virulence (Lyerly et al., 1985; 
Lyras et al., 2009).   This is also reflected in studies by Kim et al., who reported 
that there was no significant difference in disease between Toxin A 
negative/Toxin B positive strains and Toxin A positive/Toxin B positive strains 
which indicates that Toxin A doesn’t have a big impact on pathogenicity (Kim et 
al., 2012).  However, recent reports suggest that both toxins play a role in 
disease and that Toxin A is able to cause disease in the absence of Toxin B 
(Kuehne et al., 2011, 2010).   
C. difficile is a harmful pathogen and the main cause of the rise in cases 
of antibiotic-associated PMC in hospitals, therefore it is of great interest to 
understand the function of LCTs, especially with the upcoming occurrence of 
antibiotic resistance.  Structural studies have delivered an insight into the 
molecular mechanism of the LCTs, which will be detailed in the following 
sections.   
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High-Resolution Structural Aspects of LCTs 
X-Ray Crystallography Studies of LCTs 
 
 X-ray crystallography is a technique used to determine the structures of 
molecules at atomic resolution.  This experimental technique requires highly 
ordered crystals of the molecule of choice.  Crystals are mounted on a 
goniometer and are rotated whilst being exposed to a beam of X-rays.  The 
crystals diffract the X-rays producing a series of reflections called the diffraction 
pattern, which provides information about the arrangement of the molecules 
within the crystal.  The full-length crystal structures of Toxin A and B have not yet 
been elucidated, however, crystal structures of some of the individual domains 
have been solved.  The successfully solved structures of Toxin A domains are 
displayed in Figure 1.2.1c and those for Toxin B domains are displayed in Figure 













Figure 1.2.1c- Crystal structures of the ‘A’ domain, ‘C’ domain and ‘B’ domain of Toxin A.  Structures of the individual domains are coloured 
corresponding to the schematic diagram of domain organisation.  PDB codes: 4DMW and 3HO6 are ‘A’ domain and ‘C’ domain respectively.  A: A 
smaller version of the ‘B’ domain with CD-grease (synthetic derivative of a naturally occuring carbohydrate receptor) bound (PDB code: 2G7C).  B: 
Longer version of ‘B’ domain (PDB code: 2QJ6)(D’Urzo et al., 2012; Greco et al., 2006; Pruitt et al., 2009). Images were created using PyMOL 
(Version 1.5.0.4 Schrödinger, LLC).  
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A C D B Toxin B 
Figure 1.2.1d- Crystal structures of the ‘A’ domain and ‘C’ domain of Toxin B.  Structures are colour coordinated with the schematic 
representation of domain organisation.  PDB codes: 2BVL and 3PEE representing the ‘A” domain and ‘C’ domain respectively (Reinert et 
al., 2005; Shen et al., 2011).  Images were created using PyMOL (Version 1.5.0.4 Schrödinger, LLC).  
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Glucosyltransferase ‘A’ Domain 
 
The glucosyltransferase domain, which is responsible for glucosylation of 
Rho proteins, is located at the N-terminal region known as the ‘A’ domain.  The 
crystal structures of both the ‘A’ domain of Toxin A and the ‘A’ domain of Toxin B 
have been solved with resultant structures displayed in Figures 1.2.1c and 1.2.1d 
respectively, PDB codes 4DMW and 2BVL (D’Urzo et al., 2012; Reinert et al., 
2005).  This catalytic fragment of the LCTs is delivered to the cytosol where it 
glucosylates small GTPases. 
The ‘A’ domain of Toxin A consists of residues 2-538 and was crystallised 
in the presence of UDP-Glc and manganese ions, however density was not 
observed for either the UDP-Glc or the manganese ions (D’Urzo et al., 2012).  
The crystal structure shares the same common fold (consisting of 234 residues) 
seen among the glucosyltransferase type A family.  The remaining residues are 
arranged predominantly in α-helices and are thought to contribute to the 
specificity of the toxin.       
The ‘A’ domain of Toxin B consists of residues 1–543 and was co-
crystallized with UDP-Glc and manganese ions that are essential for catalysis 
(Ciesla and Bobak, 1998; Rupnik et al., 2005).  The hydrolysed products of UDP- 
Glc; α-D-glucose and UDP were identified in the electron density due to 
hydrolytic activity of the ‘A’ domain (Reinert et al., 2005).   
These two crystal structures of the ‘A’ domains share almost identical 
overall folds with a root mean square deviation (rmsd) value of 1 Å (D’Urzo et al., 
2012).  Therefore as the ‘A’ domain of Toxin B was solved with the hydrolysis 
product of UDP-Glc, the structure and active site will be looked at in more detail.  
The active site of Toxin B is displayed in Figure 1.2.1e as a stereo image, with 
the residues displayed as sticks.  The catalytic pocket is made up of the β2, β5 
and β10 strands, in addition to α12 and α18 helices, and a 510–523 residue loop 
(Ünligil and Rini, 2000).  The catalytic DXD-motif involved in the binding of UDP-
Glc and Mn2+ is composed of Asp-286 and Asp-288.  Asp-286 forms a hydrogen 
bond with a water molecule of the Mn2+ co-ordination sphere, in addition to 
binding to both the 3′-hydroxy group of UDP-ribose and glucose, making it a key 
residue for catalysis, whereas the Asp-288 residue binds directly to Mn2+ 
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(Reinert et al., 2005).  Mutational analysis by alanine scanning revealed five 
important residues specifically involved in enzyme activity: Asp-270, Arg-273, 
Tyr-284, Asn-384 and Trp-520.  In addition, the following four residues were 
reported to be important for UDP-Glc recognition: Arg-455, Asp-461, Lys-463 and 





















Figure 1.2.1e- Crystal structure of the ‘A’ domain of Toxin B.  A: Structure of Toxin B ‘A’ 
domain displayed in cyan with α -D-glucose and UDP displayed as green sticks, and the 
manganese ion as a magenta sphere.  B: A zoomed in stereo view of the catalytic 
pocket with the α -D-glucose as green sticks and UDP displayed as orange sticks, the 
coordinating water molecules as blue spheres and the manganese ion as a magenta 
sphere (Reinert et al., 2005).  Images were created using PyMOL (Version 1.5.0.4 















Toxins A and B of the LCT family target and glucosylate the Rho family of 
GTPase proteins.  These proteins are molecular switches that are predominantly 
responsible for regulating the actin cytoskeleton, but also play roles in cell 
polarity, gene transcription and cell cycle progression.  The Rho GTPase family 
of proteins consists of the Rho, Rac and Cdc42 subfamilies.  They can exist in 
two forms: firstly the GTP-bound form which is active and secondly the GDP-
bound form which is inactive, as displayed in Figure 1.2.1b.  The GTP and GDP-
bound forms are inter-convertible and are regulated by guanine-nucleotide-
exchange factors (GEFs), guanine-nucleotide-dissociation inhibitors (GDIs) and 
GTPase-activating proteins (GAPs) (Figure 1.2.1b).  GDIs bind to Rho GTPases 
at a switch I region, rendering them soluble in the cytosol and in the inactive 
form.  GEFs activate GTPases to their GTP-bound form allowing interaction with 
numerous effector molecules that control a number of signalling pathways.  
GAPs hydrolyse GTP-bound Rho GTPases into inactive GDP-bound Rho 
GTPases (Bishop and Hall, 2000).  LCTs target the Thr-37 residue on Rho 
GTPases, which is exposed when in the GDP-bound conformation.  This residue 
is glucosylated by the ‘A” domain of the toxins, which causes depolarization of 
actin filaments, leading to disruption of the cytoskeleton and cell death.  The Thr-
37 residue is not exposed when in the GTP-bound form or when their switch I 
region is complexed with GDIs.  To confirm, Rho is glucosylated in the GDP-
bound conformation by Toxins A and B, as the Thr-37 residue is exposed which 
allows an oxygen acceptor atom to be in position for attack from the C1 donor 
atom of the LCTs (Just et al., 1995a, 1995b).  Although there are reports that 
indicate that Toxin B can bind to RhoA in the Rho-GTP form (Jank et al., 2007b). 
There are two types of mechanism proposed for the glucosylation 
mechanism of the ‘A’ domain:  Firstly, a double displacement reaction (SN2-like) 
and secondly an internal return stereo-specific (SN1) reaction.  It is unlikely that 
the glucosylation occurs via an SN2-like mechanism, as this requires a 
nucleophile in position to attack the β-side of the C1 atom in glucose.  However, 
as this atom is surrounded by non-polar residues in the catalytic cleft, there is no 
nucleophile in position to attack the C1 atom, hence a double displacement 
reaction is unlikely (Davies et al., 2011).  An SN1 is plausible as the 
oxocarbenium intermediate could be stabilised by the surrounding negative 
phosphate and carboxylate groups from Asp-270, Asp-286, Asp-288 and Glu-
515, which are in turn compensated by the positively charged Arg-273 and the 
Mn2+ ion (Reinert et al., 2005).  LCTs exhibit high substrate/co-substrate 
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specificity for UDP-Glc, with two residues Ile-383 and Glu-385, located in the 
active site being responsible for this specificity as shown by mutagenesis studies 
(Jank et al., 2007b, 2005). 
Binding ‘B’ Domain 
 
The initial step in the toxication process is the binding of LCTs to specific 
cell-surface receptors of intestinal epithelial cells, which is carried out by the ‘B’ 
domain.  This ‘B’ domain interacts with carbohydrate structures such as Gal-α-
(1,3)-Gal-β-(1,4)-GlcNAc on the host epithelial cells (Krivan et al., 1986).  
Although a functional carbohydrate receptor in humans has yet to be identified, 
attempts to gain more insights into carbohydrate binding have been made 
(Davies et al., 2011).  The crystal structure of the C-terminal binding domain of 
Toxin A has been determined for two different fragment sizes.  The first fragment 
(127 residues), named TcdA-f1, was obtained by expressing a longer fragment 
and isolating a smaller cleaved fragment (PDB code 2F6E) (Ho et al., 2005).  The 
second fragment, TcdA-f2, which is a slightly longer fragment (255 residues), 
was solved in complex with a synthetic carbohydrate derivative, CD-grease [α-
Gal-(1,3)-β-Gal-(1,4)-β-GlcNAcO(CH )COCH] (Figure 1.2.1f) (PDB code: 2G7C) 
(Greco et al., 2006).   
In the TcdA-f2-CD-grease complex there are two carbohydrate-binding 
regions, however there are seven of these highly conserved binding regions in 
the full-length C-terminal fragment, which gives the ‘B’ domain its high binding 
capacity (Greco et al., 2006; Ho et al., 2005).   
Although there is little information about the binding domain of Toxin B, it 
is believed that Toxin B uses different receptors to bind to target cell surfaces 
than Toxin A, which may explain the differences observed in toxicity as discussed 
earlier (Jank et al., 2007b).  However, as Toxins A and B share 47% sequence 
identity, the structures of the binding domains may share similarities and 
therefore predictions can be made that Toxin B will interact with carbohydrate 
receptors in a similar manner to Toxin A (Davies et al., 2011).  
Sequence analysis of the Toxin A gene shows that 31.5% of the gene is 
in 38 contiguous repeating units and these repeats are located in the ‘B” domain 
region.  These repeats are split into two categories: firstly, class I (long repeats), 
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of which there are seven types, each repeat being 30 amino acids long; and 
secondly, class II (short repeats), of which there are thirty-one types, each 
consisting of either 20 or 21 amino acids (Dove et al., 1990).  TcdA-f1 consists of 
four short repeats and one long repeat whereas TcdA-f2 contains nine small 
repeats and two long repeats (Greco et al., 2006; Ho et al., 2005).  Each short 
and long repeat form β-hairpins that are connected by loops, see Figure 1.2.1f.  
In the short repeat regions the loops are made up of 7–10 residues, whereas in 
the long repeat regions the loops are made up of 18 residues (Jank et al., 
2007b).   
The β-hairpin repeat regions are related to each other by a screw-axis 
transformation, meaning that each β-hairpin is related to the adjacent hairpin by 
120 ◦ (Figure 1.2.1f) (Greco et al., 2006).  This results in a β-solenoid left-handed 
helix, which is a common conformation of many bacterial cell-surface-binding 
proteins.  The helical conformation increases the surface area of the ‘B’ domain 
optimised for binding to target cells (Figure 1.2.1f) (Greco et al., 2006).  These 
results are consistent with that of the short fragment TcdAC26–39 structure of the 
‘B’ domain from Albesa-Jové ́ et al. (Albesa-Jové et al., 2010). 
 
90 ° 
Figure 1.2.1f- Crystal structure of the binding ‘B’ domain of Toxin A (PDB code: 
2G7C).  The binding domain is displayed as purple cartoon and the bound CD-
grease molecule as magenta sticks.  The structure has a left-handed helix shape 
increasing surface area for binding.  The cross section through the helix is 
displayed illustrating the 120 ° rotation between the β-hairpins creating the helix.  
In this structure there are two long repeat regions (class I) and nine short repeat 
regions (class II), which gives a total of eleven β-hairpins.  CD-grease molecules 
are bound in the shallow troughs made up of the long repeat regions and the 
hairpin turn of the following short repeat region (Greco et al., 2006).  Images were 




Cysteine Protease ‘C’ Domain 
 
The cysteine protease ‘C’ domain (CPD) is thought to be located between 
residues 543 and 769 in Toxin A and between residues 543 and 767 in Toxin B 
(Egerer et al., 2007).  The crystal structure of the ‘C’ domain (543–809) from 
Toxin A was determined at 1.6 Å in the presence of inositol-hexakisphosphate 
(InsP6) (Figure 1.2.1g) (PDB code: 3HO6) (Pruitt et al., 2009).  It is postulated 
that the ‘C” domain is involved in autocatalytic cleavage of Toxins A and B in the 
presence of InsP6.  This autoproteolysis releases the ‘A’ domain into the cytosol 










The overall structure reveals a central nine-stranded β-sheet flanked by 
five α-helices.  The InsP6-binding site, displayed in Figure 1.2.1g is located on 
the opposite side of the central β-sheet to the active site.  These two binding sites 
are separated by a three-stranded β-hairpin, known as the ‘β-flap’.  The N-




Figure 1.2.1g- Crystal structure of the ‘C’ domain of Toxin A with InsP6 bound.  
The ‘C’ domain is displayed as green cartoon with InsP6 displayed as red 
sticks.  The proposed active site residues are displayed as cyan sticks.  The 
InsP6 binding pocket is also displayed as surface with positively charged 
residues displayed in blue (Pruitt et al., 2009).  Images were created using 
PyMOL (Version 1.5.0.4 Schrödinger, LLC).  
(“The PyMOL Molecular Graphics System, version 1.5.0.4,” n.d.).   
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binding site to the proposed active site (Pruitt et al., 2009).  The characteristic 
cysteine protease catalytic triad has been identified as Cys-700, His-655 and 
Asp-589; however, these residues are too far apart for hydrogen bond formation, 
which is normally observed amongst cysteine proteases.  Therefore the 
mechanism of catalysis may differ from other cysteine proteases (Davies et al., 
2011).  Pruitt et al. have shown that the ‘C’ domain shows significant changes in 
conformation upon InsP6 binding to a more stable form, which increases 
resistance to chymotrypsin digestion (Pruitt et al., 2009).  InsP6 is negatively 
charged and binds to a number of positively charged residues that span the 
entire domain including Arg-753, Tyr-579 and seven lysine residues: Lys-577, 
Lys-602, Lys-649, Lys-754, Lys-766, Lys-777 and Lys-794 (see Figure 1.2.1g).  
The ‘β-flap’, described earlier, is thought to be involved in relaying structural 
changes from the InsP6-binding site across to the active site, which activates an 
intramolecular autoproteolytic cleavage event.  This allows correct processing of 














Figure 1.2.1h- ‘C’ domain of Toxin A and ‘C’ domain of Toxin B.  Superposition of 
Toxin B ‘C’ domain (PDB code: 3PEE) displayed in red and Toxin A ‘C’ domain 
(PDB code: 3HO6) displayed in green, with rmsd 1.3 Å (Pruitt et al., 2009; Shen et 




Shen et al. recently solved the structure of the ‘C’ domain of Toxin B 
(PDB code: 3PEE) which shares 56% sequence identity with the ‘C’ domain of 
Toxin A and a highly similar structure [rmsd (root mean square deviation) of 1.3 
Å] (Shen et al., 2011).  The two structures share a conserved active site, a well-
conserved β-flap and highly similar InsP6 binding sites.  Using chemical probes, 
Shen et al. showed that the ‘C’ domain of Toxin B can adopt the activated 
conformation without the presence of InsP6, and in fact the presence of InsP6 
shifts the equilibrium in favour of the active conformation.  Shen et al. have used 
tryptophan fluorescence assays, structural analysis and mutagenesis studies to 
show that a conserved group of residues in the β- flap region are responsible for 
transmitting the InsP6-binding signal to the active site (Shen et al., 2011). 
 
Hydrophobic Pore-Forming ‘D’ Domain 
 
There is little known about the ‘D’ domain other than that it harbours the 
majority of the toxin’s hydrophobic residues.  It is thought to be involved in pore-
formation in the endosomal membrane allowing translocation of part of the LCTs 
into the cytosol.  The ‘D’ domain has not been characterised structurally and 
there is no structural data for homologous proteins either.  Owing to the 
hydrophobic nature of the ‘D’ domain, purification and crystallization are difficult, 
which may explain why the structure has not yet been determined (Davies et al., 
2011).  Qa’Dan et al., used bafilomycin A1, which is a potent inhibitor of the 
endosomal vacuolar ATPase pump that controls the acidity of the endosome, to 
assess the effect of endosomal acidification on the LCTs (Qa’Dan et al., 2000).  
Translocation of LCTs was measured using TNS [2-(p-toluidinyl)napthalene-6-
sulfonic acid, sodium salt] fluorescence.  For Toxin B, Qa’Dan et al., reported that 
increased TNS fluorescence was observed upon increased acidity in the 
endosome, suggesting a conformational change within Toxin B and exposure of 
the hydrophobic ‘D’ domain, thereby confirming its role in translocation (Qa’Dan 




Low-Resolution Structural Aspects of LCTs 
Small-Angle X-Ray Scattering 
 
Due to the lack of full-length X-ray diffraction data for the LCTs, small-
angle X-ray scattering (SAXS) has been employed to provide low-resolution 
structures.  Recently reported SAXS data for Toxin B have provided an ab initio, 
low resolution surface model, see Figure 2.2.1d (Albesa-Jové et al., 2010).  The 
four individual domains described in the ABCD model have been visualised for 
the first time within the SAXS envelope.  The data revealed four distinct domain 
boundaries, into which the crystal structures can be aligned.  The four domains 
are organised as demonstrated in Figure 1.2.1a.  The SAXS envelope is 
elongated in structure and has a protruding region thought to be that of the 
hydrophobic ‘D’ domain (Albesa-Jové et al., 2010).  The SAXS data were 
collected at a neutral pH, so the low pH-induced conformational change that is 
predicted to occur within this ‘D’ domain has not been shown. 
Negative Stain Electron Microscopy 
 
Recent studies have shown that Toxins A and B have similar native 
structures as determined by electron microscopy (Pruitt et al., 2010).  Both toxins 
have an elongated structure containing a ‘head’ domain, a long ‘tail’ domain and 
a short inner ‘tail’ domain.  Mapping studies were focused on Toxin A as this 
protein was considerably more homogenous in structure than Toxin B.  The 
three-dimensional structure of Toxin A was constructed using the random conical 
tilt approach where the modular domains were mapped into the corresponding 
structure (Pruitt et al., 2010).  Pruitt et al. concluded that the long ‘tail’ fragment 
corresponds to the ‘B’ domain, the short ‘tail’ corresponds to the ‘A’ domain and 
the ‘head’ corresponds to the ‘D’ domain using antibody labelling (Pruitt et al., 
2010).  The cysteine protease ‘C’ domain could not be located.  Unlike the SAXS 
structure, electron micrographs were taken of the toxins at a reduced pH and as 
predicted, conformational changes were observed in the ‘head’ shape, confirming 
the location of the ‘D’ domain in the structure (Pruitt et al., 2010).  Although 
negative stain electron microscopy provides images of the overall toxin shape, it 
is beneficial to understand the toxins at a molecular level using X-ray 
crystallography.   
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1.2.2 Binary Toxin 
Biology of Binary Toxin 
 
In addition to the LCTs, some C. difficile strains can produce an additional 
toxin called the ADP-ribosyltransferase binary toxin, CDT (Popoff et al., 1988).  
CDT is a member of the ADPRT family of binary toxins which has been divided 
into four key classes: the AB5 group, the AB-3 group, the single-polypeptide 
group and the AB group (Holbourn et al., 2006).  The AB5 group that includes 
cholera toxin, are composed of one A subunit and five B subunits, and they target 
small regulatory G-proteins.  The AB-3 group that includes diphtheria toxin have 
a binding domain, a transmembrane domain and a catalytic domain, and they 
ribosylate a diphthamide residue on elongation factor 2.  The single polypeptide 
group, which includes C3 toxin from C. botulinum are not well characterised and 
have unknown roles in pathogenesis.  The AB group, which includes C2 toxin 
from C. botulinum and Iota toxin from Clostridium perfringens, are made up of 
two subunits and target actin (Holbourn et al., 2006).  CDT is a member of the AB 
binary toxin group and is made up of two independently produced components: 
the enzymatic component, CDTa (mature length 48kDa), and the transport 
component, CDTb (mature length 74kDa); see Figure 1.2.1a for a schematic 
representation of the domain organization (Barth, 2004; Davies et al., 2011; 
Perelle et al., 1997) 
The precise role of the CDT binary toxin in pathogenesis is unclear.  Most 
research has focused on the LCTs which are the dominant exotoxins produced 
by C.difficile and are known to play key roles in pathogenesis.  In general the 
most virulent C. difficile strains maintain the dominant production of LCTs and 
lack of CDT (Perelle et al., 1997).  However, in one study of CDT genes in the 
United States, 15.5% of C. difficile strains tested had both the genes for the CDT 
components (cdtB and cdtA), 8.7% of which did not have the LCT genes (Geric 
et al., 2003).  Therefore, the binary toxin may be playing a role in pathogenesis.  
It has been shown that a CDTa–CDTb (CDT) complex is toxic to Vero cells 
(Sundriyal et al., 2010).  Using time-lapse and immunofluorescence microscopy, 
Schwan et al., have shown that CDT forms dynamic microtubule protrusions on 
the surface of human colon carcinoma cells (Caco-2) concomitantly with ADP- 
ribosylation of actin and depolymerization of microfilaments (Schwan et al., 
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2009).  It is thought that the binary toxin increases adherence of the bacteria to 
the intestinal epithelial cells using these cell surface extensions.  Schwan et al., 
noted that the protrusions form a dense meshwork in which the bacteria were 
caught, contributing to the colonization of C. difficile.  Similar results were also 
demonstrated for the homologues C. botulinum toxin C2 and C. perfringens Iota 
toxin (Schwan et al., 2009).  In addition to protrusion formation, cellular 
microtubule structures were also altered to increase bundling of microtubules.  
The two components of CDT play different roles in the toxicity process: the 
transport component, CDTb, is responsible for transport of the CDTa component 
into the cytosol, whereas the CDTa (enzymatic component) is responsible for 
ADP-ribosylation of actin in the cytosol (Barth et al., 2004).  The proposed 
mechanism of uptake of CDTa is similar to other members of the ADPRT family 
such as C. botulinum C2 toxin and Iota toxin from C. perfringens (Barth, 2004).  
The CDTb component must be activated via cleavage, after which the proposed 
mechanism is as follows: 
Step 1: The activated mature CDTb’’ forms heptamers at the cell surface 
and binds to specific cell-surface receptors, see Figure 1.2.2a.   
Step 2: CDTa binds to CDTb and together they are taken up into the cell 
by receptor-mediated endocytosis.  
Step 3: The pH of the endosomal compartment decreases causing 
conformational changes that allow pore formation and insertion into the 
endosomal membrane.   
Step 4: CDTa is translocated through the pore into the cytosol where it I
 rreversibly ADP-ribosylates monomeric G-actin (Barth, 2004; Barth et al., 
2004).   
 
The N-terminus of CDTa is responsible for interaction with CDTb, 
whereas the C-terminus harbours the enzymatic activity (Gulke et al., 2001).  
Structural evidence from the complex of actin with the enzymatic component of 
the Iota binary toxin (Ia) shows that Arg-177 of actin is the ribosylation site 
(Tsuge et al., 2008).  Therefore as Ia and CDTa are close homologs, we can 
predict that CDTa will irreversibly ADP-ribosylate monomeric G-actin at the Arg-
177 residue.  This ADP-ribosylation blocks polymerisation of G-actin to F-actin 
and subsequently disrupts the F-actin:G-actin equilibrium (Mauss et al., 1990; 
Vandekerckhove et al., 1987).  Disruption of the actin equilibrium results in 
collapse of the cytoskeleton, cell rounding and cell death. 
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Figure 1.2.2a- The proposed mechanism of entry of CDT into target cells.  The trypsin activated CDTb’’ transport component forms 
heptamers at the target cell surface binding to target cell receptors.  CDTa binds to the transport component and together they are taken up 
into endosomes by receptor-mediated endocytosis.  Upon decreasing pH in the endosomal compartment, the CDTb’’ heptamer undergoes 
conformational changes forming a pore which allows translocation of CDTa into the cytosol where it mono ADP-ribosylated G-actin.  
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Structural Aspects of Binary Toxin 
 
The crystal structure of CDTa was solved at three different pH values, 
4.0, 8.5 and 9.0 (PDB codes 2WN8, 2WN4 and 2WN5 respectively), and in 
complex with NADPH and NAD at pH 9.0 (PDB codes: 2WN6 and 2WN7) 
(Sundriyal et al., 2009).  The structure of CDTa in complex with NAD, displayed 
in Figure 1.2.2b, was determined at 2.25 Å.  Both the structure of CDTa 
combined with the mechanism of ADP-ribosylation of C. perfringens Iota toxin 
(with which CDTa shares 84 % sequence identity), have been used to propose a 
detailed mechanism of ADP-ribosylation by CDTa (Mauss et al., 1990; Sundriyal 
et al., 2009; Vandekerckhove et al., 1987).  It is thought that CDTa transfers the 
ADP ribose group of NAD/NADPH to monomeric G-actin at Arg-177, blocking 
polymerization of actin and therefore leading to the collapse of the cell 
cytoskeleton (Davies et al., 2011). 
The structure of CDTa in complex with NAD is displayed in Figure 1.2.2b. 
The N-terminal domain, which consists of five α-helices and eight β-strands, 
extending from residues 1 to 215, is displayed in purple and is thought to interact 
with CDTb.  The C-terminal domain, which extends from residues 224 to 240, 
also consisting of five α-helices and eight β-strands, is displayed in cyan and is 
thought to interact with actin.  These domains are linked by a loop extending from 
residues 216 to 223, shown in red in Figure 1.2.2b (Sundriyal et al., 2009).  Both 
NAD and NADPH bind to the catalytic cleft of CDTa via the interacting residues 
Arg-302, Arg-303, Gln-307, Asn-342 and Ser-345 (Sundriyal et al., 2009).  Figure 
1.2.2b displays these catalytic residues in addition to a number of other defining 
features of the ADPRT family of toxins, for example the PN-loop (orange) and the 
Arg-motif (yellow).  The ExE-motif which is thought to be the key motif involved in 
the ADP-ribosylation mechanism, is located on the highly flexible ARTT-loop, 
which is displayed in blue, see Figure 1.2.2b.  The ARTT-loop is an ADP-ribosyl 
turn-turn loop that is important for substrate binding.  In CDTa, the EXE-motif is 
composed of the residues Glu-385 and Glu-387, which are thought to be involved 
in stabilising the substrate–enzyme complex as confirmed with the corresponding 
residues Glu-378 and Glu-380 in Iota toxin (Tsuge et al., 2008).  The unusual 
arrangement in this structure is that these residues are not in direct contact with 
NAD or NADPH, which might suggest that the EXE-motif in CDTa is not 
necessary for ligand binding and stabilization of this complex, although there is 
! ! Chapter!1.2!
! 23!
no experimental evidence to support this.  However, this could be due to the 
location of both Glu-385 and Glu-387 on the flexible ARTT-loop (Davies et al., 






















Figure 1.2.2b- Crystal structure of CDTa, the enzymatic component of the C. difficile 
binary toxin, CDT.  The N-terminal domain is displayed in cartoon purple and the C-
terminal domain is displayed in cartoon cyan.  The active site is zoomed in and 
displayed in stereo, with the key active site structural motifs colour coordinated in 
sticks as follows:  PN-loop in orange, Arg-motif in yellow, ARTT-loop and ExE in 
dark blue, STS-motif in green and remaining residues in blue.  NAD is displayed as 
magenta sticks (Sundriyal et al., 2009).  Images were created using PyMOL (Version 
1.5.0.4 Schrödinger, LLC).  
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The final feature shown in Figure 1.2.2b is the STS-motif, which includes 
the residues Ser-345 and Ser-347.  Ser-345 forms a strong hydrogen bond with 
Glu-387, and also directly with NAD and NADPH, therefore suggesting a role for 
the STS-motif in ligand binding and catalysis (Davies et al., 2011; Sundriyal et al., 
2009). 
An SN1 mechanism has been proposed for ADP-ribosylation of 
monomeric G-actin.  The mechanism was based on the mutagenesis studies of 
Iota Ia toxin and the crystallographic structure of actin in complex with Ia toxin 
(Tsuge et al., 2008).  The SN1 reaction occurs via two intermediates: firstly an 
oxocarbenium ion intermediate and secondly a cationic intermediate.  This 
mechanism is thought to be consistent amongst the ADPRT family of toxins 
(Holbourn et al., 2006).  As Iota toxin is the closest homologue to CDT, a similar 
SN1 reaction has been proposed with the EXE-motif playing a key role (Sundriyal 
et al., 2009).   
 
The proposed mechanism is as follows (Figure 1.2.2c):   
Step 1: The NAD molecule enters the active site of CDTa where the Glu-
387 residue from the ExE-motif is positioned near the ribose group of 
NAD.  
Step 2: The catalytic glutamate Glu-387 forms a H-bond with the 2′-OH 
group of ribose, which leads to loss of the nicotinamide group. 
Step 3: This leads to the formation of an oxocarbenium intermediate 
rendering the ribose group vulnerable to nucleophilic attack, see Figure 
1.2.2c. Following cleavage of NAD and formation of an oxocarbenium ion, 
the ARTT-loop is rearranged to bring the Glu-385 residue to the reaction 
centre.  Arg-177 from ac tin is brought into the active site by Glu-385.  
Step 4: The Glu-385 residue stabilises the transfer of ADP-ribose to Arg-
177 of actin. 
Further structural and experimental evidence is required to validate this 
hypothesis, such as site-directed mutagenesis of catalytic residues in addition to 
solving the structure of a CDTa–actin complex. 









Figure 1.2.2c- Proposed mechanism of ADP-ribosylation of actin via an SN1 mechanism.  1: NAD (black) interacts with Glu-387 (blue) in the active site 
of CDTa.  2: A H-bond is formed between Glu-387 of CDTa (blue) and the 2’-OH group of the ribose ring (black).  3: An oxocarbenium intermediate is 
formed rendering the ribose group susceptible to nucleophilic attack and the ARTT-loop is rearranged so that Glu-385 of CDTa (blue) brings Arg-177 
(green) of actin into the active site.  4:  ADP-ribose is transferred onto Arg-177 (green) of actin.  Image was created using ChemDraw ®.   
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1.3 Summary and PhD Objectives 
Introductory Discussion with Primary Objectives 
 
As discussed in the previous subchapters, the individual domains of the 
LCTs are well characterised however the full-length toxins are not well 
understood at a structural level.  The LCTs tend to be produced by the more 
virulent strains of C. difficile in addition to the binary toxin, however there are 
strains of C. difficile that have variations in their ability to produce these toxins, 
and there is great uncertainty over the roles of each of these toxins individually in 
pathogenesis (Kuehne et al., 2010; Lyerly et al., 1985; Lyras et al., 2009).  As 
some of the most pathogenic strains of C. difficile produce CDT in addition to the 
LCTs, it is tempting to question whether or not CDT plays an adjunctive role to 
the LCTs in pathogenesis (Davies et al., 2011).   
In the previous section of this chapter, the structural aspects of the 
individual domains of the LCTs were discussed in detail.  The full-length 
structures of the LCTs are yet to be determined, but the structures of some of the 
individual domains of these toxins have been solved.  From the current structures 
there is now an improved understanding of the binding, the autoproteolysis and 
the mechanism by which the LCTs glucosylate Rho GTPases.  These findings 
have opened up a number of avenues that are of great value for use in drug 
therapeutics.  Determination of the crystal structures of the remaining unsolved 
domains is highly desirable, in addition to solving the structure of an enzyme–
substrate complex.  This will provide an understanding of how the toxins function 
as a whole.  However, there is some ambiguity associated with the current 
domain structures and that uncertainty is that effectively these structures are 
small fragments of the full-length toxin.  These individual domains could 
potentially behave differently when not associated with the remaining domains.  
Therefore, it is essential that the crystal structure of the full-length toxin is 
resolved.   This feat would be particularly enlightening to discern the hydrophobic 
‘D’ domain region, for which there are no high-resolution structures.  One of the 
principal objectives for this PhD was to work alongside Public Health England 
towards elucidation of the crystal structure of the full-length Toxin A.  
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In terms of CDT, the objective was to test the hypothesis that the 
enzymatic component CDTa acts via an SN1 reaction, by performing site 
directed mutagenesis of active site residues.  In addition, the intention was to 
characterize the transport component at a structural level, as currently there is 
only structural data for the enzymatic component.  As it has been shown that 
CDTa and CDTb when combined are toxic to Vero cells, it would be beneficial to 
characterize the binary toxin as a whole complex in order to elucidate their 
interactions (Sundriyal et al., 2010).  This could provide a platform for highly 
specific drug design to block translocation of CDTa into target cells.  
Concurrently, it would also be of use to characterize the interactions between the 
CDTa component and its ADP-ribosylation target, actin.  Obtaining a complex of 
CDTa-actin and solving the structure, would provide a target for drug design from 
a different perspective.  By either blocking translocation of CDTa or blocking 
ADP-ribosylation of actin, highly specific drugs designed with the aid of complex 









2.1 Crystallisation of Toxin A 
2.1.1 Introduction 
Toxin A  
 
 Clostridium difficile produces two large exotoxins: Toxin A (308 kDa) and 
Toxin B (269.6 kDa), both of which are members of the Large Clostridial Toxins 
(LCT) family.  These toxins have a multi-modular domain organisation, which is 
divided into four functional domains.  These domains are represented by an 
ABCD model, see Figure 2.1.1a (Davies et al., 2011; Jank and Aktories, 2008). 
 
 
 As discussed in detail in Chapter 1.2, Toxin A glucosylates Rho GTPases 
upon entry into target cells.  Briefly, the ‘B’ domain interacts with carbohydrate 
receptors on the cell surface and the whole toxin is taken up into endosomes by 
receptor-mediated endocytosis.  The toxin undergoes conformational changes 
upon the decreasing pH in the endosome.  The ‘D’ domain forms a pore in the 
endosomal membrane allowing the translocation of the ‘C’ domain and ‘A’ 
domain into the cytosol.  The ‘C’ domain then interacts with inositol 
hexakisphosphate (InsP6), which leads to autocatalytic cleavage releasing the 
enzymatically active ‘A’ domain into the cytosol.  The activated ‘A’ domain 
catalyses the transfer of cellular uridine diphosphate glucose (UDP-Glc) to the 
Thr-37 residue of Rho GTPases.  This disrupts the interaction with effector 
molecules leading to disorder in the cytoskeleton and cell death. 
 
Figure 2.1.1a The ABCD domain organisation of Toxin A.  The multi-modular 
arrangement of Toxin A is shown with the enzymatic glucosylating domain (‘A’ 
domain) in blue, the cysteine protease domain (‘C’ domain) in green, the 
hydrophobic pore forming domain (‘D’ domain) in magenta and the binding domain 
(‘B’ domain) in purple.   
! ! ! ! 
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 The three-dimensional structures of full length Toxin A and Toxin B are 
yet to be elucidated.  However, three of the four domains are structurally 
characterised (domains ‘A’, ‘B’ and ‘C’), but the ‘D’ domain is still poorly 
understood.  The aim was to crystallise the full length Toxin A and use X-ray 
crystallography to solve the structure.   !
Crystallisation 
 
Protein crystals are highly ordered lattices made up of non-covalently 
bound protein molecules.  As proteins tend to be irregular in shape, they do not 
make good ‘building blocks’ and so packing of proteins into lattices is a delicate 
process that is sensitive to many environmental factors, hence why crystallisation 


















When the correct conditions are met for protein crystallisation, the soluble 
protein undergoes controlled precipitation to form ordered crystals.  The solubility 
of the protein is dependent on a number of factors, which include the 
Figure 2.1.1b- Critical nuclei formation.  Proteins must overcome an energy barrier 
to form crystals.  Once the protein reaches the high-energy intermediate critical 
nuclei stage, crystals may grow (Bergfors, 2009).   
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concentration of protein, the pH, the temperature and the concentration of any 
other additives such as salts or precipitants.  
 
In order for a protein to crystallise it must overcome an energy barrier and 
enter a supersaturated state without precipitating completely, see Figure 2.1.1b.  
A schematic diagram to represent the relationship between concentration of 
protein and concentration of crystallising agent can be seen in Figure 2.1.1c 
(McPherson, 1989) . To obtain well ordered, diffraction quality crystals, the 
mechanism by which the protein enters a supersaturated state must be well 
controlled (Arakawa and Timasheff, 1985; Boistelle and Astier, 1988; Boistelle, 
1986).  A supersaturation state eventually gives rise to the formation of critical 
nuclei, which in some cases can seed crystal growth. 
 
Traditionally techniques such as batch crystallisation and equilibrium 
dialysis were used for protein crystallisation, however the vapour diffusion 
method is now favoured.  The protein and crystallising agent are mixed together, 
usually in a 1:1 ratio, in a small volume and are equilibrated against a large 
volume of the crystallising agent.  Initially the droplet containing protein and 
Figure 2.1.1c- Protein supersaturation curve.  Crystallisation occurs in the 
nucleation zone under supersaturation conditions.  However, protein can 
precipitate out of solution if this supersaturation is too high.  
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crystallising agent will have an insufficient concentration of precipitant to 
stimulate nucleation, but as vapour diffuses from the droplet to the reservoir, the 
concentration of precipitant gradually increases, leading to controlled movement 
from the metastable phase to nucleation.  If this process happens too rapidly, 
precipitation of protein can occur, or alternatively if the crystallising agent 
conditions are not appropriate for that protein specifically, crystals will not grow 
(Blundell and Johnson, 1976). 
 
There are two commonly used vapour diffusion techniques; hanging drop, 
where the droplet is suspended over the reservoir solution, and sitting drop, 
where the droplet sits in a well in close range to the reservoir solution, Figure 
2.1.1d (Feigelson, 1988).          
 
There are two distinct phases of crystallisation, the first is the preliminary 
screening of conditions required for crystal growth, and the second is 
optimisation of these conditions to improve crystal size and quality.  Once initial 
hits have been observed in the preliminary screening, these conditions can be 
optimised in attempts to improve the crystal quality.  The standard technique of 
optimising conditions includes altering temperature, buffer pH, and varying salt or 
precipitant concentrations.  In some cases, the crystals either cannot be 
reproduced or appear with the same morphology, showing no improvements.  In 
such cases, various seeding techniques can be used, three of which will be 
discussed here.  All seeding techniques share the same general principle; the 
seed provides the template and instigates the assembly of the protein molecules 
Figure 2.1.1d- Vapour diffusion methods.  Hanging drop and sitting drop vapour 
diffusion methods are displayed, showing direction of diffusion. 
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to form crystals with the same characteristics as the crystal from which the seed 
originated. 
 
Streak seeding:  A probe, usually a cat’s whisker, is used to touch an 
existing crystal to dislodge seeds from it.  These seeds are then transferred into a 
pre-equilibrated droplet containing the same conditions the seed was taken from, 
by rapidly running the whisker in a line through the drop.  This method should 
provide seed nucleated crystal growth along the line in the drop. 
 
Microseeding: In this method, pre-existing crystals are crushed to create a 
seed stock.  This stock is then diluted in series and re-introduced back into a pre-
equilibrated droplet.  This again should seed crystal growth. 
 
Macroseeding: A suitable crystal of good morphology and free of defects 
is removed from a well and is washed repeatedly in stabilising solution.  The 
crystal is then transferred to a pre-equilibrated drop where in this case the crystal 
is expected to grow in size rather than stimulate new crystal growth.          
 
 
The aim of this subchapter (Chapter 2.1) was to use X-ray 
crystallography to solve the structure of the full-length Toxin A.!!!!!!!!!!!!!!!!
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2.1.2 Materials and Methods 
Purification 
 
 Pure Toxin A was kindly provided by Dr Clifford Shone, Public Health 
England (PHE).  To ensure > 95% purity for crystallisation, a final cleaning step 
was performed.  Toxin A aliquots were thawed on ice, centrifuged at 13,000 rpm 
to remove any precipitate and passed through a gel-filtration column; superdex-
200 10/300 GL (GE Healthcare), pre-equilibrated with Toxin A buffer (50 mM 
Tris-HCl pH 7.5 and 150 mM NaCl).  Collected fractions were analysed using 4-
16 % Bis-Tris sodium-dodecyl-sulphate polyacrylamide-gel electrophoresis (SDS-
PAGE) and those fractions containing pure Toxin A were pooled and 
concentrated to 10 mg/ml using 30 kDa cut-off concentrator tubes (Amicon ® 
Ultra, Millipore).  The final purity of concentrated Toxin A was analysed by 4-16 






 A pre-crystallisation test (PCT) was carried out to determine the optimum 
protein concentration for crystallisation.  Reagents displayed in Table 2.1.2a were 
made in house following the PCT guide (Hampton Research).  A 4-well 
crystallisation plate was set up using the four reagents described in Table 2.1.2a.  
The PCT was set up using the hanging drop vapour diffusion method with a drop 
size of 1:1 µl ratio of protein to reservoir.  The PCT plate was incubated at 16 °C 
for 30 min before being analysed using a light microscope.  If the concentration of 
the protein was deemed suitable for crystallisation using the PCT guide, then the 
preliminary screens were performed.  Preliminary screens were performed with 
the Phoenix Liquid Handling System (Art Robbins Instruments) using the sitting 
drop method with a ratio of 0.3:0.3 µl protein to reservoir ratio.  Chemicals and 








It was established that the concentration range 4-10 mg/ml was suitable 
for crystallisation using the PCT.  Therefore, the following 96-well preliminary 
screens were performed with protein concentrations 4 mg/ml, 8 mg/ml and 10 
mg/ml: Clear Strategy Screen I HT-96, Clear Strategy Screen II HT-96, JCSG-
plus HT-96, Heavy + Light twin pack HT-96, Morpheus HT-96, MIDAS HT-96, 
MemGold HT-96, PGA screen HT-96, ProPlex HT-96, PACT premier HT-96, 
Stura Footprint Combination screen HT-96, and finally Structure screen I + II HT-
96 (Molecular Dimensions).  The preliminary screens performed were all 
incubated at 16 °C, and monitored initially after 24 hours followed by fortnightly 
thereafter. 
 
Optimisation of Preliminary Hits 
 
 After observation of any crystal hits from the above preliminary screens, 
the corresponding crystallisation conditions were further tested to optimise crystal 
growth.  Optimisations were performed on 24-well plates using either the hanging 
drop or sitting drop method, with a reservoir volume of either 0.5 ml or 1.0 ml.  As 
discussed previously in Chapter 2.1.1, the crystallisation screens normally vary in 
buffer type and pH, salt type and concentration, and precipitant type and 
concentration.  These various concoctions have been shown to stimulate or 
contribute to the growth of crystals.  Temperature, protein concentration and 
crystallisation techniques are also known to affect crystal growth.   
 
Reagent 1 0.1 M Tris-HCl pH 8.5, 2.0 M Ammonium sulfate 
Reagent 2 0.1 M Tris-HCl pH 8.5, 1.0 M Ammonium sulfate 
Reagent 3 
0.1 M Tris-HCl pH 8.5, 0.2 M Magnesium chloride hexahydrate 
and 30 % w/v Polyethylene glycol 4,000 
Reagent 4 
0.1 M Tris-HCl pH 8.5, 0.2 M Magnesium chloride hexahydrate 
and 15 % w/v Polyethylene glycol 4,000 
Table 2.1.2a- Pre-crystallisation screen reagents used in test. 
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 Initial crystallisation hits may often be too small, poorly diffracting or the 
crystals may dissolve easily, and thus quite often the initial crystallisation 
condition may require optimisation.  Details on optimisation techniques have 
been discussed previously in Chapter 2.1.1, and further details on the specific 
crystallisation conditions will be discussed in the results section Chapter 2.1.3.       
 
X-ray Diffraction Data Collection 
 
 Upon observation of Toxin A crystal hits, the conditions in which crystals 
were grown were examined to determine whether or not crystals should be 
treated with cryoprotectant.  This will be discussed in the following subchapters 
where relevant.  Crystals were then mounted in LithoLoops (Hampton Research), 
rapid frozen in liquid nitrogen and taken to Diamond Light Source to test for signs 
of diffraction.  During preliminary testing of crystals the LithoLoops were mounted 
on the goniometer and three images were taken at rotation angles 45 ˚ apart with 
1 second exposure.  Further details on crystal treatments and data collection will 



















Purification of Toxin A  
Gel-Filtration of Toxin A 
  
 Nearly pure Toxin A was provided by PHE, however a final polishing step 
of gel-filtration was performed using a superdex-200 10/300 GL (GE Healthcare).  
Fractions of 500 µl were collected for the duration of the run and were analysed 
by 4-16 % Bis-Tris SDS-PAGE.  As displayed in the chromatogram profile, Figure 
2.1.3a, there is a sharp peak between approximately 8-12 ml (fraction A13-B11) 
and a small contaminant peak at 14.5 ml (fraction B6).  When comparing this 
chromatogram profile with that of the calibration profile, it appears that Toxin A is 
eluted at a point at which is expected for proteins of approximately 600 kDa.  This 
could suggest that Toxin A exists as a dimer in solution, or that the superdex-200 
10/300 GL is unable to resolve high molecular weight proteins. 
Figure 2.1.3a- An example of a Toxin A gel-filtration chromatogram using a 
superdex-200 10/300 GL column.  Fractions A13-B11 contained pure Toxin A.  The 




SDS-PAGE Analysis of Purity 
 
 
 The purity of Toxin A was assessed using 4-16 % Bis-Tris SDS-PAGE, 
which was performed at 200 V for 1 hr.  The fractions A13-B11 were pooled, 
concentrated and loaded onto the gel, where the final pure Toxin A can be seen 












Crystallisation of Toxin A 
Preliminary Hits 
 
Preliminary screens for Toxin A were set up as discussed in Chapter 
2.1.2, with a range of concentrations: 4 mg/ml, 8 mg/ml and 10 mg/ml.  Tiny 
cube-like microcrystals were observed in two of the primary 96-well screens: two 
wells from the PGA HT-96 screen contained crystals in addition to two wells from 
the MemGold HT-96 screen, displayed in Figure 2.1.3.c.  The crystals observed 
in the MemGold HT-96 and PGA HT-96 crystallisation screens were all small and 
cube-like.  Their overall morphologies were similar but they differed quite 
Figure 2.1.3.b- 4-16% Bis-Tris SDS-PAGE gel picture.  The pre-stained protein 
ladder (SeeBlue® Invitrogen) is visible in lane 1, followed by the pure Toxin A in 
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significantly in size, although they were all considered to be quite small at < 50 
microns.  However, it is clear from the pictures displayed in Figure 2.1.3c that the 
crystals in well D looked most promising.    


























As discussed in Chapter 2.1.2 under ‘Optimisation of preliminary hits`, the 
crystallisation reservoir commonly contains a buffer, salt and precipitant.  The 
crystallisation hits are shown in the above figure with the corresponding 
crystallisation conditions displayed in Table 2.1.3a.  It is clear from the table that 
the most common features amongst the conditions are the presence of sodium 




Figure 2.1.3c Preliminary crystallisation hits of Toxin A.  Crystal hits were noted in 
the above four wells on the following 96-well plates: A and B: MemGold HT-96, C 





At least two crystals from each well from the initial hits were mounted in 
LithoLoops (Hampton Research) and taken to Diamond Light Source to test for 
signs of diffraction.  No additional cryoprotectant was added due to the presence 
of PEG in the crystallisation conditions.  For hits A and C from Figure 2.1.3c, 
mesh LithoLoops were used to ensure the crystals were scooped out of the wells 
successfully.   
 
One at a time, the LithoLoops containing crystals were mounted on the 
goniometer and were rotated at 45 ˚ angles whilst being exposed to a beam of X-






No diffraction was observed for any of the mounted crystals from the wells 
pictured in Figure 2.1.3c.  If the crystals had been salt we would have observed 
the characteristic large diffraction spots that are usually observed for salt crystals.  












0.05 M magnesium acetate 
0.05 M sodium acetate pH 5.0 







0.05 M sodium chloride 
0.1 M sodium citrate pH 5.5 





PGA HT-96 E10 
0.1 M ammonium sulphate 
0.3 M sodium formate 
0.1 M sodium cacodylate pH 6.5 
3% PGA-LM 





PGA HT-96 H6 
0.1 M ammonium sulphate 
0.3 M sodium formate 
0.1 M Tris pH 7.8 
3% PGA-LM 
20 % PEG 550 MME 
Table 2.1.3a Crystallisation conditions for preliminary hits.   Crystallisation 




protein, rather than salt, but that the crystallisation condition needs further 
optimisation for diffraction studies.   
Optimisation of Crystal Quality 
 
 Since the crystals from the preliminary hits showed no signs of diffraction, 
it was clear that the crystallisation conditions needed optimising.  The attempts 






The stock solutions displayed in Table 2.1.3b were filtered using 0.4 µM 
pore size, 0.33 mm sterile filters (Millex) prior to use in crystallisation 
optimisation.  The first round of optimisations were set up on a 24-well plate, at 
Screen Stock Solution Concentration Range Trialled 
MemGold HT-96 D2 
0.05 M magnesium acetate 0.05 M 
0.05 M sodium acetate pH 5.0 0.05 M 
28% PEG 400 0-30% 
MemGold HT-96 G9 
0.05 M sodium chloride 0.05 M 
0.1 M sodium citrate pH 5.5 0.1 M 
26% PEG 400 0-30% 
PGA HT-96 E10 
0.1 M ammonium sulphate 0.1 M 
0.3 M sodium formate 0.3 M 
0.1 M sodium cacodylate pH 6.5 0.1 M 
3% PGA-LM 0-8 % 
20 % PEG 550 MME 0-25 % 
PGA HT-96 H6 
0.1 M ammonium sulphate 0-0.3 M 
0.3 M sodium formate 0-0.5 M 
0.1 M Tris pH 7.8 0.1 M 
3% PGA-LM 0-8 % 
20 % PEG 550 MME 0-25 % 
Table 2.1.3b Crystallisation conditions and optimisations.  The crystal conditions 
are displayed in addition to the variations trialled in attempts to optimise the 
preliminary hits that are displayed in Figure 2.1.3c.  
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concentration 4 mg/ml, with 1 ml reservoir volumes, 2 µl: 2 µl protein to reservoir 
drop size ratio, and were performed with the hanging drop method (see Chapter 
2.1.1 for details on hanging drop methods).  The optimisation plates were set up 
at room temperature but then incubated at 16 °C.  The plates were checked after 
24 hours and then weekly thereafter.   
 
No crystals were observed on either of the two MemGold HT-96 
optimisation plates, nor the PGA HT-96 E10 plate.  A small number of cube like 
crystals were observed from the PGA HT-96 H6 optimisation plate, in the original 
crystallisation condition, however a number of crystals were also noted in wells 
containing a reduced sodium formate concentration of 0.2 M, see Figure 2.1.3d.  
The precipitant concentration should be kept constant with the original 
crystallisation condition as no crystals were observed where these concentrations 

















Using the same method as described for the initial crystallisation hits, 
crystals from each well of the optimisation hits were mounted in mesh LithoLoops 
(Hampton Research) and taken to Diamond Light Source to test for signs of 
diffraction.  One at a time, the mesh LithoLoops containing crystals were 
mounted on the goniometer and were rotated whilst being exposed to a beam of 
X-rays.  No diffraction was observed for any of the mounted crystals. 
Figure 2.1.3d- Crystals of Toxin A from optimisation trials.  A: Crystals grown in 
original PGA HT-96 H6 condition on optimisation plate.  B: crystals grown in 




As the ‘optimised’ crystals showed no signs of diffraction, seeding 
techniques were employed using the crystals displayed in Figure 2.1.3d.   
 
 
1. Initially macroseeding was attempted, whereby crystals from the PGA H6 
optimisation plate were transferred into fresh drops on a new 24-well 
plate, containing the exact same reservoir condition and protein 
concentration that had been pre-equilibrated for 5 hours prior to seeding.  
Plates were incubated at 16 °C and checked after 24 hours and then 
weekly thereafter.  After two months the macroseeded crystals showed no 
signs of improvement in terms of size or diffraction.   
 
2. Microseeding was also attempted, whereby the 4 µl drop containing the 
protein crystals was resuspended in 10 µl of reservoir.  The crystals were 
crushed using vortexing and diluted 10-fold, 100-fold, 1000-fold and 
10,000-fold.  A fresh 24-well plate was set up using the exact PGA H6 
crystallisation condition including, drop size, protein concentration and 
reservoir volume.  The dilution series of blended crystals (seeds) were 
then reintroduced into the pre-equilibrated 24-well plate; 1 µl of each of 
the diluted samples were added to the 4 µl drops on the 24-well plate.  
Plates were then incubated at 16 °C and checked after 24 hours and then 
weekly thereafter.  No signs of crystal growth were observed, even after 3 
months.      
 
3. Finally, streak seeding was employed, whereby a cat’s whisker pre-
soaked in the PGA H6 reservoir was dipped into the drop containing 
crystals and was moved around in order to make contact with the crystals.  
As with the other seeding techniques, a fresh 24-well plate of PGA H6 
crystallisation conditions was prepared in advance with the corresponding 
protein concentration and drop size.  The cat’s whisker, carrying crystal 
seeds, was then immersed into a fresh drop in a straight line (streak).  
Plates were incubated at 16 °C and checked after 24 hours.  Crystals 
were observed after 24 hours, forming a line across the centre of the 




The crystals grown from the streak-seeded plate showed a slightly different 
morphology from those previously observed, with a more elongated shape.  
Crystals shown in Figure 2.1.3e were mounted in mesh LithoLoops and were 
exposed to a beam of X-rays at Diamond Light Source.  No diffraction was 






As there had been no success up until this point at improving crystal quality, 
the preliminary screens were repeated using a slightly different approach.  Toxin 
A was exchanged into different buffers and the preliminary screens were 
repeated.  It was decided that if the buffer type was varied along with pH, this 
would extend the number of different conditions the protein would be exposed to. 
Figure 2.1.3e- Streak seed for Toxin A.  Crystals of a slightly different morphology 
grew along the line that was seeded using a cat’s whisker.  The scale bar 
represents 200 µm. 
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Buffer Exchange of Toxin A 
   
In order to maximise the chances of crystal growth in the preliminary 
screens, Toxin A, supplied by PHE was buffer exchanged into various other pH 
buffers.  Buffer exchanges were performed on a superdex-200 10/300 GL column 
(GE Healthcare).  The following buffers were chosen based on their pH range: 
 
1. 50 mM MES pH 6.0 and 150 mM NaCl (Figure 2.1.3f-A) 
2. 50 mM HEPES pH 7.0 and 150 mM NaCl (Figure 2.1.3f-B) 
3. 50 mM Bicine pH 8.0 and 150 mM NaCl (Figure 2.1.3f-C) 
  
The buffer exchange chromatograms displayed in Figure 2.1.3f show 
similar size exclusion profiles to the original pH 7.5 buffer profile.  The protein 
elutes from the gel-filtration column at fraction A13, which is at 9 ml, and is 
consistent throughout all of the different pH buffers.  As discussed earlier, 
according to the standard proteins calibration profile, Toxin A is eluting at a size 
twice of that to be expected.  This is apparent with the entire range of buffers 
used; again suggesting Toxin A exists as a dimer.   
Analysis of Buffer Exchanges using SDS-PAGE 
  
Fraction B14 from each of the buffer exchange chromatograms were 
treated with SDS-PAGE reduced loading dye and were analysed by 8 % Tris-
Glycine SDS-PAGE, which was performed at 200 V for 1 hour, see Figure 2.1.3g. 
 
As shown in the SDS-PAGE stained gel picture, Toxin A appears in both 
monomeric and oligomeric forms.  Although there are limitations when using 8% 
SDS-PAGE to analyse the size of the toxin, as it is a large macromolecule, it is 
clear that there is monomeric toxin visible on the gel and an upper band, of 
greater molecular mass.  The gel-filtration chromatogram profile indicates that the 
protein is eluting at a point where the control protein of 600 kDa elutes, therefore 












































Figure 2.1.3f- Gel-filtration chromatogram profiles for buffer exchanges.  For all 
chromatograms, the blue line represents absorbance at 280nm and the brown line 
represents conductivity.  A: Buffer exchange into 50 mM MES pH 6.0 and 150 mM NaCl.  
B: Buffer exchange into 50 mM HEPES pH 7.0 and 150 mM NaCl.  C: Buffer exchange into 
50 mM Bicine pH 8.0 and 150 mM NaCl 
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The following 96-well preliminary screens were performed for Toxin A in 
the three different buffers at protein concentrations 4 mg/ml, on intelli 3-well 
plates (Molecular Dimensions): Clear Strategy Screen I HT-96, Clear Strategy 
Screen II HT-96, JCSG-plus HT-96, Heavy + Light twin pack HT-96, Morpheus 
HT-96, MIDAS HT-96, MemGold HT-96, PGA screen HT-96, ProPlex HT-96, 
PACT premier HT-96, Stura Footprint Combination screen HT-96, and finally 
Structure screen I + II HT-96 (All screens purchased from Molecular 
Dimensions).  The crystallisation screens were all incubated at 16 °C, and 














Crystallisation hits were observed in the PGA HT-96 screen, well position 
H6 for pH 6.0 and pH 7.0, which as discussed earlier, was a hit for the pH 7.5 
preliminary screens, see Figure 2.1.3h.  The crystals have a beautiful elongated 
hexagonal-like morphology.  There were no other hits observed for any other 
screens.  It is my opinion that Toxin A is reluctant to crystallise perhaps due to 
the hydrophobic nature of approximately 50 % of the molecule.  It appears that 
PGA HT-96 H6 is certainly the only condition in which this protein crystallises.  
These crystals were again tested for diffraction at Diamond Light Source, but as 
with previous crystals, no diffraction was observed.      
 
 
Figure 2.1.3g- 8% polyacrylamide Tris-Glycine SDS-PAGE displaying Toxin A in 
four different buffers.  At buffer pH 6.0, it appears that Toxin A may be in it’s 
dimeric form whereas in pH 7.0 and more so in pH 8.0 Toxin A is in both 














After buffer exchanging Toxin A into the alternative pH buffers, and 
repeating the preliminary crystallisation screens, further attempts were directly 
focused around the PGA HT-96 H6 condition.  In previous optimisation attempts, 
extensive phase separation was noted in all of the drops that were set up by 
hand.  Therefore, 96-well plates were set up with the PGA HT-96 H6 
crystallisation solution, using a Phoenix Liquid Handling System.  The trials were 
set up on intelli 3-well crystallisation plates for each of the different pH solutions, 
at 4 mg/ml, 8 mg/ml and 10 mg/ml, using the sitting drop method with a ratio of 
0.3:0.3 µl protein to reservoir ratio.  The plates were then incubated at 16 °C, and 
monitored for crystal growth after 24 hours and weekly thereafter.   
 
Diffraction of Toxin A Crystals 
Early Signs of Diffraction 
 
 After 3 months, there were three large crystals observed in separate wells 
on the intelli 3-well plate, see Figure 2.1.3i.  Protein in buffer 50 mM Tris-HCl pH 
7.5 and 150 mM NaCl, formed crystals in PGA HT-96 H6 at concentration 8 
mg/ml, and showed improved crystal morphology from previously grown crystals.  
These crystals have more defined edges and are elongated hexagonal in shape.  
Figure 2.1.3h- Toxin A crystals grown in PGA HT-96 H6 crystallisation condition.  A: 
Toxin A crystals from buffer 50 mM MES pH 6.0 and 150 mM NaCl. B: Toxin A 
crystals from buffer 50 mM HEPES pH 7.0 and 150 mM NaCl.  The scale bar 




A cross-sectional view through the crystal reveals a perfect hexagonal shape, 
see Figure 2.1.3i-C.  The unusual aspect of this protein is that the crystals do not 
grow consistently.  Out of ninety-six wells of identical crystallisation conditions, 
only three wells on the plate contained crystals.   
 
Crystals A and B shown in Figure 2.1.3i were individually mounted into 
LithoLoops (Hampton Research) and taken to Diamond Light Source to test for 
signs of diffraction.  As crystals have shown no diffraction in the past, it was 
assumed that the protein molecules are not tightly packed, leading to the lack of 
diffraction.  Therefore crystal C from Figure 2.1.3i was treated with a cross-linking 
agent, glutaraldehyde, which in theory should stabilise any interactions within the 
protein crystal.  The reservoir for the chosen crystal was poisoned with 2 % 
glutaraldehyde and was resealed for 5 min.  The crystal was then mounted into a 
LithoLoop (Hampton Research) and taken to Diamond Light Source to test the 
effect of glutaraldehyde on diffraction.  One at a time, the LithoLoops containing 
crystals were mounted on a goniometer and were rotated at 45 ˚ angles whilst 
being exposed to a beam of X-rays.  Crystals A and B from Figure 2.1.3i showed 
no signs of diffraction, but the hexagonal crystal, treated with glutaraldehyde 
showed the first diffraction spots ever detected for Toxin A.  The crystal only 
diffracted up to a resolution of 25 Å, see Figure 2.1.3j, but it is a major step 
forward towards structure determination for Toxin A using X-ray crystallography. 
 
 Unfortunately, shortly after exposure to the beam, the crystal died and no 
longer diffracted, therefore a dataset could not be collected. 
Figure 2.1.3i- Crystals of Toxin A in buffer 50 mM Tris-HCl pH 7.5 and 150 mM NaCl, 
grown in crystallisation condition PGA HT-96 H6.  Crystals show improved crystal 
morphology to previously grown crystals at lower protein concentration.  The scale 
bar represents 100 µm.   
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Figure 2.1.3j- First diffraction spots observed for Toxin A.  A: Image of glutaraldehyde treated crystal in LithLoop during exposure to beam.  Red circle 
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Improved Diffraction and Dataset for Toxin A 
 
 After the first diffraction spots were observed for the PGA H6 crystals 
treated with glutaraldehyde, multiple plates were set up using the PGA H6 
crystallisation condition (purchased from Molecular Dimensions) on both 96-well 
plates and 24-well plates.  The plates were set up at 8 mg/ml and 10 mg/ml, at 4 
˚C, 16 ˚C and 21 ˚C.  In addition, a 3:1 molar ratio of UDP-glucose to protein was 
used and a 3:1 molar ratio of manganese chloride to protein.  This is because the 
glucosyltransferase ‘A’ domain of Toxin A binds UDP-glucose in the presence of 
divalent Mn2+ cations.  Previous studies have shown the ‘A’ domain of Toxin A will 
only crystallise in the presence of both UDP-glucose and manganese (D’Urzo et 
al., 2012).  Therefore, both were added to the protein prior to crystallisation trials 
to determine whether or not they affect crystal growth and/or crystal quality.  
Within 1 week, crystals were observed in one well on a 96-well plate at 21˚C, with 
protein at 10 mg/ml containing UDP-glucose and manganese, see Figure 2.1.3k, 
which is the fastest crystal growth noted. 
 















 The new crystals share a similar morphology to the previous diffracting 
crystals, with elongated shapes, and when viewed down one angle look perfectly 
Figure 2.1.3k- Crystals of Toxin A grown at 10 mg/ml, 21˚C, with protein buffer 
containing UDP-glucose and manganese chloride.  All crystals shown are from 
the same drop.  The scale bar represents 100 µm.   
C B A 
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hexagonal.  In order to improve diffraction, a number of methods were employed:  
Firstly crystal A from Figure 2.1.3k was washed and transferred into a new well 
containing a 10 % increase in PEG concentration, in the hope this would provide 
some cryo-protection and crystal stabilization, however the crystal dissolved.  
Secondly, the hexagonal shaped crystal in picture B was mounted directly in a 
LithoLoop with no alterations performed.  Finally, the remaining crystal in picture 
B and that in picture C were treated with 2 % glutaraldehyde (in the reservoir).  
Crystal B was mounted in a loop and rapidly frozen after 5 min, and crystal C was 




Rsymm = ΣhΣi[|Ii(h) - <I(h)>|/ΣhΣiIi(h)] where Ii is the ith measurement, and <I(h)> is the 
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glutaraldehyde 
treatment (dataset 2) 




Space Group P3121 C2 P3121 
Cell 
Dimensions 
a=400Å b=400 Å  
c=430Å 
α=90° β=90° γ=120° 
a=714Å  b=425Å  
c=443Å 
α=90° β=90.05° γ=90° 
a=400Å  b=400 Å 
c=433Å 
α=90° β=90° γ=120° 
Resolution 
Range 69.05-10.72 Å 207.71-13.23 Å 79.97-11.34 Å 
Rsymm 0.20 0.22 0.18 
I/σI (outer 
shell) 4.9 (2.1) 2.8 (1.9) 4.5 (2.3) 
Completeness 
(outer shell) 82.1 (84.3)% 51.9 (53.8)% 90.5 (93.0)% 
Total Number 
of Reflections 45812 28440 39750 
Redundancy 3.2 1.8 2.9 
Table 2.1.3c- Data collection statistics for Toxin A.  Displayed in the table are the data 
statistics for the three data sets collected for crystals displayed in Figure 2.1.3k.  Data 
was processed using XDS and table statistics were generated by POINTLESS (Evans, 
2006; Kabsch, 2010).   
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The crystals were taken to Diamond Light Source and the usual test 
images were obtained at 45 ˚ intervals at the i04 beamline.  All three crystals 
showed improved diffraction between 10.5-11 Å resolution, see Figure 2.1.3k.  
For each crystal data were collected at wavelength (λ) 0.9795 Å, 80 % 
transmission, with distance from the detector set to 1 m.  At each oscillation of 1˚, 
the crystals were exposed for 10 s and for each crystal 50 images were collected.  
The data were auto processed and indexed using XDS to provide cell dimensions 
and were analysed using POINTLESS (Evans, 2006; Kabsch, 2010).  The data 
were then scaled using SCALA (Evans, 2006).  Table 2.1.3c displays the data 

























Figure 2.1.3l- Improved Toxin A diffraction pattern displaying well ordered lunes, 
with spots observed up to 10 Å.   
! ! Chapter!2.1! ! ! ! ! ! Chapter!4.1! ! ! ! ! ! ! ! ! !!
! 54!
Although an ambitious task, attempts were made at determination of the 
three-dimensional structure of Toxin A using both datasets 1 and 3.  Intensive 
rounds of molecular replacement were performed using both Phaser and Molrep 
from the CCP4 Program Suite (McCoy et al., 2007; Vagin and Teplyakov, 1997).  
The various fragments of Toxin A and Toxin B were used as search models for 
molecular replacement including: 2BVL, 4DMW, 3HO6, 3PEE, 2G7C and 2QJ6 
(PDB codes) (D’Urzo et al., 2012; Pruitt et al., 2009; Reinert et al., 2005; Shen et 
al., 2011).  Initially, the structures of the ‘A’ domain, ‘B’ domain and ‘C’ domain of 
Toxin A (PDB 4DMW, 2QJ6 and 3HO6 respectively) were input at the same time 
to provide the optimal amount of scattering data possible for molecular 
replacement.  While the programs provided solutions, for a potential ‘A’ domain, 
the statistics were poor and there were multiple clashes between molecules.  As 
expected the electron density map was of poor quality due to low-resolution data. 
After rigid body and restrained body refinement using Refmac (Murshudov et al., 
1997), the density showed no improvement.  As an alternative method, multiple 
combinations of all of the known LCT domain structures were input into the 
molecular replacement software, and various other input factors were varied 
including ‘number of molecules to search for’.  The input models were also all 
used individually, searching for 1 molecule and 12 molecules separately, but 
again with no success.    
 
There are various analytical statistics that can be performed even though 
a structure solution was not achieved.  The Matthews Coefficient and solvent 
content were calculated from the unit cell and the molecular weight of the 




Dataset Number of molecules Probability Vm (Å
3/Da) Solvent (%) 
1 12 0.08 2.7 54.2 
2 48 0.07 2.3 45.9 
3 12 0.15 2.7 54.5 
Table 2.1.3d- Matthew’s coefficient and solvent content for the 3 datasets.  
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Given the size of the cell dimensions its not surprising that a large number of 
molecules in the asymmetric unit is predicted.  However, as there were two 
datasets collected that were consistent with each other in terms of cell 
dimensions and space group (dataset 1 and 3), we can expect there to be 12 
molecules in the asymmetric unit, or potentially 6 Toxin A dimers. 
 
 It may be ambitious to solve the structure of Toxin A at this level of 
resolution, especially due to its size and the lack of a model input for up to half of 
the protein.  The crystallographic structures used as search models make up very 
small portions of the overall toxin.  Therefore, higher to medium resolution data 








 Toxin A is a member of the Large Clostridial Toxin family of proteins, as it 
is produced by C. difficile and has a mass of 308 kDa.  The ABCD model 
accurately describes the domain organisation of Toxin A, see Figure 2.1.1a for 
details of the arrangement: the enzymatic domain (A), the binding domain (B), 
the cysteine protease domain (C) and the hydrophobic domain (D) (Jank and 
Aktories, 2008).  Toxin A glucosylates Rho-GTPases which leads to cell rounding 
and cell death, as discussed in detail in Chapter 1.2.  At present there is no high-
resolution structure of the full length Toxin A, potentially because it is a difficult 
protein to work with, due to its size and nature.  However, much effort has been 
spent solving the structures of the individual domains.          
Electron Microscopy Data for Toxin A 
 
Due to the lack of crystallographic data for Toxin A and Toxin B, some 
research groups have been working on alternative techniques to gain insight into 
the structural characteristics of these toxins.  One such technique is electron 
microscopy.  Pruitt et al. have imaged both Toxin A and Toxin B using negative 
stain electron microscopy, resulting in identification of the overall shape of the 
toxins, and have extended their analysis by modelling and mapping the domains 
of Toxin A with the electron microscopy images (Pruitt et al., 2010).  The electron 
microscopy images of Toxin A reveal homogeneous particles of non-symmetrical 
shape; see Figure 2.2.1a-A, whereas with Toxin B there was more of a 
heterogeneous selection of particles (data not shown).  
 
Both Toxin A and B share structural similarities with a well-resolved 
globular head domain, a short inner tail domain and an extended long tail domain 
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(two tails in the case of Toxin B).  After averaging a large number of particles, to 
give an overall particle shape, see Figure 2.2.1a-B, a 3D reconstruction was 
performed using the random conical tilt approach with the final result displayed 
as a mesh surface in Figure 2.2.1a-C.  After imaging the individual domains by 
electron microscopy, monitoring pH effects on conformation, and using antibody 
labelling, it was concluded that the globular head domain represents the 
hydrophobic ‘D’ domain, the long extended tail represents the binding ‘B’ domain 
and the shorter tail represents the glucosyltransferase ‘A’ domain.  The cysteine 
protease ‘C’ domain could not be located.  A model of the binding ‘B’ domain was 
placed into the electron microscopy 3D map along with the crystal structures of 
the ‘A’ domain of Toxin B and the ‘C’ domain of Toxin A, to give an indication as 
to where these domains are organised in the full-length structure, see Figure 












Figure 2.2.1a- Electron microscopy images of Toxin A and the molecular modelling 
of domains in a predicted 3D model of the full length toxin.  A:  Negative stain 
electron microscopy image of Toxin A molecules, with two molecules of Toxin A 
circled.  The scale bar represents 500 Å.  B:  A representation of Toxin A created by 
averaging approximately 5000 Toxin A molecules from the electron microscopy 
images taken.  C:  A 3D reconstruction of the Toxin A molecule filtered to 25 Å 
displayed as a mesh surface, with known structural domains docked into the 
density.  These known domains include the ‘A’ domain of Toxin B, the ‘C’ domain 
from Toxin A and a model of the ‘B’ domain from Toxin A.  All images adapted and 
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Small-Angle X-ray Scattering 
 
 
Small-angle X-ray scattering (SAXS) is a technique used to determine 
low-resolution 3D structures of macromolecules in solution, see Figure 2.2.1b, 
which can provide information about the size, distribution and overall shape of 













Figure 2.2.1c displays a flow diagram illustrating the steps taken towards 
obtaining a SAXS structure starting from expression and purification of the 
protein right through to the generation of an ab initio SAXS model. 
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Figure 2.2.1b- Small-angle X-ray scattering.  Adapted from Jacques and 
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Buffer + Protein Subtract buffer 
Figure 2.2.1c- Flow diagram showing steps taken to solve low-resolution structures 
of macromolecules using small-angle X-ray scattering  
Example of a 
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The advantage of using SAXS over crystallography is that crystalline 
matter is not required, which is often a limiting step in X-ray crystallography.  A 
small sample of pure monodisperse protein is all that is required for SAXS, 
however there are limitations, the key restriction being that only low-resolution 
data is generated.   
 
SAXS works on a similar basis to X-ray crystallography in terms of 
diffraction.  An incoming X-ray beam illuminates the macromolecules in solution 
and is scattered, whilst a beam stop absorbs the direct beam.  The scattered 
radiation is recorded on a detector, see Figure 2.2.1b.   
 
After successful data collection, the data is reduced, and the solvent is 
subtracted.  Following solvent subtraction, the data is Fourier transformed to 
obtain a radial Patterson function P(r), which describes the probable frequency of 
interatomic vector lengths (r) within the protein in question (Jacques and 
Trewhella, 2010).  The P(r) profile, as seen in Figure 2.2.1c, can indicate early 
signs of the symmetry and domain structure within the protein.  This profile can 
be used to calculate the scattering intensity I(0) which can not be measured 
directly as it cannot be distinguished from the direct beam passing through the 
sample unscattered.  In addition the profile can be used to calculate the Rg, which 
is the radius of gyration, and is defined as the averaged squared distance of each 
scatterer from the particle centre of mass (Jacques and Trewhella, 2010; Putnam 
et al., 2007).  In the final steps of SAXS structure solving, ab initio algorithms are 
employed such as DAMMIN and DAMMIF (Franke and Svergun, 2009).  Unlike 
crystallography, where diffraction is only obtained from quality crystals, with 
SAXS, scattering patterns can be collected from any quality sample.  For this 
reason, it is crucial that the protein purity and monodispersity is analysed prior to 
collecting SAXS data. 
 
The SAXS structure of Toxin B was reported in 2010 which revealed four 
distinct domain boundaries, into which the structural data and model structures 
can be aligned (Albesa-Jové et al., 2010).  The 4 domains are organised as 
demonstrated in the ABCD model in Figure 2.1.1a.  The hydrophobic 'D' domain 
contains a highly solvent-exposed region that protrudes away from the core 
structure, see Figure 2.2.1d.  The SAXS data were collected at a neutral pH so 
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the low pH induced conformational change that is predicted to occur within this 
'D' domain, has not been shown in this structure.   
 
Although the SAXS structure of Toxin B and the reconstructed electron 
microscopy model of Toxin A share some structurally similar characteristics, such 
as the elongated length feature, they do differ more than anticipated.  Toxin A 
and B are homologous proteins, with the same domain organisation and 
properties, therefore some structural similarities are to be expected, but Toxin A 




























shown to enhance autocatalysis, it has been sug-
gested that the active-site cysteine is involved in a
disulfide bond that required reduction.15 Data
presented in the recent structure of the cysteine
protease domain from TcdA suggest that a disulfide
bond would involve a cysteine residue from another
domain.18 The orientation of the cysteine protease
domain in the SAXS model does not place either of
the two conserved cysteine residues (C595 and the
active-site C698) near a domain interface where an
intramolecular disulfide bridge formation would be
favored. However, our model does not discount the
formation of intermolecular disulfide bonds be-
tween two or more TcdB polypeptide chains. Such
bonds would likely be reduced under the conditions
of our SAXS experiments, which included the
addition of 1 mM dithiothreitol. Taken together, it
appears that complex and dynamic interactions
Fig. 5. SAXS shape depicting four domains in TcdB. Panels (a) and (b) show two orientations of the SAXS-derived
shape of TcdB, with the proposed boundaries for four distinct domains shown in view (a). Orientations of the crystal
structure of the N-terminal glucosyltransferase (purple) and the homology models of the cysteine protease domain (red)
and the CRR (green) within the SAXS shape are shown. Domain 3 and the region of domain 4, which are not occupied by
the homology models, are predicted to contain residues 802–1830.
1266 Three-Dimensional Model of Native TcdB
Figure 2.2.1d- SAXS structure of T xin B.  Figure adapte  from Albesa-Jové et al., 
2010.  The crystal structures of the ‘A’ domain, ‘C’ domain and ‘B’ domain are 
superimposed onto the SAXS envelope.      
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Dynamic Light Scattering     
 
 Dynamic Light Scattering (DLS) is a technique used to determine the size 














     
In order to understand the concept of using DLS to determine particle 
size, it is important to understand that particles are moving randomly in solution 
by Brownian motion.  A key feature of Brownian motion that is exploited in DLS is 
that particles of different size move in solution at different speeds, the larger the 
molecule the slower the movement in solution (Lorber et al., 2012).  The solution 
is exposed to a monochromatic coherent laser, through which the particles in 
solution scatter a small fraction of the light, the intensity of which is recorded, see 
Figure 2.2.1e.  As the particles are moving by Brownian motion, the intensity of 
scattered light detected fluctuates due to the constantly changing distance 
between particles.  This constant movement of particles causes the scattered 
light to undergo either constructive or destructive interference from the 
surrounding particles.  The measured intensity fluctuations gives some 
information about how fast the particles are moving in solution and from that the 
size can be predicted.  For example smaller particles have higher intensity 


















The size of the particle in solution (RH) is then calculated using the 
Stokes-Einstein equation: 
 
RH = kT/6πηD 
 
In the Stokes-Einstein equation, k represents the Boltzmann’s constant, T 
represents temperature, η represents the viscosity and D is the diffusion 
constant.  The Zetasizer software autocorrelates the intensities of the scattered 
light for the duration of the experiment.    In DLS, this time autocorrelation 
function of scattered light is used to determine the distribution of size across the 
particles in solution.  
 
 
The aim of this chapter was to solve the SAXS structure of Toxin A 
and cross check any results with the published low-resolution toxin data 





2.2.2 Materials and Methods !
Preparation of Toxin A for SAXS  
 
 Pure Toxin A was provided by PHE at 1 mg/ml concentration.  This 
protein was concentrated to 10 mg/ml using 30 kDa cut off concentrator tubes 
(Amicon ® Ultra, Millipore) at 4,000 xg.  The concentrated protein was then 
centrifuged at 13,000 rpm to remove any precipitated protein, and was loaded 
onto a superdex-200 gel-filtration column (GE Healthcare), as a final cleaning 
step.  It is essential for the SAXS technique that the protein is free of 
contaminants and is 100 % monodisperse, hence the final cleaning step of Toxin 
A to ensure complete removal of contaminants and heterogeneous material.  The 
fractions of the gel-filtration run were analysed by 8% Tris-glycine SDS-PAGE 
and those containing pure Toxin A were pooled and analysed by dynamic light 
scattering (DLS).        
 
Analysis of Toxin A by Dynamic Light Scattering 
 
 DLS is a technique used to detect protein aggregates in solution, the size 
of proteins, and whether or not proteins are monodisperse in solution.  DLS 
analysis was performed using a Zetasizer Nano S (Malvern Instruments) which 
uses a 4 mW He-Ne laser with wavelength (λo) = 633 nm, and a scattering angle 
of θ = 173°.  The protein sample was prepared by centrifugation at 13,000 rpm to 
remove any large particles or precipitate and was filtered through a 0.45 µm 
millex-HA filter (Millipore).  Nitrile gloves were worn to avoid fingerprints on the 
sample cuvette and to prevent contamination of the sample during handling.  A 
low volume 12 µl glass cuvette (QS 3.00 mm) was equilibrated by rinsing in the 
Toxin A buffer: 50 mM Tris-HCl pH 7.5 and 150 mM NaCl.  A 50 µl sample of 
filtered Toxin A at concentration 0.5 mg/ml was loaded into the cuvette and the 
external surfaces of the cuvette were gently wiped with soft lens cleaning tissue 
to ensure no particles were present that could lead to false readings.  The 
cuvette was placed in the sample holder and was allowed to equilibrate to 19 °C 




A series of three scans were performed and subsequent intensity 
fluctuations were recorded which contain information about the time scale 
movement of the scattering particles.  DLS results determined whether or not the 
Toxin A sample was suitable for use in SAXS data collection.              
 
SAXS Data Collection and Ab Initio Model Building 
 
Toxin A samples prepared as above were taken to Diamond Light Source 
for SAXS data collection.  Experiments were performed at the I22 beamline, at 20 
°C using the Pilatus 2M detector.  Concentrations of 0.5 mg/ml, 1 mg/ml, 2.5 
mg/ml and 5 mg/ml were used in the scattering experiments, along with four 
buffer samples.  Calibration was carried out using BSA at 5 mg/ml in 50 mM Tris-
HCl pH 7.5 as a molecular weight standard.  Data was integrated using Dream 
(SAXS software utilities at Diamond Light Source) and the subsequent data 
collected for the buffer samples was averaged and subtracted from the Toxin A 
data using PRIMUS (Konarev et al., 2003).  An indirect Fourier Transformation 
automated by GNOM was used to generate a particle distribution function P(r) of 
the samples, which in turn was used to calculate the radius of gyration (Rg) and 
the maximum particle size (Dmax) (Svergun, 1992).  Ab initio modelling was 
performed using the on-line server for DAMMIF, whereby 20 models were 
produced (Franke and Svergun, 2009).  The models were then averaged using 
DAMAVER (Volkov and Svergun, 2003).  The final averaged ab initio model was 
then visualised using PyMOL and modelling of the domains in the SAXS 
molecular envelope was performed manually using PyMOL (version 1.5.0.4, 





Preparation of Toxin A for SAXS  
 
As it is essential when using the SAXS technique that the protein is free 
of contaminants and is 100 % monodisperse, a final polishing step of Toxin A 
was performed to ensure complete removal of contaminants and heterogeneous 
material, see Figure 2.2.3a.  The fractions from the gel-filtration chromatography 
were analysed by 8% Tris-glycine SDS-PAGE and those containing pure Toxin A 




Figure 2.2.3a- Chromatogram of Toxin A size-exclusion chromatography performed 
on a superdex-200 10/300 GL column (GE Healthcare).  The blue line represents 
absorbance at 280nm and the brown line represents the conductivity.  Fractions 

























The SDS-PAGE gel picture displayed in Figure 2.2.3b shows protein 
bands of a molecular weight greater than 212 kDa.  The gel system cannot 
resolve proteins of higher molecular weights than 200 kDa, hence why the 
protein bands are right at the top of the gel.  However, it is clear that there are no 
contaminants of smaller molecular weight and that Toxin A is pure.  To further 
confirm the purity of Toxin A, and to ensure that the protein is monodisperse, 
DLS data were collected.   
 
Dynamic Light Scattering of Toxin A 
 
Fractions A15-B12 containing Toxin A from the size-exclusion 
chromatography purification step were pooled and concentrated to 0.5 mg/ml for 
use in DLS experiments.  Three DLS scans were performed consecutively at 19 
°C for Toxin A.  The Zetasizer software uses various algorithms to extract decay 
rates for a number of size classes to produce a size distribution.  
 
Figure 2.2.3c-A displays the correlation function for the collected data, 
with the red line representing the decay over time.  The decay is extended and is 
slow suggesting a large particle size.  In addition the baseline is flat indicating a 









kDa Marker A15 B15 B14 B13 B12 
Toxin A 
Figure 2.2.3b- 8 % Tris-glycine SDS-PAGE gel picture displaying fractions of the 




Figure 2.2.3c- DLS results for Toxin A.  A: The Correlation Function showing the time 
at which the correlation starts to decay, providing an indication of the mean sample 
size.  B:  The Count Rate displaying the intensity fluctuations, again providing a size 
indicator.  C:  The Intensity PSD graph, which gives the intensity of each particle 
found and the size of the particle. 
A 
 B 
  C 
! ! Chapter!2.2!!
!! 69!
Figure 2.2.3c-B displays the count rate, which represents the intensity 
fluctuations and typically the smaller the particle the larger the fluctuations as the 
particles are moving faster in solution, whereas larger particles have lower 
fluctuations, such as those displayed in the figure.  Finally, the intensity PSD 
graph displayed in Figure 2.2.3c-C provides details on the intensity of scattered 
light from each particle and the size of the corresponding particle.  The X-axis 
shows the distribution of size classes whilst the Y-axis shows the relative 
intensity of scattered light.  In this case we have a large intensity peak of about 
12.5 % between 8-50 nm in diameter and one very small peak of <1  %, which is 
considered large and is most likely due to dust particles.  
     
The Mie theory can be used to convert the fundamental size distribution 
generated from an intensity distribution to a volume distribution as shown in 
Figure 2.2.3d (Wiscombe, 1980).  Although the Mie theory assumes that the 
particles are all spherical, homogenous and the optical properties of the particles 
are known, it can be useful to examine a volume PSD graph in comparison to an 
intensity PSD graph.  The volume PSD describes the relative proportion of 
multiple components in the sample based on their mass or volume (rather than 
their scattering intensity).  From the single peak on this graph it is clear that the 
sample is monodisperse and suitable for SAXS data collection.  




   
 
The Z-Average size is also known as the cumulants mean and is defined 
as the hydrodynamic particle size.  This measurement represents the diameter of 
a sphere that has the same drag coefficient as a given particle, so the Z-Average 
size is a predicted particle size based on the movement of the standard particles 
in solution.  This estimated value is based on the theory that all of the particles 
are spherical in shape, with the Z-Average particle size diameter of 23.36 nm.  As 
1 nm = 10 Å we can predict that if Toxin A were spherical, it would have a 
diameter of approximately 234 Å.  The Polydispersity Index (PDI) is a measure of 
the width of molecular weight distributions, and is an indication of variance in the 
sample.  A PDI value of 0.2 or less is expected for monodisperse samples, 
therefore the value of 0.21 for Toxin A, is highly suggestive of monodisperse 
data.  The distribution result describes the percentage of each identified particle 
in the solution along with the estimated diameter size of each of these particles, 
corresponding to peaks on the intensity PSD graph.  Toxin A is 99.9 % 
monodisperse and is suitable for SAXS data collection, see Table 2.2.3a for 
statistics. 
 
Small-Angle X-ray Scattering of Toxin A 
Data Processing and Analysis of Scattering Data 
 
 Given the absence of structural data for the full-length Toxin A, ab initio 
modelling was performed using the program DAMMIF, whereby 20 models were 
generated and were averaged using the DAMAVER program (Franke and 
Svergun, 2009; Volkov and Svergun, 2003).   
Light Scattering Data Statistics Toxin A 
Cumulants result 
Z-Average size 23.36 d.nm 
PDI 0.210 
Distribution result 
Peak 1 (Mean/ Area) 14.39 d.nm/ 99.9 % 
Peak 2 (Mean/ Area) 4897 d.nm/ 0.1 % 
Table 2.2.3a- Dynamic Light Scattering Data Statistics 
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During the averaging, DAMAVER excluded 1 of the 20 ab initio models as 
it had a large normalized spacial discrepancy (NSD), therefore the final model is 
an average of 19 ab initio models, see Table 2.2.3b for detailed statistics.  The 
distance distribution function (P(r)) from GNOM was used to calculate the radius 
of gyration (Rg) and the maximum particle dimension (Dmax).  The discrepancy 
between experimental and ab initio data (χ2) was calculated by the program 




Scattering Data Statistics Toxin A 
P(r) Function 
Rg (Å) 89.3 
Dmax (Å) 268.0 
Structural Modelling 
Discrepancy (χ2) 1.7 




The Rg value was calculated using a Guinier plot, which is a form of 
analysis of the SAXS scattering curve at the smallest scattering angles, which 
corresponds to the upper portion of the scattering plot displayed in Figure 2.2.3e-
A.  The Rg value describes the size of the particle in terms of the root mean 
square distance from the outer edge of the particle to its centre.  The Dmax value 
is the maximum particle dimension, calculated from the P(r) curve in Figure 
2.2.3e-B.  The Dmax in this case is 268 Å, which is in the same region as the Z-
Average size from the DLS results.  The Discrepancy (χ2) value and NSD value 
are both calculated during ab initio modelling and averaging.  The χ2 value is a 
measure of how well the theoretical data fits the experimental data.  Ideally the 
value should be less than 1.5, however this value of 1.7, is still a decent result.  
The NSD is a measure of similarity between the three-dimensional points of the 
models.  NSD values above 2.0 are considered outliers and are rejected by 
DAMAVER for averaging.  An NSD value of 1.28 suggests the models 
systematically differ from one another; however it is clear that the selection of 
models all have a similar overall shape, as indicated by Figure 2.2.3f. 









































Figure 2.2.3e- SAXS scattering data.  A: Scattering curve of Toxin A, where the red 





















































Figure 2.2.3f- Selection of four of the models generated by DAMMIF.  19 of the 20 
models generated by DAMMIF were averaged using DAMAVER.  Displayed in this figure 
are 4 of the 19 models generated, which shows the similarities between the models 
(Franke and Svergun, 2009; Volkov and Svergun, 2003). !
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Ab initio Modelling of Toxin A 
 























The SAXS structure of Toxin A displayed in Figure 2.2.3g, reveals an 
overall non-symmetrical elongated shape which is thicker and ‘head-like’ at one 
end and more narrow and ‘tail-like’ at the other.  The structure is approximately 
265 Å long, and 36 Å wide at the more narrow end and 75 Å wide at the thicker 
end. 
! ! 
  75 Å !
  36 Å !
  265 Å !
90 ° !
Figure 2.2.3g- The finalised SAXS structure of Toxin A after averaging 19 
constructed ab initio models using DAMMIF and DAMAVER, displaying 
dimensions and a rotation along the X-axis of 90 °.  
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Modelling of Toxin A Domains in the SAXS Envelope 
 
The individual domains of Toxin A were placed into the SAXS envelope 
manually, where thought appropriate, using PyMOL (version 1.5.0.4, 
Schrödinger, LLC), see Figure 2.2.3b.  As it is difficult to tell from the SAXS 
envelope where to appropriately place the domains, the domain organization as 
proposed by Pruitt et al., with antibody labelling data, was used as an indicator 
























Figure 2.2.3h- Modelling of crystal structures of three of the four domains of Toxin 
A in the SAXS envelope.  The SAXS envelope is displayed as mesh, the ‘C’ domain 
of Toxin A is displayed as a green cartoon, the ‘A’ domain of Toxin A is displayed 
as a blue cartoon, and finally the ‘B’ domain of Toxin A is displayed as a purple 
cartoon.  Images rendered with PyMOL (version 1.5.0.4, Schrödinger, LLC). 





The elongated tail-like portion of the SAXS envelope is thought to be the 
binding ‘B’ domain, which potentially extends beyond the ‘A’ domain and ‘C’ 
domain.  The large hydrophobic region (‘D’ domain) may reside within the thicker 
‘head’ region of the envelope, as this is the largest portion of the envelope 
unaccounted for, and the ‘D’ domain does make up for approximately half of the 





Crystal Growth and X-ray Crystallography 
 
Toxin A is a large protein that shares similar properties to membrane 
proteins in that it has a large hydrophobic region, spanning almost 50 % of the 
whole toxin.  It has a multi-modular domain organisation with each domain 
playing a key role in cytotoxicity.  The ‘B’ domain is required for binding to target 
cell surfaces and the ‘D’ domain, which is the most hydrophobic region, is 
required for translocation of the toxin into the cytosol.  The ‘C’ domain is 
responsible for autocatalytic cleavage of the toxin, which releases the ‘A’ domain 
into the cytosol.  This ‘A’ domain holds the enzymatic activity which glucosylates 
host cell Rho GTPases causing disrupt to cellular processes including 
cytoskeleton maintenance (Davies et al., 2011).        
 
Toxin A contains a high percentage of leucine, isoleucine, phenylalanine 
and tyrosine residues, which gives the protein hydrophobic properties commonly 
seen in membrane proteins.  The majority of the hydrophobic residues are 
located in the ‘D’ domain, as this is the membrane insertion domain.  This 
hydrophobic element may be one of the reasons for the difficulties experienced 
during crystallisation.  In addition, the ‘B’ domain structure reveals a helical 
region which is thought to increase surface area for optimised binding to target 
cells (Greco et al., 2006).  This region binds carbohydrate receptors on target cell 
surfaces.  It is long, helical and may be quite flexible, which could explain why the 
protein molecules in the crystal are not packed tightly.  
 
 Although the Toxin A appeared recalcitrant to crystallisation during early 
stage crystallisation screening, eventually a crystallisation condition was obtained 
in which Toxin A crystals would grow but not consistently.  For example, if a 
crystallisation plate was set up using the sitting drop method on a 96-well plate 
containing the exact conditions in every well, crystals would grow in 
approximately 3-5 of the wells, even though all of the conditions were identical.  
However, after extensive optimisation trials crystals that diffract up to 10 Å were 




Attempts were made at solving the structure using the best 10 Å dataset 
(dataset 3), because even though the resolution is low, the data is 90.5 % 
complete and has an Rsymm of 18 %.  After extensive attempts at solving the 
structure using dataset 3 (dataset 1 and 2 were also used), as anticipated there 
was no success.  Multiple attempts were made at solving the structure using 
molecular replacement, however the combination of low-resolution data and lack 
of homology model for 50 % of the toxin is a challenging problem.  There are 
potentially up to 12 molecules in the asymmetric unit, so if the resolution of the 
crystal diffraction can be improved to at least 6 Å or higher then it may be 
feasible to solve the structure by molecular replacement.   
Future Work Towards Obtaining Crystal Structure of Toxin A   
 
In order to solve the structure of Toxin A, the diffraction quality of the 
crystals must be significantly improved.  As multiple optimisation trials have been 
performed, the next stage in this progression should be to try co-crystallising 
Toxin A with various molecules to stabilise the protein.  This could include 
carbohydrates or cell surface receptors for the ‘B’ domain or antibody fragments 
such as Fab fragments.  In addition there still are a number of crystallisation 
methods that differ from vapour diffusion that could be tested such as 
microdialysis, crystallisation under oil, sandwich drop and free interface diffusion.       
 
Low Resolution Structure of Toxin A 
 
Due to the lack of success in high-resolution structural studies for Toxin 
A, low-resolution structural techniques were employed, including dynamic light 
scattering (DLS) and small-angle X-ray scattering (SAXS).  The DLS method 
provided insight into the dispersity and approximate size distribution of Toxin A.  
The single sharp peak on the volume PSD chromatogram indicates the protein is 
monodisperse and the corresponding distribution result concluded 99.9 % 
monodispersity.  These conclusive results provide confidence that any scattering 




SAXS data collected for Toxin A were used for ab initio modelling to 
produce a low-resolution structure.  The P(r) distribution function, Rg and Dmax 
were calculated using GNOM, which provide information about the particle size 
and shape (Glatter, 1977).  The P(r) curve, displayed in Figure 2.2.3e-B provides 
an indication as to the overall shape of the molecule in solution.  A perfect bell-
shape curve would normally indicate a spherical shape, whereas the curve 
distribution observed for Toxin A indicates an elongated and multi-modular shape 
(Jacques and Trewhella, 2010).  The Rg value which describes the root mean 
square distance from the outer particle to its centre (similar to a radius) and the 
Dmax value, which is the maximum particle dimension, were calculated to be 89.3 
Å and 268.9 Å respectively.  If the molecule was perfectly spherical, the Rg 
should effectively be half of the Dmax, however in the case of Toxin A, the P(r) 
curve indicates an elongated structure hence why the values are not directly 
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Figure 2.3a- SAXS Structure of Toxin A and comparison of the SAXS structure with 
the electron microscopy reconstruction. A: Finalised SAXS structure of Toxin A 
after averaging 19 constructed ab initio models using DAMMIF and DAMAVER, 
displaying dimensions and a rotation along the X-axis of 90°.  B: 3D model structure 
of Toxin A constructed from electron micrographs, adapted and modified from 
Pruitt et al. (Pruitt et al., 2010).  C: Electron microscopy generated model of Toxin A 




DAMMIF was used to generate 20 ab initio models from the SAXS 
experimental data, which were then averaged using DAMAVER.  One of the 
models was excluded due to the large NSD value, as calculated by DAMAVER, 
therefore only 19 models were used in the final averaging step to provide a final 
ab initio SAXS structure for Toxin A, displayed in Figure 2.3a-A.  The structure is 
consistent with the statistics derived from GNOM, in that the structure is 
elongated rather than spherical, and the overall length is 265 Å, which is 
consistent with the calculated Dmax value.      
 
The SAXS statistics correlate with the DLS statistics in that the particle 
length in the SAXS structure is 265 Å and the Z-Average size particle diameter 
calculated from DLS data is 230 Å, which are fairly similar in size.  The DLS Z-
Average size particle calculation is slightly less accurate for elongated molecules, 
as it is based on globular proteins, hence the slight variation from that of the 
SAXS Dmax.     
 
One significant observation made during the purification of Toxin A at the 
gel-filtration cleaning step was that the protein eluted at a point which is to be 
expected for a protein of approximately 600 kDa in size, which would indicate 
that Toxin A is dimeric, as discussed in section 2.1.3.  However, both the DLS 
results and the final SAXS structure indicate that Toxin A is in fact monomeric as 
the size distribution directly corresponds to the size observed for the low-
resolution SAXS structure.  This could be due to a concentration effect, as the 
size-exclusion step is performed when Toxin A is highly concentrated, where as 
DLS was performed at 0.5 mg/ml and SAXS data was collected at a low 
concentration range.  This could be the reasoning behind the presence of dimers 
during purification procedures and monomers during structural data collection 
analysis.     
 
The SAXS structure of Toxin A, displayed in Figure 2.3a-A shares a 
similar overall shape to the Toxin A reconstruction generated from electron 
micrographs, Figure 2.3a-B (Pruitt et al., 2010).  The model structure of Toxin A 
generated from electron microscopy data was superimposed onto the SAXS 
envelope of Toxin A, Figure 2.3a-C, which clearly shows their similarities.  
Bfrapidlyoth structures have a globular head domain and an extended long tail 
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domain.  When comparing the Toxin A SAXS structure with the Toxin B SAXS 
structure, there are few similarities other than that they are both elongated and 
approximately 265-275 Å.  The Toxin B structure lacks the globular head domain 
and instead has a protruding domain mid way along the envelope, see Figure 
2.2.1d (Albesa-Jové et al., 2010).  There has not been a successful three-
dimensional reconstructed structure reported for Toxin B from electron 
microscopy data as yet.  Previous attempts found that the electron micrographs 
of Toxin B displayed a more heterogeneous field of particles rather than the 
significantly more homogeneous field of particles reported for Toxin A (Pruitt et 
al., 2010).  The characteristic globular head was still present amongst the 
heterogeneous particles, but due to the heterogeneity of the sample, a model 
was not constructed.   
 
 To conclude, elucidating the 3D-structure of Toxin A proved challenging 
using crystallographic techniques, however preliminary success was achieved 
using low-resolution structure techniques.  A SAXS structure of Toxin A was 
obtained, which provided the first visualisation of Toxin A from X-ray scattering 
data.  This structure was consistent with the model reconstruction structure 
obtained by electron microscopy.  This chapter provides details of the 
achievements made in the contribution to characterising the structure of full 



















Clostridium difficile produces two potent exotoxins, Toxin A and Toxin B, 
which are part of the Large Clostridial Toxin family, and induce mucosal 
inflammation and diarrhoea (Borriello, 1998; Kelly and LaMont, 1998; Voth and 
Ballard, 2005).  In addition to these two exotoxins, some C. difficile strains 
produce an ADP-ribosylating binary toxin (CDT), the role of which is unknown 
(Perelle et al., 1997; Popoff et al., 1988).  CDT is a member of the AB binary 
toxin group and so as with other members is made up of two independently 
produced components; the enzymatic component, CDTa (48kDa), and the 
transport component, CDTb (99kDa). 
 
As discussed in Chapter 1.2, it is postulated that the enzymatic component, 
CDTa, irreversibly ADP-ribosylates monomeric G-actin in the host cells.  The 
ADP-ribosylation of G-actin prevents polymerisation disrupting the G-actin–F-
actin equilibrium, which causes cell rounding and cell death.  The CDTa 
component alone is not toxic to cells, but when combined with the transport 
component, CDTb, cell death occurs (Sundriyal et al., 2010).  Therefore the aim 
was to characterise the transport component at a structural level in order to 
determine it’s specific role in CDTa uptake into the cells.  It is hypothesized that 
the CDTb component undergoes modifications including trypsin cleavage, to 
remove the signal peptide domain and activation domain to form CDTb’’.  This 
mature CDTb’’ component is then thought to oligomerize into heptamers and 
interact with the target cells.  Upon binding to target cells, it is thought that CDTa 
binds and together they are taken up into the cell by receptor-mediated 
endocytosis.  Here, the active CDTb’’ may undergo structural rearrangements 
upon pH changes, which occur naturally in the endosomes, inserting a pore into 
the endosomal membrane allowing the translocation of CDTa into the cytosol, 
see illustration in Figure 3.1.1a. 
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In this Chapter, the aim was to characterise the CDTb component structurally, 
in all forms, CDTb, CDTb’ and CDTb’’, see Figure 3.1.1b.  The prospect being 
that we would hopefully see the structural changes taking place during the CDTb 
transport process, such as the heptamer formation.  In order to analyse the 
structural changes taking place as the CDTb becomes activated, we need to 
solve the structures of each of the CDTb forms, as there is no structural 
information available at all for any of the CDT components.  The technique of 
choice for structure solving was X-ray crystallography.  In the preliminary stages 
of crystallography, the first step is to obtain large quantities of protein to be 





The following section describes the process of expression of large 
amounts of soluble protein, followed by the purification techniques used 
for obtaining the required level of purity for crystallisation, for each of the 
CDTb forms.  
! ! ! 









CDTb 99 kDa 
CDTb’ 94 kDa 
CDTb’’ 74 kDa 
Figure 3.1.1b- Domain organisation of the CDTb variants.  CDTb’’ is the fully 
activated functional variant, CDTb’ is the non-activated variant and CDTb is the full 
length variant with the N-terminal signal peptide and activation domain still intact.   
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3.1.2 Materials and Methods 
Expression of CDTb 
 
The previously established protocol for recombinant expression of CDTb’ 
and CDTb’’ was used as a template for expression of all variants, with some 
minor alterations made for optimized expression (Sundriyal et al., 2010).  In 
summary for CDTb: E. coli BL21 (DE3) codon plus cells (Novagen) were 
transformed with the pGEX-6p1-cdtB expression construct (provided by the 
PHE). Overexpression of soluble CDTb was obtained in a highly controlled 
environment using a BIOFLO-3000 bioreactor (New Brunswick Scientific) with a 4 
L bioreactor culture vessel.  The fermenter was prepared according to the 
manufacturer’s manual.  The pH, temperature and dissolved oxygen (DO) were 
controlled in a proportional-integral-derivative (PID) manner, initially programmed 
to pH 7.0, 37 °C, 60 % DO and agitation 200 rpm.  The vessel containing 4 L of 
TB media (see appendix for recipe) supplemented with 1X TB salts, 0.5 % 
glucose and 100 µg/ml ampicillin, was allowed to equilibrate to the correct pH 
and temperature prior to inoculation.  The medium was then inoculated with 40 
ml overnight culture of the expression host, grown at 37 °C in LB (see appendix 
for recipe) supplemented with 100 µg/ml ampicillin.  Once the culture reached 
OD600 = 0.8-1.0, the temperature was reduced to 16 °C.  After the temperature 
reached 16 °C, 1 mM IPTG was added to induce expression of CDTb.  The 
cultures were harvested after 20 hours, using 500 ml centrifuge tubes in a 10:500 
rotor, spinning at 8,500 rpm for 10 min at 4 °C.  The cell pellets were re-
suspended in 2 ml/g of pellet in lysis buffer: 50 mM Tris-HCl pH 7.5, 150 mM 
NaCl and 2 mM DTT.  The re-suspended pellets were then rapidly frozen in liquid 
nitrogen and stored at -80 °C until further use. 
 
The above optimised protocol for overexpression of soluble CDTb was 
also used for CDTb’ and CDTb’’.                                                                                                                                           
Purification of CDTb 
 
A protocol for CDTb’ and CDTb’’ purification has previously been 
established (Sundriyal et al., 2010), however this protocol does not yield high 
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quantities of protein and involves a four step purification over a long period of 
time.  This protocol serves the purpose for which it was designed.  However a 
large yield of pure protein at high concentrations is required for structural studies.  
Hence the previously-established protocol required optimization.  This protocol 
involved an initial GST-affinity step immediately followed by an anion-exchange 
step.  The GST tag was then cleaved overnight and the following day the protein 
was dialyzed into an alternative buffer overnight.  The next step involved another 
GST-affinity step followed again by an anion-exchange step.  This protocol was 
optimized to exclude the anion-exchange step and with the addition of a final gel-
filtration step. 
 
The final optimised protocol for CDTb purification is as follows: A cell 
pellet, stored at -80 °C from the batches of expressed protein, was thawed and 
diluted in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl and 2 mM DTT) until 
a total volume of 10 ml/g of pellet was reached.  The cells were then passed 
through a homogenizer twice at 20 kpsi at 4 °C.  Throughout the duration of the 
purification from this point onwards the protein was kept on ice.  The cell lysate 
was centrifuged at 25,000 rpm for 35 min at 4 °C and the resultant supernatant 
was filtered through both a mini-sart GF-pre-filter (Sartorius) and 0.45 µm millex-
HA filter (Millipore).  The filtered supernatant was then loaded onto a 5 ml 
GSTrap-FF column (GE Healthcare) at 0.5 ml/min, pre-equilibrated with lysis 
buffer.  The column was then washed in lysis buffer until the absorbance at 280 
nm reached a constant stable base line.  The bound protein was eluted at 0.5 
ml/min in 20 mM reduced glutathione in lysis buffer.  Sufficient amount (1 U per 
100 µg of protein) of PreScission protease (GE Healthcare) was added to ensure 
complete cleavage of the GST tag.  The protein was dialyzed against 100 vol of 
lysis buffer, using 12-14 kDa cut off dialysis tubing (Medicell International Ltd) 
and was allowed to dialyze and cleave overnight at 4 °C.  Dialyzed protein was 
then centrifuged at 4,000 g to remove any precipitated protein and was re-loaded 
back onto the GSTrap-FF column, pre-equilibrated in lysis buffer, at 0.5 ml/min, 
collecting the pure CDTb in the flow through.  The column was then washed until 
a constant stable base line was reached and the bound GST tag was eluted 
using 20 mM reduced glutathione in lysis buffer.  If any GST tag was still present 
after the above 2-day purification protocol, the protein was concentrated to 1 ml 
and loaded onto a superdex-200 10/300 GL column (GE Healthcare) to achieve 
complete separation.  The final pure CDTb was concentrated to 3.9 mg/ml using 
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30 kDa cut-off hydrosart membrane concentrators (Sartorius, Vivaspin), rapid 
frozen in liquid nitrogen and stored at -80 °C. 
 
 The above optimised purification protocol was also used for the 
production of high yields of pure CDTb’ and CDTb’’. 
 
 
Verification of CDTb Variants 
 
 
In order to confirm the pure proteins are in fact the CDTb variants, 
attempts were made at analysing the samples by Mass Spectrometry (Mass 
Spec).  CDTb, CDTb’ and CDTb’’ were all concentrated to 10 mg/ml and 0.1 % 
formic acid was added in preparation for Mass Spec.  For reasons that will be 
explained in the results section, another batch was concentrated and 0.1 % 
acetic acid was added.  In addition, a separate batch of proteins were slowly 
dialysed into 0.1 % formic acid and concurrently 0.1 % acetic acid.   
 
A Western blot was performed using an antibody specific for GST, to 
confirm the presence of GST on the blot, particularly before and after cleavage of 
the GST-tag from CDTb to ensure that the proteins being expressed and purified 




Expression of All CDTb Variants 
 
 The expression of all three CDTb variants was optimised to provide a high 
yield of soluble protein for use in purification trials.  CDTb variants were all 
expressed using the same optimised protocol whereby E. coli BL21 (DE3) codon 
plus cells were transformed with the pGEX-6p1-cdtB expression constructs 
(provided by the PHE).  Over-expression of soluble CDTb variants was obtained 
in a highly controlled environment using a BIOFLO-3000 bioreactor (New 
Brunswick Scientific) with a 4 L bioreactor culture vessel. Samples of the cultures 
were taken prior to induction with IPTG and post induction.  Expression levels 
were analysed by 10% Bis-Tris SDS-PAGE, see Figure 3.1.3a.   
 
 Figure 3.1.3a displays the three gel pictures from the SDS-PAGE with 
both the pre-induced and post-induced samples in lanes 2 and 3 respectively, 
and the markers in lane 1.  For the CDTb variant in gel picture A, it is clear that 
there is no protein at approximate molecular weight 127 kDa prior to induction, 
and then a significantly large band at post-induction, indicating successful 
expression levels.  CDTb’ also shows good expression levels as indicated by gel 
picture B, where there is little sign of the protein prior to induction and then a 
larger protein band at approximately 122 kDa after induction.  CDTb’’ again 
shows successful expression levels post-induction in gel picture C at 103 kDa.  
The comparison between pre-induced and post-induced samples provides an 
indication that the cells are expressing a protein that is not normally expressed 
upon addition of IPTG.   
 
For proteins CDTb and CDTb’ the expression bands on the gel are 
slightly lower than expected for proteins of molecular weight 127 kDa and 122 
kDa respectively, which is most likely due to overloading of protein on the gel.  









































kDa Marker Pre Post 
CDTb’’ 
Figure 3.1.3a- Expression of CDTb, CDTb’ and CDTb’’ analysed by 10 % Bis-Tris SDS-PAGE.  Marker displayed on all images is the broad range 2-212 
kDa protein parker (New England BioLabs ®) A: Expression of CDTb shown by the presence of a strong band at molecular weight 100 kDa that is not 
present in the pre-induced samples.  B:  Expression of CDTb’ shown by the presence of a strong band at molecular weight 100 kDa that is not present in 
the pre-induced samples.  C:  Expression of CDTb’’ again shown by a strong band at molecule weight 100 kDa, not observed in the pre-induced sample.      
A B C 
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Purification of CDTb Variants 
 
 A protocol for the purification of CDTb’ and CDTb’’ had previously 
been established however the resultant output from this protocol is a low yield of 
pure CDTb’ and CDTb’’ after four days.  Therefore, the protocol was optimised to 
provide an overall higher yield during a shorter time frame.  The final optimised 
protocol for all CDTb variants involved a 3-day protocol, in brief, as follows: 
 
Day 1:  
• Cell lysis using cell disruptor  
• Centrifugation to remove cell debris 
• Supernatant preparation including filtration 
• GST-affinity chromatography 
• Cleavage of GST-tag using PreScission Protease 
• Dialysis overnight to remove reduced gluthatione 
Day 2: 
• Spin cleaved protein to remove any precipitate 
• GST-affinity chromatography to remove tag 
• Collecting pure CDTb protein in the flow through 
• Concentration pure CDTb protein 
• Size-exclusion chromatography overnight 
Day 3: 
• Analyse size-exclusion fractions 
• Pool and concentrate pure fractions of CDTb protein 
• Perform structural or functional experiments 
 
As observed in the chromatogram for Day 1 of the purification step, 
Figure 3.1.3b-A, the signature profile for GST-affinity chromatography initially 
starts with a large broad peak, which represents non-GST-tagged proteins that 
do not bind to the GSTrap column.  During this time, GST-tagged CDTb protein 
binds the GSTrap column.  Once the supernatant was loaded, the column was 
washed in buffer until a steady flat UV baseline is reached.  Reduced glutathione 
was then added to the buffer to elute the GST-tagged CDTb protein from the 
column.  Once the UV reading reached a steady flat base line again, the elution 






 Non-specific flow through 
CDTb-GST 
elution 




Figure 3.1.3b- Purification of CDTb variants.  The blue lines represent the 
absorbance at 280 nm and the brown/red lines represent the conductivity.  A:  
First step of GST-affinity chromatography with GST-tagged CDTb binding to the 
GSTrap column.  Non-GST-specific proteins do not bind the column and pass 
through in the flow through.  The CDTb-GST is eluted from the column using 
reduced glutathione.  B:  The second step of GST-affinity chromatography.  After 
the eluted protein from step 1 is treated with PreScission Protease, the CDTb 
does not bind the GSTrap but is collected in the flow through.  The bound GST-
tag is then eluted in reduced glutathione as previously.        
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 The collected CDTb-GST elution was dialysed to remove the reduced 
glutathione and PreScission protease was added to cleave off the GST-tag.  In 
the second step GST-affinity chromatography CDTb would no longer bind to the 
GSTrap column and was collected in the flow through, see Figure 3.1.3b-B.  The 
GST-tag was then eluted using reduced glutathione. Occasionally this method 
doesn’t allow complete removal of the GST-tag, therefore a final cleaning step by 














All of the CDTb variants are purified using the same protocol, and each 
behaves in a similar manner throughout the purification.  The first two steps using 
GST-affinity chromatography were identical as expected, however all three CDTb 
variants elute at the same point which is predicted for proteins greater than 500 
kDa.  This was unexpected as it is thought that only the CDTb’’ which has been 
trypsin activated forms oligomers.  In addition, the predicted size is larger than 





Figure 3.1.3c- Example of gel-filtration chromatography step for all CDTb variants to 
ensure complete removal of GST-tag.  The blue line represents the absorbance at 
280 nm and the brown line represents conductivity.  All of the CDTb variants form 
oligomers that start to elute from the superdex-200 10/300 GL at approximately 7 ml.  
A monomeric peak is often visible at approximately 14 ml if full oligomerisation has 


























Figure 3.1.3d- 4-15 % Tris-glycine SDS-PAGE gel pictures displaying purification steps 
for each CDTb variant.  For each image lanes 1 and 2 correspond to the protein loaded 
onto the column and the subsequent flow through respectively.  Lanes 3 and 4 represent 
the eluted GST-tagged protein and the dialysed cleaved protein loaded back onto the 
GST column respectively.  Lanes 5 and 6 represent the ‘pure’ protein flow through and 
the eluted GST-tag respectively.  For gels A and B, lanes 7 and 8 represent peaks 1 and 2 
from the size-exclusion chromatogram, whereas for gel C lanes 7, 8 and 9 represent the 
third, second and first peaks respectively.   A: CDTb purification displaying final product 
in lane 8.  B: CDTb’ purification displaying final pure product in lane 8.  C: CDTb’’ 














































Figure 3.1.3d displays the CDTb variants at each step during the 
purification protocol as analysed by 4-15 % Tris-glycine SDS-PAGE.  For gel 
pictures A, B and C the first 4 lanes represent the cell supernatant load, the non-
specific flow through, the CDTb-GST elution and the PreScission protease cleave 
result respectively.  For all three of the variants, it is clear from lane 4 that the 
GST-tag has been cleaved, as the CDTb-GST band from the elution step in lane 
3 has dropped down in size by approximately 30 kDa in lane 4, and a band at 30 
kDa has appeared representing the cleaved GST-tag.  However, in some cases, 
particularly obvious with CDTb (gel A) there is not complete cleavage suggesting 
that sufficient amounts of PreScission protease were not added.  However, step 
2 in the purification using the GSTrap column removes most of this uncleaved 
protein and any remaining is removed during size exclusion.  Lane 8 on all three 
gels displays the final pure product for all three variants, with each protein 
showing > 95% purity.   
 
The unusual observation noted during the purification of CDTb variants 
was in the final cleaning step of gel-filtration chromatography.  All of the variants 
eluted earlier than is expected for proteins of their size.  In addition, if the fully 
processed CDTb’’ variant were to form heptamers as predicted, the protein would 
certainly elute earlier, however, all of the variants are eluted from the size-
exclusion column at a point which is to be expected for proteins greater than 500 
kDa.  Brief attempts were made at trying to prevent oligomerisation for CDTb’’ 
whereby the large oligomeric elution peak was passed back through the size-
exclusion column pre-equilibrated with a range of different buffers targeted 
towards preventing oligomerisation.  Such buffers included the standard 50 mM 
Tris-HCl pH 7.5 with increased salt (200 mM NaCl, 300 mM NaCl and 500 mM 
NaCl), increased DTT (2 mM, 5 mM and 10 mM DTT) and addition of detergent 
Tween-20 (0.1 %, 0.2 %, 1 % and 2 %).  As a result there was no shift in the 
elution peak, CDTb’’ continued to elute at the same point.       
Verification of CDTb Variants 
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 Multiple attempts were made to prepare CDTb pure proteins for Mass 
Spectrometry, however addition of acid using any of the methods described in 




 As Mass Spectrometry was not a suitable option for CDTb, CDTb’ and 
CDTb’’, as the proteins crash out of solution upon addition of acid, a Western blot 
was performed using a GST-specific antibody for the CDTb’ variant.  The 
samples analysed on the gel were those taken during the various steps of 
purification, therefore GST should appear at approximately 130 kDa when bound 
to CDTb’’ and at 27 kDa after cleavage with PreScission protease, see Figure 













The Western blot displayed in Figure 3.1.3e represent the first two steps 
in the purification of CDTb’.  CDTb’-GST bands are present in the load, flow 
through and elution fractions as observed in lanes ‘L’, ‘FT’ and ‘E’ on the blot, at 
approximately 130 kDa.  There are numerous other bands present, but at this 
point in the purification there are still multiple E.coli proteins present.  After 
cleavage, the band at 130 kDa decreases in size by approximately 30 kDa and a 
strong band appears at 27 kDa indicating GST cleavage from CDTb’.  This is a 
strong indication that the correct protein is being expressed and purified, as the 
PreScission protease cleavage site is highly specific, and the bands are of the 
correct molecular weight.  The ‘FT’ and ‘GST’ lanes representing the CDTb’ pure 
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kDa        Marker     L         FT         E         Cl         FT       GST 
Figure 3.1.3e- Western blot using GST-specific antibody to confirm purification 
of CDTb’.  ‘L’ and ‘FT’ lanes represent the loaded cell supernatant and non-
specific flow-through from GSTrap column.  ‘E’ represents the CDTb’GST 
elution from the column.  ‘Cl’ represents PreScission protease cleavage.  ‘FT’ 
represents the flow-through when passed back through a GSTrap column after 
cleavage.  ‘GST’ represents the final elution from the GSTrap column using 
reduced glutathione.      
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flow through (with some small CDTb’GST and GST contamination as normally 
observed at this point) and the final GST elution are as expected.  There is still 
some uncleaved CDTb’-GST present across all of the lanes, which is not 
uncommon during purification.  There is however an unusual band at 
approximately 40 kDa which appears prominent at the elution step and is present 
throughout the purification.  It is GST specific, hence it is flagged up in the 
Western blot, but it clearly doesn’t affect CDTb’ purification as it is not present in 
the second flow-through step which contains pure CDTb’.  It has a high binding 
affinity for the GST-column, but is not overexpressed as it does not stand out as 
a strong band in the ‘L’ and ‘FT’ lanes.  It is likely to be an E.coli protein with GST 








 Clostridium difficile produces an ADP-ribosylating binary toxin (CDT) that 
is made up of two independently produced components: CDTa and CDTb.  As 
mentioned in the introduction, the role of CDT in pathogenesis is unknown, 
however what is understood is that both components are required for toxicity 
(Sundriyal et al., 2010).  As discussed previously in Chapter 3.1.1, there are 
three forms of CDTb; the full length early form (CDTb) which has both an N-
terminal signal peptide domain and an activation domain, the pre-activated form 
which does not have the signal peptide domain (CDTb’) and lastly the active 
pore-forming form without the activation or signal peptide domains (CDTb’’), see 
Figure 3.1.1a.   
 
The aim of this subchapter was to crystallise the varying forms of 
CDTb and solve their structures using X-ray crystallography, in the hope 
that this structural information would contribute to the understanding of 




Crystallisation techniques employed in this chapter have been described 
extensively in Chapter 2.1.1.    
 
 As will become clear in the following sections of this chapter, 
crystallography can be a challenging field of biology, but some preliminary results 
show a promising outlook for further research into CDTb structural analysis.  !!
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3.2.2 Materials and Methods 
Crystallisation of CDTb variants 
Preliminary Screening 
 
High yields of CDTb, CDTb’ and CDTb’’ were obtained using the 
optimised expression and purification protocols in Chapter 3.1.2.  A pre-
crystallization test (PCT) was performed to determine a suitable concentration 
range for optimal crystal growth, see Chapter 2.1.2 for details on PCT protocol.  
 
 A 4-well crystallisation plate was set up using the four reagents described 
in Table 2.1.2a.  The PCT was set up using the hanging drop vapour diffusion 
method with a drop size of 1:1 µl ratio of protein to reservoir.  The PCT plate was 
incubated at 16 °C for 30 min before being analysed using a light microscope.  If 
the concentration of the protein was deemed suitable for crystallisation in the 
PCT, then the preliminary screens were performed.  Unless stated otherwise, 
preliminary screens were performed with the Phoenix Liquid Handling System 
(Art Robbins Instruments) using the sitting drop method with a ratio of 0.3:0.3 µl 
protein to reservoir ratio.   
 
The following 96-well crystallisation screens were used: Clear Strategy 
Screen I HT-96, Clear Strategy Screen II HT-96, JCSG-plus HT-96, Heavy + 
Light twin pack HT-96, Morpheus HT-96, MIDAS HT-96, MemGold HT-96, PGA 
screen HT-96, ProPlex HT-96, PACT premier HT-96, Stura Footprint 
Combination screen HT-96, and finally Structure screen I + II HT-96 (All screens 
were purchased from Molecular Dimensions).  The crystallisation screens were 
all incubated at 16 °C, and monitored initially after 24 hours and then fortnightly 
thereafter.  The concentration at which the above screens were performed varies 
for each of the CDTb forms, based on the PCT results, and will be discussed in 
more detail in Chapter 3.2.3.  In such cases where no hits were observed during 
preliminary screening, the above screens were also performed at 21 °C and 4 °C, 





Optimisation of Preliminary Hits 
 
 After observation of any initial hits during the preliminary screens, the 
corresponding crystallisation conditions were further tested to optimise crystal 
growth.  Optimisations were performed on 24-well plates using either the hanging 
drop or sitting drop method, with a reservoir volume of either 0.5 ml or 1.0 ml.  
Generally speaking, crystallisation screens have various combinations of buffers, 
salts and precipitants that promote crystal growth.  In order to determine the 
optimal condition, the individual components are varied independently.  Typically 
the precipitant concentration was varied first at between 0-30 %, and in some 
cases the precipitant was substituted for an alternative of different molecular 
weight.  The salt concentration was varied to ±10-100 mM of the original 
concentration, and was in some cases substituted with other salts containing 
similar elements.  The buffer pH was also varied by up to two units on either side 
of the original pH, however this buffer was rarely substituted for an alternative.  
Temperature and method of vapour diffusion were also variables tested for 
optimisation. 
 
Alternative Techniques to Promote or Optimise Crystal Growth   
 
Under such circumstances where no initial hits were observed, or crystal 
hits showed little or no diffraction, further steps were taken to encourage crystal 
growth.  One such step involved buffer exchanging the proteins into a different 
buffer and pH, or alternatively water, prior to the initial screens. 
 
 In some cases where initial hits were observed, but the crystals showed 
no diffraction, or in cases where optimisations had no effect on crystal quality, 
additional additive screens were performed.  When performing additive screens, 
the initial condition was used as the primary reservoir and then various 
compounds were added in small quantities.  The additive screens performed 
include Silver Bullets and Additives Screen HT (Both from Hampton Research).  
 
 For some of the CDTb forms, seeding technique were used in an attempt 
to improve crystal quality and size.  Further details and results will be provided for 




Crystallisation of CDTb 
Preliminary Screens 
 
Preliminary screens for CDTb were set up as discussed in Chapter 3.2.2, 
at 3.9 mg/ml, which was considered a suitable concentration for crystallisation by 
the PCT results.  Tiny cube-like microcrystals were observed after 1 month in one 
of the performed 96-well screens: MemGold HT-96.  Two wells from the 
MemGold HT-96 screen had small crystals in, displayed in Figure 3.2.3a.  For 
details on the crystallisation conditions, see Table 3.2.3a. 
 
 
At least two crystals from each well of the initial hits were mounted in 
LithoLoops (Hampton Research) and taken to Diamond Light Source to test for 
signs of diffraction.  For hits A and B from Figure 3.2.3a, mesh LithoLoops were 
used to ensure the crystals were scooped out of the wells successfully.  One at a 
Figure 3.2.3a- Preliminary crystallisation hits of CDTb. A: MemGold HT-96 well B8, 3.9 
mg/ml.  B: MemGold HT-96 well H6, 3.9 mg/ml.  Both wells contain crystals of CDTb 
purified in buffer 50 mM Tris-HCl  pH 7.5, 150 mM NaCl and 2 mM DTT.  Scale bar 




time, the LithoLoops containing crystals were mounted on the goniometer and 
were rotated whilst being exposed to a beam of X-rays.  No diffraction was noted 
for any of the mounted crystals from the wells pictured in Figure 3.2.3a.  
 
If the crystals had been salt we would have observed the characteristic 
large diffraction spots that are usually noted during diffraction of salt crystals.  
The lack of diffraction spots observed indicates that the crystalline material is 
protein, rather than salt, but that the conditions required optimisation for 
diffraction studies.   
 
Optimisation of CDTb Crystals 
 
As discussed in Chapter 2.1.1 under ‘Optimisation of preliminary hits`, the 
crystallisation reservoir commonly contains a buffer, salt and precipitant.  The 
crystallisation conditions displayed in Table 3.2.3a are the corresponding 
conditions to the crystallisation hits displayed in the Figure 3.2.3a.  In order to 
improve the crystal quality to a diffracting standard, the buffer, salt and precipitant 
concentrations were all varied.  Initially for hit A in MemGold HT-96 B8, the 
precipitant PEG 4k concentration was varied between 0-10 % and the NaCl 
concentration was varied between 0-0.15 M.  For hit B in MemGold HT-96 H6, 
the lithium sulphate concentration was varied between 0-0.1 M and the PEG 3k 
concentration was varied between 0-10 %.  The stock solutions used for the 
optimisation trials were filtered using 0.4 µM pore size, 0.33 mm sterile filters 
(Millex) prior to use in crystallisation optimisations.  The trials were performed on 
24-well plates using both hanging and sitting drop methods, with a protein to 
reservoir ratio of 2:2 µl, at 16 °C.  The optimisation plates were checked initially 
Crystal Screen and Well Details Crystallisation Condition 
A MemGold HT-96 B8 
0.1 M NaCl 
0.02 M KMES pH 6.7 
6.6 % PEG 4k 
B MemGold HT-96 H6 
0.05 M lithium sulphate 
0.1 M Tricine pH 7.4 
7 % PEG 3k 
Table 3.2.3a- Crystallisation conditions for preliminary crystallisation hits observed 
for CDTb.  For crystal pictures see Figure 3.2.3a. 
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after 24 hours and then fortnightly thereafter.  After 1 month, crystals were 
observed in some of the wells on the optimisation plates.  The crystals displayed 
in Figure 3.2.3b show a slightly different morphology to the preliminary hits.  
There was one flat square plate crystal and multiple non-cube-like crystals with 
rigid edges.   
 
  
The crystals were mounted in LithoLoops (Hampton Research) and taken 
to Diamond Light Source to test for signs of diffraction.  As with the previous 
crystals no diffraction was noted for any of the mounted crystals from the 
optimisation trials.  Due to the time restraints for the project, no further 
crystallisation trials were performed. 
 
Crystallisation of CDTb’ 
Preliminary Screens 
 
Preliminary screens for CDTb’ were set up as discussed in Chapter 3.2.2, 
at 4.2 mg/ml, incubated at 16 °C, which was considered a suitable concentration 
for crystallisation by the PCT results.  Tiny cube-like crystals were observed in 
one well of JCSG-plus HT-96, 2 months after the plate was set up, see Figure 
3.2.3c-A.    This was the only condition in which crystals grew during the 
preliminary screens (well E10 from JCSG-plus HT-96: 0.1 M Bicine pH 9.0 and 
10 % PEG 6k). The crystals were mounted in mesh LithoLoops and taken to 
Diamond Light Source to test for signs of diffraction.  One at a time, the 
Figure 3.2.3b- Crystal hits of CDTb from optimisation trials, displaying different 
morphology to preliminary hits.  Scale bar represents 200 µm. 
A B C 
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LithoLoops containing crystals were mounted on the goniometer and were 
rotated whilst being exposed to a beam of X-rays.  No diffraction was noted for 
any of the mounted crystals from the well pictured in Figure 3.2.3c-A.   
 
Optimisation of CDTb’ Crystals 
 
As with the previous crystals for CDTb, attempts were made at optimising 
crystal quality in order to see diffraction.  Initially, the concentration of PEG 6k 
was varied 0-30 %, followed by variation of the temperature at which the plates 
were incubated at: 4 °C, 16 °C and 21 °C.  The concentration at which 
crystallisation plates were set up was also varied 2-15 mg/ml, in addition to the 
method of vapour diffusion used (hanging drop and sitting drop).  An additives 
screen (Hampton Research) was also performed, whereby the initial 
crystallisation condition was used as the primary reservoir and then a 
concentration of 10 % of the additive reagents were added.   
 
Crystals of CDTb’ did not grow in any of the performed optimisations 
screens however, there was some success in crystal growth with the additive 
screen, where small cube-like crystals, of similar morphology to those grown 
previously, grew in the presence of 0.01 M betaine hydrochloride, see Figure 
3.2.3c-B.  These crystals were mounted in mesh LithoLoops and again were 
tested for signs of diffraction at Diamond Light Source.  However, as with the 
original preliminary hits, no diffraction was observed. 
A B 
Figure 3.2.3c- Crystals of CDTb’.  A: Preliminary crystallisation hits for CDTb’ 
observed in one well on the JCSG-plus HT-96 screen.  B:  Crystallisation hits for 




As discussed in Chapter 3.1.3, the CDTb variant proteins all appear much 
larger than expected when purified using size-exclusion chromatography, which 
could be due to oligomerisation or aggregation.  In case the proteins were 
aggregated, CDTb’ was purified in the presence of 0.2 % Tween-20, in the usual 
buffer of 50 mM Tris-HCl pH 7.5, 150 mM NaCl and 2 mM DTT, in attempts to 
prevent aggregation.  The purified protein was concentrated to 4 mg/ml and was 
screened as usual for crystal growth.  After 3 months, crystals were observed in 
the Structure screen I & II HT-96 screen, the JCSG-plus HT-96 screen and the 
Figure 3.2.3d- CDTb’ crystals from purification using buffer 50 mM Tris-HCl pH 
7.5; 150 mM NaCl; 2 mM DTT and 0.2 % Tween-20.  A: Small bundle like crystals 
observed in Structure screen I & II HT-96 screen, well B10.  B:  Unusual blue 
crystal observed in JCSG-plus HT-96 screen, well E10.  C: Cluster of small cube-
like crystals observed in JCSG-plus HT-96 screen, well C12.  D: Thin plate-like 
crystal observed in Clear Strategy screen I HT-96 screen, well E11.  Scale bar 





Clear Strategy I HT-96 screen, see Figure 3.2.3d for crystal pictures and Table 







The small bundles of crystals observed in Figure 3.2.3d-A were too fine to 
collect data from; therefore they were used for seeding, which will be explained 
later.  The small blue crystal in Figure 3.2.3d-B, was observed in the same 
condition as the original CDTb’ crystal hit from the preliminary screens from 
JSCG-plus HT-96 E10.  The crystal was stuck to the bottom of the well, so 1 µl of 
reservoir solution was added to the drop to aid in crystal mounting.  However, the 
crystal dissolved completely upon addition of reservoir solution. The crystals in 
Figure 3.2.3d-C were mounted in LithoLoops and taken to Diamond Light Source 
but showed no signs of diffraction and finally the crystal in Figure 3.2.3d-D 
dissolved when attempting to mount in a LithoLoop. 
 
Table 3.2.3b describes the variations in crystallisation conditions used 
during the optimisation attempts.  The buffer in each of the conditions was kept 
constant whilst the PEG and salt concentrations were varied.  After six months 
there was still no sign of crystal growth.   
Crystal Screen Crystallisation Conditions Optimisation Range 
A 
Structure 
Screen I & II 
HT-96 well 
B10 
0.2 M magnesium 
chloride 
0.1 M sodium HEPES 
pH 7.5 
30 % 2-propanol 
0-0.3 M magnesium chloride 
0.1 M sodium HEPES pH 7.5 kept 
constant 





0.1 M Bicine pH 9.0 
10 % PEG 6k 
0.1 M Bicine pH 9.0 
kept constant 





10 % PEG 1k 
10 % PEG 8k 
5-15 % PEG 1k 





96 well E11 
0.2 M potassium 
thiocyanate 
0.1 M Tris pH 7.5 
15 % PEG 4k 
0.2 M potassium thiocyanate 
kept constant 
0.1 M Tris pH 7.5 
kept constant 
5-30 % PEG 4k 
Table 3.2.3b- the details of the crystallisation conditions for crystal hits displayed in 




Microseeding plates were set up as discussed in Chapter 2.1.1, using the 
bundle of fine crystals displayed in Figure 3.2.3d-A, in attempts to improve crystal 
morphology.  In brief, the crystals in the well were crushed until no longer visible 
using a needle.  The drop was diluted in 2 µl of reservoir and was aspirated and 
dispensed into a small Eppendorf tube.  The tube was mixed by vortex for 5 min 
at room temperature to ensure complete crushing of the crystals.  A 24-well plate 
was set up using the same batch of protein that produced the small crystal 
bundles in Figure 3.2.3d-A, with the original crystallisation condition.  The 
hanging drop method was used with a drop size ratio of 1 µl: 1 µl.  The plate was 
incubated at 16 °C for 3 hours prior to microseeding.  The solution containing 
crushed crystal fragments was then diluted in series as displayed in Table 3.2.3c, 
which represents a 24-well plate and 1 µl of the diluted seeds was added to each 
of the pre-equilibrated drops.  The microseeded plate was then incubated at 16 









After 3 months, more bundles of fine crystals were observed on the 
microseeded optimisation plate, which were unsuitable for data collection, see 
Figure 3.2.3e-A.  Therefore as used previously, the Additive Screen (Hampton 
Research) was performed using the successful crystallisation conditions for the 
crystals in Figure 3.2.3d-A, B, C and D as the primary reservoir.  Additionally the 
Silver Bullet screen was performed in the same manner.  There was one 
successful crystallisation hit which was observed on the Additive Screen plate 
that was set up using the crystallisation condition form JCSG-plus HT-96 well 
 1 2 3 4 5 6 
A 1:50 1:50 1:50 1:100 1:100 1:100 
B 1:200 1:200 1:200 1:400 1:400 1:400 
C 1:500 1:500 1:500 1:5000 1:5000 1:5000 
D 1:10000 1:10000 1:10000 1:25000 1:25000 1:25000 
Table 3.2.3c- Dilution series for 24-well microseeding plate.  Small bundles of 
crystals were crushed and diluted as in the table.  The diluted CDTb’ crystals were 
added to drops pre-equilibrated with 1 µl: 1 µl ratio of protein to reservoir, to make 
the final ratio 2 µl: 1 µl of protein to reservoir.   
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E10 which had shown small blue crystal growth previously.  The crystals are 
displayed in Figure 3.2.3e-B and were grown in the presence of the additive 0.01 
M betaine hydrochloride.  During attempts to mount the crystals in LithoLoops, 
the crystals were fixed to the bottom of the well, so an additional 2 µl of reservoir 
solution was added to help with mounting. Unfortunately the crystals dissolved 
upon addition of the reservoir.  This indicated that the crystals were likely to be 
protein, and so optimisation plates were set up where the original reservoir of 10 
% PEG 1k and 10 % PEG 8k was kept constant and a range of 0-0.1 M betaine 
hydrochloride was trialled.  As yet, no crystals have been observed in the betaine 
hydrochloride optimisation trial.   
 
  
As discussed earlier, the preliminary screens were performed using 
CDTb’ purified in the standard buffer with the addition of 0.2 % Tween-20.  After 
3 months, crystals were observed as displayed in Figure 3.2.3d, however after 6 
months, one other crystallisation hit was observed in the Clear Strategy Screen I 
HT-96 well F4, displaying in Figure 3.2.3e-C.  These crystals had a triangular 
morphology, which is different to all of the previously observed crystal hits.  The 
crystal was mounted in a LithoLoop and taken to Diamond Light Source to test 
for signs of diffraction.  The loop showed a large quantity of ice formation and the 




Figure 3.2.3e- Crystals of CDTb’ grown using various optimisation methods.  A: 
Bundles of fine crystals grown from the microseeding plate, showing no 
improvement of crystal morphology.  B:  Small cube-like crystals observed from the 
Additive Screen, grown in the presence of betaine hydrochloride.  C:  Alternative 
triangular morphology crystals observed 6 months after preliminary screens were 




more crystals in this specific condition so that a broad range of cryo-protectants 
could be trialled to reduce the ice problem, however there have been no 
indications of crystal growth as yet.   
 
In addition, optimisation plates were set up using the same technique as 
previously.  The original crystallisation condition contained 0.2 M potassium 
bromide, 0.1 M Tris pH 7.5, 10 % PEG 8k, 10 % PEG 1k.  Therefore, Tris buffer 
was kept constant, potassium bromide was varied 0-0.5 M, PEG 8k was varied 0-
30 % and PEG 1k was varied 0-30 %.  These optimisations were performed 
towards the end of the project, and until date there have been no crystals 
observed for this batch of optimisations, however the preliminary crystals took 6 
months to grow, and so this time frame is yet to be reached. 
 
Concurrently, an alternative method to produce diffraction quality crystals 
was used whereby the preliminary 96-well screens were performed with the 
protein in different buffer systems.  This method is used to extend the range of 
pH buffers the protein is subjected to during crystallisation.  In the final stages of 
purification of CDTb’, the pure protein was dialysed separately into the following 
three buffers, using 50 x volume at 4 °C: 
 
1. Buffer 1: 50 mM MES pH 6.5; 150 mM NaCl; 2 mM DTT 
2. Buffer 2: 50 mM HEPES pH 7.0; 150 mM NaCl; 2 mM DTT 
3. Buffer 3: 50 mM Bicine pH 8.5; 150 mM NaCl; 2 mM DTT 
 
After dialysis, CDTb’ was concentrated to 4 mg/ml and the crystallisation 
screens JCSG-plus HT-96, Clear Strategy Screen I HT-96, Clear Strategy 
Screen II HT-96, MIDAS HT-96, and Structure screen I + II HT-96 (Molecular 
Dimensions) were performed and incubated at 16 °C.  Samples of the CDTb’ 
purification, and of the buffer exchanges were analysed using 12 % Tris-glycine 
SDS-PAGE, see Figure 3.2.3f.  By setting up crystallisation screens using a 
variety of protein buffers, there should be a greater variation in crystallisation 
conditions during the screening.  The gel picture in Figure 3.2.3f, shows the 
buffer exchanged protein in lanes 7, 8 and 9.  The protein looks to be stable in 
the three alternative buffers, although there appears to be more smaller bands 
below the CDTb’ band, this could be a concentration effect rather than unstable 

















Two months after the new screens were performed with the alternative 
buffers, two crystal hits were observed.  There were micro-crystals noted for 
protein in buffer 3 at pH 8.5, see Figure 3.2.3g-A, and one larger crystal had 
grown for the protein buffer 1 at pH 6.5, see Figure 3.2.3g-B.  Crystals from 
Figure 3.2.3g-A were mounted in mesh LithoLoops and were taken to Diamond 
Light Source to test for diffraction.  As expected for crystals of this size, following 
a similar pattern to previous crystals, no signs of diffraction were observed.  The 
crystal in Figure 3.2.3g-B was noted in the Clear Strategy Screen I HT-96 screen, 
well F3, containing the following crystallisation condition: 0.1 M Tris pH 7.5, 0.2 M 
magnesium chloride, 10 % PEG 8k and 10 % PEG 1k.  The crystal was mounted 
in a LithoLoop and taken to Diamond Light Source to test for signs of diffraction.  
The LithoLoop containing the crystal was mounted on a goniometer and was 
rotated whilst being exposed to a beam of X-rays.  The crystal showed some 
small spots at very low resolution (approximately 50 Å) but after exposure to the 
beam for a short period of time the crystal lost its diffracting ability.  This is the 
first concrete evidence obtained from these trials that these crystals are protein 
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Figure 3.2.3f- 12 % Tris-glycine SDS-PAGE gel picture displaying the purification of 
CDTb’ and the subsequent buffer exchanges.  Lane 1: Loaded cell lysate onto 
GSTrap column.  Lane 2: Non-bound protein flow-through.  Lane 3: Bound 
CDTb’GST eluted from the GSTrap column using 20 mM reduced glutathione.  Lane 
4: Cleavage of GST-tag using PreScission Protease.  Lane 5: GST-tag removed.  
Lane 6: Final pure CDTb’ in buffer pH 8.0.  Lane 7: Dialysis into pH 6.5 buffer 1.  





In order to improve the quality of the CDTb’ crystal, optimisation trials 
were performed whereby the individual components of the successful 
crystallisation condition were varied.  The Tris buffer was kept consistent whilst 
the magnesium chloride concentration was varied 0-25 M, the PEG 8k was 
varied 0-25 % and the PEG 1k was also varied 0-25 %.  Both sitting and hanging 
drop methods of vapour diffusion were used in addition to varying the protein 
concentration 2-10 mg/ml.   
 
In addition to the above screens and optimisation trials, the Additive 
screen and Silver bullet screen were performed, using the same batch of protein 
that the diffracting crystal was grown from (buffer 1 pH 6.5), and the Clear 
Strategy Screen I F3 reservoir as purchased from Molecular Dimensions.  These 
additional screens were performed at 2 mg/ml, 4 mg/ml, 6 mg/ml and 8 mg/ml, 
using the sitting drop method and were incubated at 4 °C, 16 °C and 21 °C, to 
ensure maximum chance of crystal growth. 
 
After approximately one week, crystals were observed on the Additive 
screen optimisation plate in positions A5 and E3 which contained the additives 
copper (II) chloride dihydrate and dextran sulphate sodium salt respectively.  The 
morphologies of these crystals varied significantly from the original large crystal, 
see Figure 3.2.3h-A-D.   
Figure 3.2.3g- Crystal hits of CDTb’ from the optimisation trials after the buffer 
exchanges.  A: Crystals hits for CDTb’ in buffer 3 pH 8.5.  B: Large crystal hit for 











All of the crystals were mounted in LithoLoops (Hampton Research) and 
taken to Diamond Light Source to test for signs of diffraction.  Crystal hits A, B 
and C from Figure 3.2.3h disappointingly turned out to be salt crystals, most likely 
of dextran sulphate sodium salt.  Crystal D however diffracted to 8 Å, which is a 
significant improvement on the last crystal that diffracted.  However, the crystal 
suffered radiation damage from the beam before enough data could be collected 
for processing.  Figure 3.2.3i displays the image of the crystal mounted in the 
LithoLoop (A), with the beam position marked as a red circle with a cross in the 
middle, and a diffraction image (B) with a close up (C).  
 
Figure 3.2.3h- Crystals of CDTb’ observed during additive screen optimisation 
trials.  A: Crystals were grown at 4 mg/ml in dextran sulphate sodium salt.  B: 
Crystal was grown at 6 mg/ml in dextran sulphate sodium salt.  C: Crystal was 
grown at 2 mg/ml in dextran sulphate sodium salt.  D: Crystals were grown at 2 
mg/ml in copper (II) chloride dihydrate.  All the above crystals were grown at 16 












Figure 3.2.3i- CDTb’ diffraction.  A:  Crystal of CDTb’ mounted in LithoLoop during exposure to beam at Diamond Light Source with red circle 
indicating beam position.  B:  A diffraction image collected for CDTb’ displaying the 5 Å resolution ring.  C: A closer look at the diffraction 







CDTb’ Data Analysis 
 
Data were collected at wavelength (λ) 0.9795 Å, 50 % transmission, with 
distance from the detector set to 1 m.  Data were collected at 0 ˚, 45 ˚ and 90 ˚ 
oscillation angles, with the crystal subjected to 10 s of beam exposure at each 
angle.  Diffraction spots observed for one of the images are displayed in Figure 
3.2.3i-B and C.  Attempts were made at indexing the data using Mosflm, in 
addition to the autoprocessing tools at Diamond Light Source; xia2 and fast_dp 
(Winter, 2010).  However, the data could not be indexed and so cell dimensions 
could not be obtained.    
 
Crystallisation of CDTb’’ 
Preliminary Screens 
 
Purified CDTb’’ in buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM 
DTT and 10 % glycerol was used to set up crystallisation trials.  Preliminary 
screens for CDTb’’ were set up as discussed in Chapter 3.2.2, at 5 mg/ml, which 
was considered a suitable concentration for crystallisation from the PCT result.  
The plates were checked after 24 hours and weekly thereafter.  After 
approximately 2 months, tiny cube-like crystals were observed in the JCSG-plus 













A B C 
Figure 3.2.3j- CDTb’’ preliminary crystallisation hits.  A: Small cube-like crystals 
observed in JCSG-plus HT-96 well E1.  B:  Tiny cube-like crystals observed in 
JCSG-plus HT-96 well F10.  C:  Slightly larger cube-like crystals observed in 
ProPlex HT-96 well H4.  Scale bar represents 200 µm. 
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The small cube-like crystals were mounted in mesh LithoLoops and taken 
to Diamond Light Source for signs of diffraction.  Unfortunately none of the 
crystals mounted showed signs of diffraction and so optimisation trials were 
performed. 
Optimisation of CDTb’’ Crystals 
 
24-well crystallisation plates were set up using both the sitting and 
hanging drop methods.  The plates were incubated at 16 °C and monitored after 
24 hours in the first instance and then weekly thereafter.  The variations in 
crystallisation condition content tested are displayed in Table 3.2.3d.  After 2 
months, crystals were observed in one well of the optimisation plate, which 






On checking the preliminary screens on a weekly basis, more crystals 
were observed on the ProPlex HT-96 screen in wells F12, G9, G10, and H5, 3 
months after the plates were initially set up, see Figure 3.2.3k.  The small cube-
like crystals were mounted in mesh LithoLoops and taken to Diamond Light 
Source for signs of diffraction.  Unfortunately none of the crystals mounted 
showed signs of diffraction, therefore optimisation trials were performed using 24-





0.1 M sodium 
cacodylate pH 6.5 
0.1 M sodium cacodylate pH 6.5 
kept constant 





1.1 M sodium 
malonate 0-2.0 M sodium malonate 
0.1 M HEPES pH 7.0 0.1 M HEPES pH 7.0 kept constant 
0.5 % Jeffamine ED-
2001 0-1 % Jeffamine ED-2001 
C ProPlex HT-96 well H4 
1.4 M sodium 
malonate 
0-2.0 M sodium malonate 
Alternative of 0-2.0 M sodium 
formate 
Table 3.2.3d– Crystallisation hit conditions from crystals in Figure 3.2.3j and the 
variations in concentration tested during optimisation attempts.   
! ! Chapter!3.2! !
! 116!
well plates, with both the sitting and hanging drop methods, using the standard 
protocol discussed previously of varying salt and precipitant concentrations 
initially, see Table 3.2.3e for details. 
 
 
After three months there was no sign of crystal growth in any of the 
optimised conditions.  Therefore, CDTb’’ was purified en masse over the period 
of two months to gain enough protein to set up a range of different screens.  In 
addition, a range of salt concentrations of 50 mM, 100 mM and 150 mM were 
used in the purification buffer.   
 
All of the preliminary screens discussed in Chapter 3.2.1 were performed 
at a large range of concentrations: 2 mg/ml, 3 mg/ml, 4 mg/ml, 5 m/ml, 6 mg/ml, 7 
Figure 3.2.3k- CDTb’’ crystals all grown in various wells on the ProPlex HT-96 
crystallisation screen.  A:  Small cube-like crystal grown in ProPlex HT-96 well F12.  
B: Smaller cube-like crystals grown in ProPlex HT-96 well G9.  C:  Small cube-like 
crystal grown in ProPlex HT-96 well G10.  D:  Two slightly larger cube-like crystals 
grown in ProPlex HT-96 well H5.   Scale bar represents 200 µm. 
A B 
D C 
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mg/ml, 8 mg/ml, 9 mg/ml and 10 mg/ml, at three different temperatures: 4 °C, 16 
°C and 21 °C.  After three months, there were some signs of crystal growth 
observed on the Structure screen I & II HT-96, which was set up at 6 mg/ml and 
incubated at 16 °C, see Figure 3.2.3l.  The crystals shown in Figure 3.2.3l were 
mounted in mesh LithoLoops and taken to Diamond Light Source to test for signs 
















Crystals Screen and Well Crystallisation Condition Optimisation Trials 
A ProPlex HT-96 well F12 
0.1 M sodium HEPES pH 
7.0 
0.1 M sodium HEPES pH 
7.0 
kept constant 
1.5 M ammonium sulphate 0-2.0 M ammonium sulphate 
B ProPlex HT-96 well G9 
1.3 M sodium potassium 
hydrogen phosphate pH 7.0 
0-2.0 M sodium potassium 
hydrogen phosphate pH 
7.0 
kept constant 
C ProPlex HT-96 well G10 
1.6 M sodium potassium 
hydrogen phosphate pH 6.5 
0-2.0 M sodium potassium 
hydrogen phosphate pH 
6.5 
kept constant 
D ProPlex HT-96 well H5 
0.1 M Tris pH 8.0 0.1 M Tris pH 8.0 kept constant 
1.2 M sodium potassium 
tartrate 
0-2.0 M sodium potassium 
tartrate 
Table 3.2.3e– Crystallisation hit conditions for crystals from Figure 3.2.3k and the 
variations in concentration trialled during optimisation attempts.   
A B  C 
Figure 3.2.3l- Preliminary signs of CDTb’’ crystallisation.  A: Crystals grown in 0.2 M 
magnesium chloride, 0.1 M sodium HEPES pH 7.5 and 30 % PEG 400.  B: Crystals 
grown in 0.2 M magnesium chloride, 0.1 M Tris pH 8.5 and 30 % PEG 4k.  C: Crystals 
grown in 0.2 M magnesium formate.  Scale bar represents 200 µm. 
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As the aforementioned screens and optimisations were unsuccessful up 
until this point, the next steps taken to produce diffraction quality crystals was to 























































Irrelevant purification samples 
  
7.5 7.0 8.0 8.5 
A 
Figure 3.2.3m- A 12% Tris-glycine SDS-PAGE gel pictures displaying pure CDTb’’ 
in the various buffers.  A: CDTb’’ purification using standard GST-affinity 
chromatography with final protein in Buffer 1, pH 6.5.  B: CDTb’’ purification using 
standard GST-affinity chromatography at pH 7.5 with final pure protein dialysed 
into Buffers 2 (pH 7.0), 3 (pH 8.0) and 4 (pH 8.5).  
B 
! ! Chapter!3.2! !
! 119!
 
In the final stages of purification of CDTb’’, the pure protein was dialysed 
separately into the following four buffers, using 50 x volume buffer at 4 °C: 
 
 
1. Buffer 1: 50 mM MES pH 6.5; 150 mM NaCl and 2 mM DTT 
2. Buffer 2: 50 mM HEPES pH 7.0; 150 mM NaCl and 2 mM DTT 
3. Buffer 3: 50 mM Tris pH 8.0; 150 mM NaCl and 2 mM DTT 
4. Buffer 4: 50 mM Bicine pH 8.5; 150 mM NaCl and 2 mM DTT 
 
 
The purity of CDTb’’ in the various buffers was analysed by 12 % Tris-
glycine SDS-PAGE, see Figure 3.2.3m.   After CDTb’’ was deemed suitably pure 
in the range of buffers, the protein was concentrated to 5 mg/ml and some of the 
preliminary screens were performed at 16 °C: Clear Strategy Screen I HT-96, 
Clear Strategy Screen II HT-96, JCSG-plus HT-96, Morpheus HT-96, MIDAS HT-
96 and Structure Screen I & II HT-96.  This technique was used because the 
range of buffers will slightly alter the buffer in the crystallisation condition during 
screening, which should give a wider variety of alternate conditions during 
screening.  This technique was also used with no buffer whereby CDTb’’ was 
dialysed into HPLC-grade water and 150mM NaCl, the protein was concentrated 
to 2 mg/ml and all of the preliminary screens available were performed and 
incubated at 16 °C. 
 
After two months, one large piece of crystalline matter was noted in one 
well from the JCSG-plus HT-96 screen, well G6, and small fragments were noted 
in the screen JCSG-plus HT-96, well B12.  Both wells contained crystals from 
protein purified in HPLC-grade water and 150 mM NaCl, at a concentration of 
only 2 mg/ml, see Figure 3.2.3n.  
 
Crystals displayed in Figure 3.2.3n-B were fused to the bottom of the well 
and so could not be mounted.  The crystals dissolve during attempts to mount in 
LithoLoops.  The large crystal from Figure 3.2.3n-A was mounted in a LithoLoop 
and taken to Diamond Light Source to test for signs of diffraction.  For the first 
time, diffraction spots were observed up to 8 Å for the CDTb’’ crystal, however 
upon exposing the crystal to the beam for more than a few seconds, the crystal 
suffered radiation damage, losing its diffraction quality 
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Table 3.2.3f displays the conditions in which CDTb’’ crystals grew, and the 
variations in the components tested for optimisation trials.  The original 
crystallisation conditions were also used as the primary condition to which the 
Additive screen and Silver Bullet screen were added.  These primary conditions 
were purchased from Molecular Dimensions to ensure no variations by in-house 
production.  The purchased buffers were used to set up three 96-well plates of 
identical conditions, for each of the three different temperature incubators, 4 °C, 
16 °C and 21 °C, in attempts to reproduce the original diffracting crystals.   





0.2 M sodium malonate pH 
7.0 
0-0.3 M sodium malonate pH 
7.0 





0.2 M tri-potassium citrate 0-0.3 M tri-potassium citrate 
20 % PEG 3350 0-25 % PEG 3350 
Table 3.2.3f– Crystallisation hit conditions for crystals from Figure 3.2.3i and the 
variations in concentration tested during optimisation trials. 
Figure 3.2.3n- Crystals of CDTb’’ from protein purified using HPLC-grade water 
and 150 mM NaCl and no buffer.  A: Crystals of CDTb’’ from screen JCSG-plus 
HT-96, well G6.  B: Crystals of CDTB’’ from screen JCSG-plus HT-96, well B12. 













Figure 3.2.3o- CDTb’’ diffraction.  A:  Crystal of CDTb’’ mounted in LithoLoop during exposure to beam at Diamond Light Source with red circle 
indicating beam position.  B:  A diffraction image collected for CDTb’’ displaying the 5 Å resolution ring .  C: A closer look at the diffraction spots of 






In addition, 24-well and 96-well plates were set up using these purchased 
buffers at a protein concentration range of 2 mg/ml, 4 mg/ml, 6 mg/ml, 8 mg/ml 
and 10 mg/ml and a temperature range of 4 °C, 16 °C and 21 °C.  The 96-well 
plates were set up using the sitting drop method whereas the 24-well plates were 
set up using both sitting and hanging drop methods.   
 
These optimisations were performed towards the end of the project, and as 
yet crystals have not appeared in the wells, but due to the extensive range of 




Analysis of the First Diffraction Spots Observed for CDTb’’  
 
As with the CDTb’ crystal, data were collected at wavelength (λ) 0.9686 
Å, 20 % transmission on the I24 beam line at Diamond Light Source, with 
distance from the detector set to 1 m.  At each oscillation of 1 ˚, the crystal was 
exposed for 2 seconds and 3 images were collected.  Diffraction spots observed 
for one of the images are displayed in Figure 3.2.3o-B and C.  The crystal 
stopped diffracting shortly after the third image was taken. 
 
The data were indexed using Mosflm, to give the following cell 
dimensions: a= 173 Å b= 173 Å c= 126 Å and α= 90 ˚ β= 90 ˚ γ= 120 ˚, the space 
group prediction is P3.  The Matthew’s coefficient and solvent content were 
calculated to be 2.72 and 54.8 % respectively with a predicted 6 molecules in the 
asymmetric unit.    
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 As discussed in previous chapters, C. difficile produces an ADP-
ribosylating toxin, amongst other potent exotoxins.  The ADP-ribosylating toxin, 
CDT is made up of two components, CDTa (enzymatic component) and CDTb 
(transport component).   The main focus of Chapter 3 was to characterise CDTb 
variants at a structural level in order to understand the preparations that CDTb 
undertakes prior to uptake into the cells.  The CDTa component has been 
characterised structurally, however the CDTb component has proven difficult to 
work with in terms of crystallography techniques, see Chapter 3.2.  As discussed 
previously, each of the forms of CDTb have been crystallised, two of which have 
shown diffraction (CDTb’ and CDTb’’).  However, the quality of the crystals is 
poor and in order to solve the three-dimensional structure at high resolution, 
better quality crystals are required.  Extensive attempts at improving crystal 
quality have not as yet been successful.  Therefore in this section a number of 
low-resolution structural analysis techniques have been employed to decipher 
some three-dimensional aspects of CDTb variants.  
Dynamic Light Scattering     
 
 Dynamic Light Scattering (DLS) is a technique used to determine the size 
of proteins, nucleic acids, and complexes, and to detect aggregates in 
macromolecular solutions.  However, DLS will be used in this Chapter to 
determine whether CDTb variants are monodisperse or polydisperse, hence 
whether or not the CDTb samples are suitable for SAXS data collection.  For 
details on the theory of DLS see Chapter 2.2.1.   
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Small-Angle X-ray Scattering 
 
 Small-angle X-ray scattering (SAXS) is a technique used to determine 
low-resolution structures of macromolecules in solution, which can provide 
information about the size, distribution and overall shape of the macromolecule.  
The advantage of using SAXS over crystallography is that crystalline matter is not 
required, which is often a limiting step in X-ray crystallography.  A small sample 
of pure monodisperse protein is all that is required for SAXS, however there are 
limitations, the key restriction being the low-resolution data that is generated.  For 
a detailed explanation of the theory of SAXS and the methods used to generate 
low-resolution structures of proteins see Chapter 2.2.1.      
 
Circular Dichroism Spectroscopy 
 
 
In some cases where high-resolution methods such as X-ray diffraction 
are not feasible, other techniques that yield less detailed results but still hold 






























Figure 3.3.1a- CD spectra showing signatures for secondary structure.  Adapted from 
Compton et al.  (Compton and Johnson, 1986) 
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 Unlike SAXS, which can detail overall shape, symmetry and domain 
arrangements in solution, circular dichroism (CD) spectra can provide useful 
information about the secondary structure of proteins.  CD spectroscopy involves 
measuring the CD of a protein molecule over a range of wavelengths.  CD occurs 
as a consequence of the interaction of polarised light with chiral molecules such 
as amino acids, and is defined as the difference between the absorption of left-
handed circularly polarized light (L-CPL) and right-handed circularly polarised 
light (R-CPL)(Compton and Johnson, 1986; van Stokkum et al., 1990). 
 
CD spectroscopy is a useful technique that only requires small volumes of 
protein.  The CD signatures can provide information about the α-helical and β-
sheet secondary structural elements, see Figure 3.3.1a.  There are various 
algorithms used to decipher the CD spectra signature, and in some such cases 
the percentage of each structural element in the protein can be predicted.  CD 
spectroscopy will be used in this chapter to identify secondary structural features 
of the CDTb variants.       
 
 
Size-Exclusion Chromatography Multi-Angle Light Scattering !
 As there is some ambiguity as to what the oligomeric state is of the CDTb 
variants as noted during size-exclusion chromatography, DLS can be used to 
determine whether or not the protein is monodisperse and can provide an 
approximate particle size.  However, for more specific molar mass determination, 
size-exclusion chromatography multi-angle light scattering (SEC-MALS) can be 
employed. 
 
 SEC-MALS is a technique that combines a number of protein analysis 
techniques in one system.  A size-exclusion column is linked to an HPLC 
machine with two additional detectors: a light scattering (LS) diode array and a 
refractive index (dRI) detector, see Figure 3.3.1b. This online measurement 
allows for calculation of the absolute molecular mass of each molecule eluted 
from the size-exclusion column.  The light scattering module is similar to DLS as 
discussed in detail in Chapter 2.2.1, however unlike the DLS data collected in 
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Chapter 2.2.2 and Chapter 3.3.2, this module uses a multi-angle detector rather 
than a single angle detector as in DLS.  When the electric field of a 
monochromatic coherent laser impacts a molecule in solution, a dipole is 
generated causing light scattering (Wang et al., 1979).  The intensity of scattered 
light is determined with a detector array at multiple angles, and this is directly 

























The concentration of the molecules in solution is analysed by measuring 
the refractive index of the solution (dRI).  The ratio of the LS to the dRI provides 
the absolute molar mass (Wang et al., 1979; Wyatt, 1998).  SEC-MALS will be 
used in this chapter to determine the absolute molar mass of CDTb’ and CDTb’’ 
which will resolve the current ambiguity of oligomeric state of both proteins. 
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Electron Microscopy  
 
Negative stain electron microscopy is slowly becoming a popular method 
for low-resolution structure determination for proteins that are recalcitrant to 
crystallisation.  This technique is most commonly used for membrane proteins, 
macromolecules and macromolecular complexes.  
 
 In this subchapter, the aim was to visualise CDTb’’ using electron 
microscopy and SAXS to determine whether or not CDTb’’ is forming the 
























! ! Chapter!3.3! ! ! ! ! ! Chapter!3.3!
! 128!
3.3.2 Materials and Methods 
Dynamic Light Scattering 
 
The various forms of CDTb were purified as discussed previously in 
Chapter 3.1.2.  Due to time limitations, only the CDTb’ and CDTb’’ forms were 
prepared for DLS and SAXS.  The protein samples were prepared by 
centrifugation at 13,000 rpm to remove any large particles or precipitate and were 
filtered through a 0.45 µm millex-HA filter (Millipore).  Nitrile gloves were worn to 
avoid fingerprints on the sample cuvette and to prevent contamination of the 
samples during handling.  A low volume 12 µl glass cuvette (QS 3.00 mm) was 
equilibrated by rinsing in the CDTb buffer: 50 mM Tris-HCl pH 7.5, 150 mM NaCl 
and 2 mM DTT. 
  
DLS was performed using a Zetasizer Nano S (Malvern Instruments) 
which uses a 4 mW He-Ne laser with wavelength λo = 633 nm, and a scattering 
angle of θ = 173°.  A 50 µl sample of each of the CDTb forms at concentrations 
of 0.5 mg/ml were loaded in succession into the cuvette and the external 
surfaces of the cuvette were gently wiped with soft lens cleaning tissue to ensure 
no particles were present that could lead to false readings.  The cuvette was 
placed in the sample holder and was allowed to equilibrate to 19 °C for 2 min.  A 
series of three scans were performed for each CDTb form and subsequent 
intensity fluctuations were recorded which contained information about the time 
scale movement of the scattering particles.  DLS results will confirm whether or 
not the CDTb samples are suitable for use in SAXS data collection.            
 
Multiple crystallisation plates were set up in Chapter 3.2.3 after buffer 
exchanging CDTb variants into alternative buffer systems to provide a wider 
variety of crystallisation conditions.  DLS data were also collected for the buffer 
exchanged CDTb’ and CDTb’’ variants to confirm that there was no effect on the 
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SAXS Data Collection and Ab initio Model Building 
 
CDTb’ and CDTb’’ samples prepared as above were taken to Diamond 
Light Source for SAXS data collection.  Experiments were performed as with 
Toxin A in Chapter 2.2.2, on the I22 beam line, at 20 °C using the Pilatus 2M 
detector.  Concentrations of 0.5 mg/ml, 1 mg/ml, 2.5 mg/ml and 5 mg/ml were 
used in the scattering experiments, along with four buffer samples.  Calibration 
was carried out using BSA at 5 mg/ml in 50 mM Tris-HCl pH 7.5 as a molecular 
weight standard.  Data was integrated using Dream (in-house software, Diamond 
Light Source) and the subsequent data collected for the buffer samples was 
averaged and subtracted from the CDTb data using PRIMUS (Konarev et al., 
2003).  An indirect Fourier Transformation automated by GNOM was used to 
generate a particle distribution function P(r) of the samples, which in turn was 
used to calculate the radius of gyration (Rg) and the maximum particle size (Dmax) 
(Svergun, 1992).  Ab initio modelling was performed using the on-line server for 
DAMMIF, whereby 20 models were produced (Franke and Svergun, 2009).  The 
models were then averaged using DAMAVER (Volkov and Svergun, 2003).  The 





As discussed in Chapter 3.2.1, X-ray crystallography techniques have not 
been successful for the CDTb forms up until this point and so other techniques 
that yield less detailed results but still hold valuable information have been used.  
One such technique is CD Spectroscopy that provides secondary structural 
information of the protein.   
 
CD spectroscopy was performed using a Jasco J-600 spectropolarimeter 
with a 2 mm rectangular cell.  CDTb samples were diluted to 0.5 mg/ml and 
dispensed into the cell that had been pre-rinsed with CDTb buffer.  The 
wavelength scans were performed at 20 ˚C over a range of 195-250 nm at a 50 
nm/min rate. 
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Size-Exclusion Chromatography Multi-Angle Light Scattering 
 
 The SEC-MALS setup was as demonstrated in Figure 3.3.1b.  A silica 
based size-exclusion column (TSK-G3000SW, Sigma Aldrich) was connected to 
an HPLC (Agilent Technologies, UK) instrument.  This was then connected to a 
light scattering diode array (Dawn Heleos II, Wyatt, USA) and a differential 
refractive index detector (Optilab rEX, Wyatt, USA) in series.  The column was 
pre-equilibrated overnight in CDTb’’ buffer: 50 mM Tris-HCl pH 7.5 and 150 mM 
NaCl (2 mM DTT was removed to prevent any low-level interference with the UV 
absorbance detector) at 1 ml/min to achieve stable base lines as well as low 
background scatter.   
 
 Initially the final purification step of CDTb’’ was performed during the 
SEC-MALS so that any monomer present would be detected and also GST as a 
control to ensure the size-exclusion column yielded similar results to those 
performed on the regular superdex-200 10/300 GL.  90 µl of the CDTb’’ sample 
was injected onto the system.  The respective molar masses of subsequent 
peaks were calculated from resulting LS and dRI data using the software ASTRA 
(Wyatt).   
 
 Concurrently a standard superdex-200 10/300 size-exclusion run was 
performed to separate the CDTb’’ oligomer, monomer and GST using the 
standard purification technique as described in Chapter 3.1.2.  90 µl of the high 
molecular weight oligomeric peak was then injected into the SEC-MALS system.  
The predicted monomeric peak was also injected into the SEC-MALS system and 
also a concentrated sample of the monomeric peak to determine whether or not 
oligomerisation was affected by concentration. 
 
 All of the SEC-MALS experiments were performed at 1 ml/min in buffer 50 
mM Tris-HCl pH 7.5 and 150 mM NaCl.  The experiments were carried out with 
the help of Dr Christian Pernstich, in Professor Steve Halford’s research 








CDTb’’ at 4 mg/ml was centrifuged at 13,000 rpm to remove any large 
particles or precipitate and were filtered through a 0.45 µm millex-HA filter 
(Millipore).  The prepared protein was then adsorbed onto glow discharged 
carbon-coated copper grids.  The grids were then negatively stained using 0.75 
% (w/v) uranyl formate.  Micrographs were recorded at a magnification of 
500,000x using a JEOL JEM1200EXII transmission electron microscope, 
operating at 120 kV.  Electron micrographs were recorded with the help of Iain 
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3.3.3 Results 
Dynamic Light Scattering !
Pure CDTb samples were diluted to 0.5 mg/ml for use in DLS 
experiments.  Due to time restraints, DLS was performed only for CDTb’ and 
CDTb’’, at the range of pHs discussed in Chapter 3.2.2.  Three DLS scans were 
performed consecutively at 19 °C for each sample and the Zetasizer software 
auto processed the scattering data to extract decay rates to produce a size 
distribution.  
 
Figure 3.3.3a displays the DLS results for both CDTb’ and CDTb’’ in the 
standard purification buffer at pH 7.5.  The correlation function for the collected 
data, is displayed in Figure 3.3.3a A2 and B2 for CDTb’ and CDTb’’ respectively.  
The red line represents the decay over time, which is extended and is slow 
suggesting a large particle size.  In addition the baseline is flat indicating a lack of 
larger particles or aggregates.  Figure 3.3.3a A3 and B3 displays the count rate 
for CDTb’ and CDTb’’ respectively, which represents the intensity fluctuations.  
Typically the smaller the particle the larger the fluctuations as the particles are 
moving faster in solution, whereas larger particles have lower fluctuations, such 
as those displayed in this figure.  Finally, the intensity PSD graph displayed in 
Figure 3.3.3a A4 and B4 provides details on the intensity of scattered light from 
each particle and the size of the corresponding particle, for CDTb’ and CDTb’’ 
respectively.  The X-axis shows the distribution of size classes whilst the Y-axis 
shows the relative intensity of scattered light.  For both CDTb’ and CDTb’’ there is 
a single large intensity peak of about 16 % between 20-200 nm in diameter.  This 
is to be expected as both CDTb’ and CDTb’’ behave in a similar manner during 
size exclusion and elute as if similar size proteins.  However, if the theory of 
oligomerisation is correct then CDTb’’ should appear approximately seven times 
bigger than CDTb’, however that is not the case. 
 
The Mie theory can be used to convert the fundamental size distribution 
generated from an intensity distribution to a volume distribution as shown in 
Figure 3.3.3a A1 and B1.  Although the Mie theory assumes that the particles are 
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all spherical, homogenous and the optical properties of the particles are known, it 
can be useful to examine a volume PSD graph in comparison to an intensity PSD 
graph.  The volume PSD describes the relative proportion of multiple components 
in the sample based on their mass or volume (rather than their scattering 
intensity).  The single peaks on these graphs for CDTb’ and CDTb’’ suggest 
monodispersity for both proteins rendering them suitable for SAXS data collection 
(Wiscombe, 1980).  The correlation function, count rate, intensity PSD and 
volume PSD graphs for CDTb’ at pH 6.5 and 7.0 are displayed in Figure 3.3.3b 
and for pH 8.0 and 8.5 in Figure 3.3.3c.  It is immediately apparent that there are 
multiple peaks on all of the intensity PSD graphs for CDTb’ at all pH variations 
except for the original pH 7.5.  However when looking at the relative proportion of 
these components based on the volume PSD graphs the sample appears to be 
predominantly monodisperse.  This is reflected in the distribution results 
displayed in Table 3.3.3a, which will be discussed in detail later in this section. 
 
The correlation function, count rate, intensity PSD and volume PSD 
graphs for CDTb’’ at pH 6.5 and 7.0 are displayed in Figure 3.3.3d and for pH 8.0 
and 8.5 in Figure 3.3.3e.  At pH 6.5 and 7.0, the CDTb’’ data does not look 
monodisperse, there are multiple peaks on the intensity PSD graphs and the 
same applies for the volume PSD graphs.  The higher pH buffer; pH 8.5 doesn’t 
appear to have affected CDTb’’ dispersity as the results are similar to that of the 
standard pH 7.5 results.  The pH 8.0 buffer however has affected the dispersity 
as reflected in the volume PSD graph which shows a slightly warped peak and a 
much larger peak which again could suggest the presence of aggregated protein 
or dust particles.  In summary the DLS results indicate that pH 7.5 buffer is most 
suitable for CDTb’ and CDTb’’ to maintain the protein in a monodisperse state.  
All changes in pH affect the dispersity of CDTb’ where as only the lower pH 
buffers have a significant affect on CDTb’’ dispersity.   
 
Table 3.3.3.a displays both the cumulants and distribution results 
obtained for CDTb’ and CDTb’’ for the different pH buffers.  The Z-Average size 
is also known as the cumulants mean and is defined as the hydrodynamic 
particle size.  This measurement represents the diameter of a sphere that has the 
same drag coefficient as a given particle, so the Z-Average size is a predicted 
particle size based on the movement of the standard particles in solution.  This 
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estimated value is based on the theory that all of the particles are spherical in 
shape.  The Z-Average particle size for CDTb’ varies between 40.1 nm and 55.3 
nm which is considered fairly consistent.  This value indicates that CDTb’ is 
approximately 400-550 Å, which is much larger than anticipated, especially 
considering this is the monomeric form of CDTb.  However, this does correspond 
with the size-exclusion chromatogram whereby CDTb’ elutes at a point expected 
for high molecular weight proteins > 500 kDa.  The range of particle sizes for the 
differing pH buffers is broad enough to suggest that the pH of the buffer is 
altering the oligomeric state of the protein.  The Z-average size particle diameter 
for CDTb’’ ranges between 40.5 nm and 100.9 nm, which is a large range and 
indicates the protein could have an approximate diameter between 400-1000 Å.  
This range is far too broad which may indicate that the pH variation does affect 
the oligomeric arrangement of CDTb’’ too.   
 
The Polydispersity Index (PDI) is a measure of the width of molecular 
weight distributions, and is an indication of variance in the sample.  A PDI value 
of 0.2 or less is expected for monodisperse samples, therefore from Table 3.3.3a 
it is clear that only two samples on the table are likely to be monodisperse, which 
are CDTb’ and CDTb’’ at pH 7.5.  The remaining data all have PDI values of 
greater than 0.2, which indicates that these samples are not monodisperse. 
 
The distribution result describes the percentage of each identified 
particles of the same size in the solution along with the estimated diameter size 
of each of these particles, corresponding to peaks on the intensity PSD graph.  
Both CDTb’ and CDTb’’ in the different pH buffers have multiple peaks with a 
variety of distribution results, but for the two samples mentioned above with low 
PDI values (CDTb’ and CDTb’’ at pH 7.5) the distribution result is 100 % and 99.7 
% for CDTb’ and CDTb’’ respectively.  The data collected at pH 7.5 indicates that 
both CDTb’ and CDTb’’ are approximately 530-560 Å and are monodisperse.    
 
 To conclude, all of the DLS results reveal that oligomeric states of CDTb’ 
and CDTb’’ vary with pH.  The key finding is that CDTb’ and CDTb’’ share a 
similar overall particle size diameter of 530-560 Å at pH 7.5, which correlates with 
the size-exclusion chromatogram observed for both proteins.   
Chapter(3.3(( ( ( ( ( ( ( ( 135(
(
Light Scattering Data 
Statistics CDTb’ CDTb’’ 
 pH 6.5 pH 7.0 pH 7.5 pH 8.0 pH 8.5 pH 6.5 pH 7.0 pH 7.5 pH 8.0 pH 8.5 
Cumulants 





















 PDI 0.432 0.453 0.182 0.725 0.444 0.290 0.529 0.187 0.372 0.229 
Distribution 
result 
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Table 3.3.3a- Dynamic light scattering data statistics for both CDTb’ and CDTb’’ at a pH range of 6.5-8.5.  The cumulants results include 
the Z-Average size, which is defined as the hydrodynamic particle size, and the Polydispersity Index (PDI) which is a measure of the 
molecular weight distributions.    The distribution result describes the percentage of each identified particles of the same size in the 
solution and includes the estimated diameter size of these particles. 
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Figure 3.3.3a- Dynamic light scattering results for CDTb’ at pH 7.5 (A) and CDTb’’ at pH 7.5 (B).  For both A and B: graph 1 displays the 













Figure 3.3.3c- Dynamic light scattering results for CDTb’ at pH 8.0 (A) and pH 8.5 (B).  For both A and B: graph 1 displays the volume 









Figure 3.3.3d- Dynamic light scattering results for CDTb’’ at pH 6.5 (A) and pH 7.0 (B).  For both A and B: graph 1 displays the 
















Figure 3.3.3e- Dynamic Light Scattering results for CDTb’’ at pH 8.0 (A) and pH 8.5 (B).  For both A and B: graph 1 displays the 








Small-Angle X-Ray Scattering !
CDTb’ SAXS Structure !
Given the absence of structural data for all CDTb variants, SAXS data 
were collected, processed and ab initio modelling was performed to generate a 
low resolution SAXS envelope.  Initially the data was reduced and the solvent 
subtracted using PRIMUS (Konarev et al., 2003).  The scattering data displayed 
in Figure 3.3.3f-A was Fourier transformed using GNOM to obtain the P(r) 
function, also displayed in Figure 3.3.3f-B, from which the Rg was calculated.    
!!!!
The Rg value was calculated using a Guinier plot, which is the analysis of the 
scattering curve at the smallest scattering angles.  The Rg value describes the 
size of the particle in terms of the root mean square distance from the outer 
particle to its center.  The Rg for CDTb’ as stated in Table 3.3.3b was calculated 
to be 139.6 Å.  The Dmax value is the maximum particle dimension calculated 
from the P(r) curve in Figure 3.3.3f-B, with final result displayed in Table 3.3.3b.  
The Dmax was calculated to be 420 Å, which correlates approximately to the Z-
Average particle size obtained from DLS data.  The profile of the P(r) curve can 
provide information as to the overall particle shape.  In general, a bell-shaped 
curve indicates a perfect spherical shape.  A shift in this bell-shaped curve to the 
left indicates a more elongated globular structure, which is indicated in the P(r) 
curve for CDTb’ (Jacques and Trewhella, 2010).   
Scattering Data Statistics CDTb’ 
P(r) Function 
Rg (Å) 139.6 
Dmax (Å) 420 
Structural Modeling 
Discrepancy (χ2) 0.038 
NSD 1.18 ± 0.02 
Table 3.3.3b- Scattering data statistics obtained during SAXS data processing. 
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Figure 3.3.3f- Scattering curve and P(r) Curve for CDTb’ (non-activated form of 
CDTb transport component).  A: Scattering curve for CDTb’ SAXS data.  B: The 
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DAMMIN was used to generate 20 ab initio models of CDTb’ which were 
then averaged using DAMAVER to provide a final low-resolution SAXS envelope 
of CDTb’ (Franke and Svergun, 2009; Volkov and Svergun, 2003).  The structural 
modeling statistics are displayed in Table 3.3.3b.  The discrepancy between 
experimental and ab initio data χ2 was calculated using DAMMIF and the 
normalized special discrepancy (NSD) for the 20 models was calculated by 
DAMAVER (Franke and Svergun, 2009; Jacques and Trewhella, 2010; Volkov 
and Svergun, 2003).  The χ2 value is low suggesting low discrepancy between 
experimental and modeling data.  In addition the low NSD value indicates there is 











The final SAXS structure of CDTb’ is displayed in Figure 3.3.3g, 
represented as a surface diagram in blue.  The envelope is approximately 443 Å 
long and 190 Å wide.  When you consider that CDTb’ as a monomer is 99 kDa, 
this envelope is much larger than expected.  A model of CDTb’ was created using 
SWISS-MODEL with the C2 toxin from Clostridium botulinum as a model, see 
Figure 3.3.3h, which was then placed into the SAXS envelope of CDTb’ for size 
comparison (Arnold et al., 2006; Schleberger et al., 2006).  It is clear that the 
SAXS envelope is much larger than anticipated for a protein of this size. 
 
Figure 3.3.3g- Ab initio SAXS structure of CDTb’.  The CDTb’ SAXS envelope is 
approximately 443 Å in length and 190 Å wide, which is uncharacteristically large for 
a protein of 99 kDa.  Images created using PyMOL (version 1.5.0.4, Schrödinger, LLC).   
443 Å  
190 Å  










CDTb’’ SAXS Structure !
SAXS data for CDTb’’ were collected in the same manner as CDTb’, 
using the samples that had been analysed by DLS.  On plotting of the scattering 
curve, it became apparent that the sample might have aggregated.  A suitable 
Guinier plot could not be produced which caused inconsistent Rg calculations.   
The Guinier plot is taken from the scattering curve at the smallest scattering 
angle and inspection of the Guinier region can reveal the presence of 
aggregation in the sample which can result in non-reliable model generation 
(Putnam et al., 2007).  The data scattering at the smallest scattering angle was 
non-linear for CDTb’’, hence the difficulties in calculation of an accurate Rg value.  
If the Guinier plot is non-linear, the protein sample may be aggregated and so 
data-processing was not taken further for CDTb’’.   
90 ° 
Figure 3.3.3h- Ab initio SAXS structure of CDTb’ with CDTb’ model placed in the 
SAXS envelope.  The CDTb’ SAXS envelope is approximately 443 Å in length and 
190 Å wide, which is uncharacteristically large for a protein of 99 KDa.  Displayed 
above is the CDTb’ monomer model created using C2 toxin from Clostridium 
botulinum, superimposed into the SAXS envelope to illustrate the size differences 
(PDB: 2J42) (Schleberger et al., 2006). 
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Circular Dichroism Spectroscopy ! !Circular Dichroism Spectroscopy was performed on CDTb’ and CDTb’’, 
primarily for secondary structure information, but also to cross check the results 
with the secondary structure features in the homology model created using C2 





























Figure 3.3.3i – Circular dichroism spectroscopy data for CDTb’ (A) and CDTb’’ (B). 
B 
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 Both the CDTb’ and CDTb’’ spectra share the same CD spectra profile.   
The Δ ε-1 starts to decrease at approximately 202 nm and reaches its minimum at 
approximately 217 nm whereupon the Δ ε-1 starts to increase until the base line is 
reached at 250 nm.  Unlike the CD spectra from Figure 3.3.1a, the Jasco J-600 
spectropolarimeter used for this experiments doesn’t have the same wavelength 
range.  The CDTb’ and CDTb’’ spectra profiles do not follow the signature profile 
usually observed for unfolded protein, which indicates both CDTb’ and CDTb’’ are 
folded.  The CDTb’ and CDTb’’ spectra do share similarities to the signature 
profile for both α-helices and β-sheets, indicating that they have α-helical and β-
sheet content.  The percentage of α-helices and β-sheets in the samples cannot 
accurately be determined using data collected from this equipment due to the 
small wavelength range.  The C2 binary toxin transport component contains both 
α-helices and β-sheets, which indicates the model may be a fairly accurate 
CDTb’ representation.      !
Size-Exclusion Chromatography Multi-Angle Light Scattering  !
The SEC-MALS technique was used to determine the molar mass of 
CDTb’’.  The theory is that CDTb’ is trypsin activated to form CDTb’’ which then 
oligomerises, most likely to a heptamer form prior to CDTa binding.  All of the 
CDTb variants elute from the gel-filtration column at the same point which is 
expected for proteins  > 500 kDa in size.  Initially it was thought that both CDTb 
and CDTb’ could also form heptamers prior to activation.  However it has slowly 
become apparent from both DLS data and SAXS data that the heptameric pore 
may not have formed, and it is more likely that the CDTb variants are in a 
different oligomeric state, potentially multiple states.  SEC-MALS was performed 
using purified CDTb’’ to determine the molar mass of the peak that elutes from 
the gel-filtration column at approximately 500 kDa.   A crude sample of CDTb’’ 
that had not been subjected to the final size-exclusion chromatography cleaning 
step was injected onto the SEC-MALS system, so that the CDTb’ monomeric 
peak and GST peak would be present for control comparisons of molar mass 
calculations.  In addition, some of the crude CDTb’’ was subjected to the final 
cleaning step and the monomeric peak eluted at approximately 15 ml was 
injected onto the SEC-MALS system on a separate run so that the results could 
be directly compared, see Figure 3.3.3j. 
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Figure 3.3.3j- SEC-MALS CDTb’’ crude fraction results (black line) superimposed onto the SEC-MALS CDTb’’ monomeric peak results 
(blue line).  Note the monomeric peak usually elutes at approximately 15 ml and the oligomeric peak at approximately 7 ml.  The lines 
above the peaks represent the molar mass calculations for the protein eluted in those fractions. Dotted line represents dRI and 




Figure 3.3.3j displays the CDTb’’ crude SEC-MALS results (black line) 
superimposed on the CDTb’’ monomeric peak fraction results (blue line).  The 
continuous line represents the Rayleigh Ratio (LS) and the dotted line represents 
the differential refractive index trace (dRI).  The Rayleigh Ratio is an indication of 
the size and weight of the particle whereas the dRI is a measurement of 
concentration comparable to a UV trace.  
 
 For the crude CDTb’’ sample, the graph displays the standard profile 
observed in the final cleaning step, with the oligomeric peak eluting at 7-8 ml, the 
monomeric peak eluting at 15 ml and the GST elution peak shortly after.  The 
oligomeric peak dRI and LS are much higher than that for the monomeric peak 
which is consistent with the cleaning step chromatogram profile.  The horizontal 
line across each peak indicates the selected data used for the molecular mass 
calculations performed using the software ASTRA (Wyatt).  A reasonably flat line 
indicates a mono-dispersed species whereas a rapidly descending or ascending 
line is indicative of dynamically interchanging species.  The oligomeric peak 
shows a rapidly descending line indicating this fraction of CDTb’’ is actually 
multiple conformations of species rather than a specific oligomeric species as 
originally predicted.  The CDTb’’ monomeric peak at 15 ml shows a relatively flat 
line of approximately 0.7 x 105 g/mol which is 70 kDa.  CDTb’’ in monomeric form 
is 67 kDa so this SEC-MALS results confirms the peak eluting at 15 ml is CDTb’’ 
in monomeric form.  The CDTb’’ oligomeric peak has a calculated molar mass 
range of 1.3 x 106 g/mol to 1.7 x 106 g/mol which is 1.3-1.7 MDa. 
 
 A sample of BSA was also injected onto the SEC-MALS system as a 
control.  The calculated molar mass of BSA from the SEC-MALS data is 
displayed in Figure 3.3.3k in pink at approximately 60 kDa.  The exactly molar 
mass of BSA is 66 kDa, so this would indicate the system is working properly.  
This result was superimposed onto the CDTb’’ monomeric fraction result which 
has a calculated molar mass from the SEC-MALS of slightly under 70 kDa which 






















Figure 3.3.3k- SEC-MALS CDTb’’ monomeric peak fraction results (blue line) superimposed onto the SEC-MALS BSA control results 
(pink).  Dotted line represents dRI and continuous line represents LS.  The lines within the peaks represent the molar mass calculations 




















 Figure 3.3.3l- SEC-MALS CDTb’’ monomeric peak fraction results (blue line) superimposed onto the SEC-MALS CDTb’’ crude results 
(black) and the concentrated CDTb’’ monomeric peak in brown.  Dotted line represents dRI and continuous line represents LS.  The lines 





Figure 3.3.3l displays the SEC-MALS result for the original crude sample 
(black), the CDTb’’ monomeric fraction (blue) and the CDTb’’ monomeric fraction 
concentrated up (red), to determine whether or not oligomerisation into 
dynamically interchanging species is a result of concentration.  The key 
observation from this graph is that after concentration of CDTb’’ monomer a peak 
has appeared at the same position observed for oligomeric CDTb’’ that was not 
there previously at lower CDTb’’ monomer concentrations indicating 
oligomerisation is observed at high concentrations but not low concentrations.     
 
 
Electron Microscopy for CDTb’’ 
 
 CDTb’’ was purified using the standard optimised protocol as discussed in 
Chapter 3.1.3 and was adsorbed to a glow-discharged carbon-coated copper 
grid.  The grid was then stained with 0.75 % uranyl formate and was visualised 
using a JEOL JEM1200EXII transmission electron microscope.  The results are 
displayed in Figure 3.3.3m. 
 
 Figure 3.3.3m displays the electron micrographs of CDTb’’ at 4 mg/ml.  
Image A from Figure 3.3.3m displays the first electron micrograph of CDTb’’ that 
was taken at the very edge of the copper grid.  It is clear from this that the 
concentration used was too high and in future a concentration of 0.5 mg/ml may 
be more suitable.     
 
The electron micrographs reveal that CDTb’’ presents as large globular 
spheres.  They are not clear heptameric pore-shaped as would be expected 
based on the theory of CDTb’’ oligomerisation, but large inconsistently shaped 
spheres.  A closer look as displayed in Figure 3.3.3m B shows that they do differ 
in size and are not perfectly spherical.  They range from approximately 3 nm to 
10 nm, which is consistent with results from DLS.  Another distinctive feature of 
the electron micrographs is the presence of a variety of large well-structured 
species, Figure 3.3.3m-C and D.  Some of these structures are elongated and 
with rigid edges whereas some are more irregular in shape but again with rigid 
edges.  It is possible these are CDTb’’ microcrystals. 
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Figure 3.3.3m- Electron micrographs of CDTb’’.  All images are taken from the 
same plate.  A: Scale bar represents 20 nm. B: A zoomed in version with scale bar 
representing 20 nm. C: Scale bar represents 50 nm.  D: scale bar represents 50 nm. 
A B 
C D 
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3.4 Discussion 
CDTb Variant Expression, Purification and Crystallisation 
 
Some Clostridium difficile strains produce an ADP-ribosylating binary 
toxin; CDT, alongside the two potent exotoxins; Toxin A and B.  The role of the 
binary toxin in pathogenicity is unclear, however some studies have shown that 
CDT causes the formation of microtubule-based protrusions on the cell surface of 
target cells (Schwan et al., 2009).  It is postulated that these protrusions promote 
adherence of C.difficile to the intestinal epithelial cells (Schwan et al., 2009).    
The binary toxin is made up of two independently produced components; CDTa, 
the enzymatic component and CDTb, the transport component.  The transport 
component is thought to interact with cell surface receptors on target cells.  This 
component forms oligomers, interacts with the enzymatic component, CDTa, and 
both components are taken up into the cells by receptor mediated endocytosis.  
Studies have shown that individually CDTa and CDTb are non-toxic, however 
when the components are combined CDT is toxic to Vero cells (Sundriyal et al., 
2010). 
 
 CDTb is produced independently from CDTa and has an N-terminal signal 
peptide and an activation domain, see Figure 3.1.1a for the domain organisation.  
It is thought that CDTb must be activated by trypsin cleavage to form the full 
matured CDTb’’ form.  The aim of this chapter was to crystallise the individual 
CDTb variants: CDTb, CDTb’ and CDTb’’ and solve their structures using X-ray 
crystallography.  Elucidating the high-resolution structures of the individual CDTb 
variants may contribute towards a greater understanding of the process by which 
CDTb oligomerises in preparation for translocation into the cytosol.           
  
CDTb, CDTb’ and CDTb’’ were all expressed and purified successfully 
using the optimised technique as outlined in Chapter 3.1.2.  One surprising 
observation made during the final cleaning step of size-exclusion was that all 
three variants eluted from the column at a point which is expected for proteins of 
> 500 kDa.  This was unexpected as it is thought that only CDTb’’ forms 
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oligomers, however, it was assumed that potentially all three variants form 
oligomers and so crystallisation trials were initiated. 
 
Extensive attempts were made at crystallisation of CDTb variants, with 
some success.  Diffraction quality crystals were obtained for CDTb’ and CDTb’’ 
but crystals stopped diffracting shortly after exposure to the beam.  It is possible 
that this peak shift to high molecular weight observed at the size-exclusion 
chromatography step could be affecting crystallisation of CDTb variants, as 
obtaining crystals of CDTb, CDTb’ and CDTb’’ has proved extremely difficult.  
Therefore, efforts were made to elucidate the oligomeric state of the proteins.    
 
Alternative Structural and Biochemical Techniques  
Dynamic Light Scattering  
 
Due to time restraints, CDTb’ and CDTb’’ were chosen for oligomeric 
state determination as these are functionally the most important CDTb variants.  
Initially DLS was used to determine whether or not the eluted protein was 
monodisperse because the superdex-200 10/300 column used in the final size-
exclusion step cannot resolve proteins > 500 kDa, so it is possible that the peak 
observed contains multiple oligomeric arrangements.  There are some 
homologous pore-forming toxins that are known to form more than one type of 
oligomer, for example the anthrax protective antigen (PA) transport component of 
the anthrax binary toxin (Atx) forms both heptamers and octamers (Kintzer et al., 
2009).  The DLS data suggests that in the standard Tris-HCl pH 7.5 buffer used 
to purify CDTb’ and CDTb’’, the proteins are 100 % and 99.7 % monodisperse 
respectively.  This is a strong indication that both CDTb’ and CDTb’’ are forming 
single state homogenous oligomers.  The Z-average particle size prediction for 
CDTb’ and CDTb’’ from the DLS data processing are 53.1 nm and 56.6 nm 
respectively.  As CDTb’ is slightly larger at 94 kDa than CDTb’’ at 67 kDa, but 
with a lower predicted Z-average size, it is possible that the variants are forming 
different sized oligomers.  As discussed in Chapter 3.3.3, changing the pH of the 
buffer appears to affect the dispersity of the proteins, therefore pH 7.5 was kept 
consistent for the remaining alternative techniques used to characterise CDTb 
variants. 
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Small-Angle X-Ray Scattering 
 
The SAXS data processing results are displayed in Chapter 3.3.3 along 
with the ab initio model generated for CDTb’.  There were some difficulties 
encountered during processing of the data for CDTb’, as there were some 
indications that the samples may be aggregated; however the DLS data suggests 
otherwise.  There were problems generating a liner Guinier plot, however there 
were consistencies in calculation of Rg values and so the data were taken to the 
model building stage, with the final SAXS structure displayed in Figure 3.3.3g.  
The structure is approximately 443 Å long and 190 Å wide, which is slightly 
smaller than expected when compared to the predicted Z-average size from the 
DLS data of 530 Å.  During processing of CDTb’’ SAXS data it became apparent 
from the Guinier plot that the CDTb’’ samples may be significantly aggregated, 
which again does not correspond to the DLS results, therefore data were not 
processed further so as to not cause biased model building.     
 
Size-Exclusion Chromatography Multi-Angle Light Scattering 
 
As the DLS data and SAXS data are creating some ambiguity as to the 
oligomeric state of CDTb’ and CDTb’’, SEC-MALS experiments were performed 
to calculate the exact molar mass of the high molecular weight peak eluted from 
the size-exclusion column in the final purification step of CDTb’’.  SEC-MALS 
combines a size-exclusion column with a UV detector, light scattering (LS) 
detector and a refractive index detector (dRI) (Wang et al., 1979; Wyatt, 1998).  
The ratio of LS to dRI provides the absolute molar mass of a particular selected 
peak.  The SEC-MALS results are displayed in Figures 3.3.3j, 3.3.3k and 3.3.3l.  
SEC-MALS confirmed that the high molecular weight elution peak from the size-
exclusion column is in fact a mixture of dynamically interchanging oligomeric 
species in the mega Dalton range of sizes.  The second peak observed in the 
final purification step was confirmed as monomeric CDTb’’, which was noted to 
be of very low concentration.  This fraction was then concentrated and again 
analysed by SEC-MALS.  After concentration, this peak shifted to the left joining 
the high molecular weight fraction forming interchanging oligomers.  Therefore, 
this confirms that oligomerisation occurs as a result of concentration.  This may 
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explain why the DLS results suggest monodispersity as they are performed at 0.5 
mg/ml whereas the SAXS data was collected at a range of 0.5-5.0 mg/ml.   
Electron Microscopy 
 
 CDTb’’ was concentrated to 4 mg/ml and adsorbed onto to a glow-
discharged carbon-coated copper grid, stained with 0.75 % uranyl formate.  A 
concentrated sample of CDTb’’ was used so that these interchangeable 
oligomers could be visualised directly at low-resolution.  The electron 
micrographs displayed an array of large inconsistently shaped species, which 
was to be expected after the observations from SEC-MALS.   
 
Future Work  
 
 The objective is still to determine the 3D-structure of CDTb at high 
resolution, particularly the mature CDTb’’ form.  The current crystallisation 
conditions that have yielded diffraction quality crystals should be focused on to 
optimise crystal growth to obtain higher resolution diffraction from the crystals.  
High concentrations of pure protein are required for crystal growth, however 
SEC-MALS data and electron microscopy data have confirmed that CDTb’’ is 
forming interchangeable oligomers of high molecular mass at high concentration.  
Therefore, efforts should be focused on stopping this sporadic oligomerisation 
during concentration, as this oligomerisation may prevent protein from forming 
tightly packed crystals, hence the lack of high resolution diffraction from CDTb’’.  
In order to prevent this oligomerisation, a new range of buffers should be used 
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Clostridium difficile has a number of virulence factors that contribute to its 
pathogenicity, but this chapter will focus on one of the secreted toxins.  The 
pathogenic strains of C. difficile produce two potent exotoxins: Toxin A and Toxin 
B (often called TcdA and TcdB) which both induce mucosal inflammation and 
diarrhoea.  In addition to these exotoxins, some C. difficile strains produce an 
ADP-ribosylating binary toxin (CDT), however, the role of this toxin in disease is 










CDT is a member of the ADPRT family of binary toxins (Popoff et al., 
1988).  It is a Type IV ADPRT meaning it is made up of two independently 
Figure 4.1.1a- Schematic representation of the domain organisation of the two 
components: CDTa and CDTb of the C. difficile ADPRT binary toxin.  The N-terminal 
signal peptides are displayed in green for both components. The active CDTa' 
domain is coloured with the N-terminal domain (purple) and the C-terminal domain 
(cyan). The CDTb component has an activation domain (yellow) that must be 
cleaved to give the activated domain (red). 
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produced components; the enzymatic component, CDTa (48kDa), and the 
transport component, CDTb (99 kDa).  The enzymatic component irreversibly 
ADP-ribosylates G-actin, which reduces the ability of actin to polymerise into F-
actin.  This disruption of actin polymerisation leads to disturbance of the 
cytoskeletal architecture, which can lead to cell death. The closely related 
homologues of CDT: C2 toxin from C. botulinum and Ia toxin from C. perfringens, 
that are both Type IV ADPRTs have been shown to ADP-ribosylate G-actin at 
residue Arg-177 (Vandekerckhove et al., 1988, 1987).  Therefore we can predict 
that CDT behaves in a similar manner and will also ADP-ribosylate G-actin at 
Arg-177.  There is poor understanding of this group of ADPRTs structurally as 
whole functioning toxins, and little understanding of the individual components 
 The focus of this chapter is to elucidate where possible more information 
about the enzymatic component, CDTa, in terms of both mechanism of ADP-
ribosylation and interactions with CDTb and actin.  For clarity in this chapter, the 
fully activated cytotoxic enzymatic component will be denoted CDTa (instead of 
CDTa’).  The crystal structure of the CDTa component was solved previously at 
three different pH values, 4.0, 8.5 and 9.0 (PDB codes: 2WN8, 2WN4 and 2WN5 
respectively). In addition the structure was solved in complex with ADP ribose 
donors NADPH and NAD at pH 9.0 (PDB codes: 2WN6 and 2WN7). The 
structure in complex with NAD was determined at 2.25Å and detailed mechanistic 
implications of CDTa have been proposed based on this structural data 
(Sundriyal et al., 2009).  The structure of CDTa in complex with NAD is displayed 
in Figure 1.2.2b.  
The overall structure of CDTa is similar to that of its closest homologues; 
Ia from C.perfringens (PDB code: 1GIQ) and C2-I from C.botulinum (PDB code: 
2J3X), as illustrated in Figure 4.1.1b (Schleberger et al., 2006; Tsuge et al., 
2003).  The core catalytic domain of the ADPRT structures is observed which 
consists of a network of perpendicular β-strands flanked by alpha helices.  The 
active site structural motifs are located in equivalent positions in all three of the 
structures and are colour coordinated as demonstrated in Figure 1.2.2b.  In order 
to compare the structural differences between these three homologues, the 
structural coordinates of Ia were superimposed onto those of CDTa (Figure 
4.1.1c-A), and C2-I coordinates were separately superimposed onto CDTa 
(Figure 4.1.1c-B).  As clearly demonstrated in Figure 4.1.1c, Ia and CDTa are 





















Figure 4.1.1b- CDTa, Ia and C2-I structures.  A: The structure of CDTa with NAD bound (Sundriyal et al., 2009), with the various structural 
motifs of the active site displayed in colour: substrate NAD in magenta, STS-motif in green, ARTT-loop and ExE-motif in blue, and the PN-
loop in orange.  The N-terminal domain is coloured purple, the C-terminal domain is coloured cyan and their connecting loop is coloured 
red.  B: The structure of Ia with NAD bound (Tsuge et al., 2003), with the corresponding characteristic structural motifs coloured in 
accordance with CDTa.  C: The structure of C2-I (Schleberger et al., 2006) with the corresponding characteristic structural motifs coloured in 
accordance with CDTa.  Images rendered using PyMOL (Version 1.5.0.4 Schrödinger, LLC).    
 





















Figure 4.1.1c- Root mean square deviation (RMSD) of CDTa superimposed onto Ia (A) and C2-I (B).  A: Structure of CDTa superimposed 
onto the structure of Ia revealing only small variations in the structure (RMSD 0.84 Å) with 80 % sequence identity.  B: Structure of CDTa 
superimposed onto the structure of C2-I revealing more structural deviations than that of the Ia toxin (RMSD 2.05 Å) with 40 % sequence 
identity.  Images rendered using PyMOL (Version 1.5.0.4 Schrödinger, LLC).     
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As CDTa and Ia are structurally more similar than C2-I, particularly in the 
catalytic core region, we can use the structural information known about Ia and 
the structure of Ia in complex with actin (see Figure 4.1.1d) to predict how CDTa 
will behave in terms of mechanism of ADP-ribosylation and the interactions with 





















Mutagenesis studies performed for Ia revealed that the ExE-motif glutamic 
acid residues are essential for both NAD binding and hydrolysis (NADase 
activity) and ADP-ribosylation (ARTase) (Nagahama et al., 2000).  Therefore, we 
predict that the equivalent residues, Glu-385 and Glu-387 in CDTa will also be 
Figure 4.1.1d- The structure of the Ia-actin complex (Tsuge et al., 2008).  The Ia 
component is displayed in grey, with the non-hydrolysable NAD analogue (β-TAD) 
displayed as sticks in magenta.  The ExE-motif and STS-motif of Ia are displayed 
as sticks in blue and green respectively.  Actin is displayed in green with ATP 
bound in cyan and Latrunculin A displayed in orange.  The Arg-177 residue of 
actin that is ribosylated during ADPRT activity is displayed as sticks in red.  
Images rendered using PyMOL (Version 1.5.0.4 Schrödinger, LLC).    
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essential for NADase and ARTase activity.  We can therefore deduce the 
following mechanism for ADP-ribosylation of actin, see Figure 4.1.1e (Davies et 
al., 2011): 
 
A. NAD enters the active site where the ribose group is positioned in 
proximity to the catalytic Glu-387 residue.   
B. The catalytic glutamate Glu-387 will form a H-bond with the 2’OH group of 
ribose and the nicotinamide group leaves. 
C. An oxocarbenium intermediate is formed which is susceptible to 
nucleophilic attack.  The ARTT-loop is rearranged to bring the Glu-385 
residue into the reaction centre stabilising the transfer of ADP-ribose to 
Arg-177 on actin. 

















Figure 4.1.1e- Predicted mechanism for ADP-ribosylation of actin by CDTa.  A: H-
bond formation between E387 (blue) and 2 OH’ of ribose (black).  B: Loss of the 
nicotinamide group.  C: E385 (blue) brings R177 (green) into active site and the 
ribose group oxocarbenium ion is susceptible to nucleophilic attack.  D: R177 is 
ADP-ribosylated by CDTa.  Figure adapted from Davies et al. (Davies et al., 2011).  




! ! ! ! ! ! Chapter!4.1!164!
Further structural and experimental evidence is required to validate this 
hypothesis, which will be discussed in the following subchapters. 
 
 
For CDTa the aims for this section were as follows: 
 
4.1: Firstly to form a CDTa-actin complex and solve the structure and 
secondly to form a CDTa-CDTb complex and solve the structure. 
 




The above aims and outcomes will be discussed in subchapters 4.1 and 4.2 
respectively.  In order to have performed the experiments for the following 
chapters it was necessary to have a large quantity of pure CDTa, however the 
established protocols were limited in terms of yield.  Therefore this present 
chapter will be focused on the optimisation of the established protocol for CDTa 
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4.1.2 Materials and Methods 
Pre-existing Protocols 
Expression of CDTa 
 
The expression protocol for CDTa has previously been established 
(Sundriyal et al., 2010).  In brief, Escherichia coli BL21 (DE3) codon plus 
competent cells (Novagen ®) were transformed with pMAL-p2x-cdtA.  Expression 
was carried out using Terrific broth (TB) medium supplemented with 1X TB salts, 
0.5 % glucose and 100 µg/ml ampicillin.  The TB medium was inoculated with 10 
% overnight grown culture in Luria-Bertani (LB) medium supplemented with 100 
µg/ml ampicillin.  The cultures were allowed to grow at 37 °C until they reached 
an OD600= 0.6-0.8 whereupon the temperature was then reduced to 20 °C.  
Protein expression was induced using 1 mM IPTG and cultures were harvested 
after 4 hours of expression, by centrifugation at 8,500 rpm for 10 min at 4 °C. 
 
Purification of CDTa 
 
 The purification protocol for CDTa has previously been established 
(Sundriyal et al., 2010).  In brief, E. coli BL21 (DE3) codon plus cells containing 
expressed CDTa were lysed in buffer (50 mM Tris-HCl pH 8.0, 20 mM NaCl and 
5 mM CaCl2) using a French press in two cycles and cell debris was removed by 
centrifugation at 75,000 xg for 30 min at 4 °C.  The supernatant was loaded onto 
Q-Sepharose Fast Flow resin (GE-Healthcare) pre-equilibrated with the lysis 
buffer.  The resin was then washed until the absorbance at 280 nm base line was 
flat and stable.  Protein was then eluted in 10 % of elution buffer (50 mM Tris-
HCl, 1000 mM NaCl, and 5 mM CaCl2) and sufficient Factor Xa (Novagen) was 
added to cleave the maltose binding protein (MBP) tag at 20 °C for 24 hour.  The 
protein was then dialysed over night against 50 volumes of dialysis buffer (50 mM 
Tris-HCl pH 8.0 and 20 mM NaCl) at 20 °C.  The protein was reloaded onto Q-
Sepharose Fast Flow resin pre-equilibrated with dialysis buffer and the cleaved 
CDTa was collected in the flow through.  CDTa was stored at -80 °C until further 
required. 
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Optimisation of Expression and Purification of CDTa 
Initial Attempts at Optimisation of Purification 
 
The above purification protocol resulted in low yield of pure CDTa.  The 
following adjustments were implemented to optimise the purification protocol: 
 
1. Use MBP column instead of Q-Sepharose resin, as the expressed CDTa has 
an MBP tag. 
2. Try Source-Q resin, as it is designed to be more effective than Q-Sepharose 
resin. 
3. Try using various additives such as 1 mM EDTA and 1 mM DTT. 
4. Use alternative lysis technique such as bead beating instead of lysis by 
French press. 
5. Use batch-binding technique instead of flow binding. 
6. Clone CDTa DNA into a different vector and retry expression and purification 
tailored to the new plasmid. 
 
Cloning of CDTa into Alternative Vector 
 
 CDTa DNA in vector pMAL-p2x was digested using BamH1 and Sal1. 
Concurrently pGEX-6p1 was digested with the same enzymes.  The digest was 
analysed by an 0.8 % agarose gel, which was run at 120 V for 1 hour.  The CDTa 
dropout bands were excised and gel purified (Wizard ® genomic DNA purification 
kit, Promega).  The gel purified CDTa dropout DNA was then ligated into the 
digested pGex-6p1 vector using T4 DNA ligase.  This was repeated twelve times 
to ensure ligation success of at least one reaction.  The reactions were left at 22 
°C for 30 min, and were then tested for the insert by performing rapid digests with 
BamH1 and Sal1. 
 
Successfully ligated DNA was initially sequenced and then transformed 
into Top10 cells, using standard transformation techniques.  Colonies of Top10 
cells containing pGex-6p1-cdtA were used to inoculate an overnight culture in LB 
medium.  The pGex-6p1-cdtA DNA was extracted from the overnight culture of 
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Top10 cells and was rapidly digested to check for the presence of the CDTa DNA 
insert, which was then analysed by an 0.8 % agarose gel.  Where the dropout 
was present, the DNA was sent for sequencing to ensure successful ligation into 
the pGex-6p1 vector. 
Optimised Expression of CDTa 
 
E. coli BL21 (DE3) codon plus cells were transformed with the pGEX-6p1-
cdtA expression construct.  Overexpression of soluble CDTa was obtained using 
2 L baffled flasks containing 1 L of LB medium supplemented with 100 µg/ml 
ampicillin.  The medium was inoculated with 10 ml overnight culture of the 
expression host, grown at 37 °C in LB medium supplemented with 100 µg/ml 
ampicillin.  Once the culture reached OD600 = 0.8-1.0, the temperature was 
reduced to 20 °C.  After the temperature reached 20 °C, 1 mM IPTG was added 
to induce expression of CDTa.  The cultures were harvested after 4 hours, using 
500 ml centrifuge tubes in a 10:500 rotor, spinning at 8,500 rpm for 10 min at 4 
°C.  The cell pellets were re-suspended in 2 ml/g of pellet in lysis buffer; 50 mM 
Tris-HCl pH 8.0 and 20 mM NaCl.  The re-suspended pellets were then rapid 
frozen in liquid nitrogen and stored at -80 °C until further use. 
Optimised Purification of CDTa 
 
A cell pellet, stored at -80 °C from the batches of expressed protein, was 
thawed and diluted in lysis buffer (50 mM Tris-HCl pH 8.0, 20 mM NaCl and 1 
mM EDTA) until a total volume of 10 ml/g of pellet was reached.  The cells were 
then passed through a homogenizer twice at a pressure of 20 kpsi, and 
temperature of 4 °C.  Throughout the duration of the purification from this point 
onwards the protein was kept on ice.  The cell lysate was centrifuged at 25,000 
rpm for 35 min at 4 °C and the resultant supernatant was filtered through both a 
mini-sart GF-pre-filter (Sartorius) and 0.45 µm millex-HA filter (Millipore).  The 
filtered supernatant was then loaded onto a 5 ml GSTrap-FF column (GE 
Healthcare) at 0.5 ml/min, pre-equilibrated with lysis buffer.  The column was 
then washed in lysis buffer until the absorbance at 280 nm reading reached a 
constant stable base line.  The bound protein was eluted at 0.5 ml/min in 20 mM 
reduced glutathione in lysis buffer.  A sufficient amount (1 U per 100 µg of 
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protein) of PreScission protease (GE Healthcare) was added to ensure complete 
cleavage of the GST tag.  The protein was dialyzed against 100 vol of dialysis 
buffer (50 mM Tris-HCl pH 8.0 and 20 mM NaCl), using 12-14 kDa cut off dialysis 
tubing (Medicell International Ltd) and was allowed to dialyze and cleave 
overnight at 4 °C.  Dialyzed protein was then centrifuged at 4,000 g to remove 
any precipitated protein and was re-loaded back onto the GSTrap-FF column, 
pre-equilibrated in lysis buffer, at 0.5 ml/min, collecting the pure CDTa in the flow 
through.  The column was then washed until a constant stable base line was 
reached and the bound GST tag was eluted using 20 mM reduced glutathione in 
lysis buffer.  After washing the column in 3 CVs of water followed by 3 CVs of 
lysis buffer, the above step was repeated to ensure complete separation of the 
cleaved GST tag.  The final pure CDTa was concentrated to 5.0 mg/ml using 10 
kDa cut-off concentrators (Amicon Ultra-15, Millipore), rapid frozen in liquid 
nitrogen and stored at -80 °C. 
 
Formation of CDTa-Actin Complex 
Attempt 1- Following Ia-Actin Protocol 
 
Initially, the protocol used for the Ia-actin complex was followed (Tsuge et 
al., 2008).  For the Ia-actin complex, 15 mg/ml of rabbit skeletal actin was mixed 
with 0.34 mM Latrunculin A (laγA) in buffer 2mM Tris pH 8.0, 0.2 mM ATP, 0.5 
mM DTT, 0.2 mM CaCl2 and 0.02% NaN3.  This was then mixed with 17-20 
mg/ml of Ia to which 0.5 mM β-TAD was added, kindly provided by Dr Victor 
Marquez, Centre for Cancer Research, NCI-Frederick.  LaγA is a small molecule 
that prevents actin from polymerising and β-TAD is a non-hydrolysable NAD 
analogue that helps stabilise the complex.  As we have a much lower yield of 
CDTa, the same ratio of components were combined but at lower concentrations.  
The protocol was performed in an identical manner, 31 nM was combined with 29 
nM laγA in buffer 2mM Tris pH 8.0, 0.2 mM ATP, 0.5 mM DTT, 0.2 mM CaCl2 
and 0.02% NaN3 which was then combined with 36 nM pure CDTa and 43 nM β-
TAD.  As with the Ia-actin compex, no analytical steps were taken to ensure 
complex formation, however, the components were incubated overnight at 4 °C.  
The following five crystallisation screens were performed: Morpheus HT-96, 
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JCSG-plus HT-96, PACT premier HT-96, ProPlex HT-96 and Structure screen I + 
II HT-96.  
 
Upon observation of any crystal hits, crystals were taken to Diamond 
Light Source, mounted in LithoLoops (Hampton Research) and one at a time, the 
LithoLoops were mounted on a goniometer and were rotated whilst being 






Attempt 2- Adding a Gel-Filtration Step 
 
For the second attempt at CDTa-actin complex formation, the same ratio 
of components were added in a similar manner, see Table 4.1.2a, however the 
mixture was incubated overnight at 16 °C instead of 4 °C, as this is the 
temperature at which crystallisation plates would be set up.  As a precaution, the 
complex mixture was passed through a superdex-200 10/300 GL column (GE 
Healthcare) to check for the presence of the complex.  As CDTa and actin have 
Complex Enzyme  Actin  Latrunculin A  β-TAD  
Ia-actin 420 nM 360 nM 340 nM 500 nM 
CDTa-actin 
attempt 1 36 nM 31 nM 29 nM 43 nM 
CDTa-actin 
attempt 2 36 nM 31 nM 29 nM 43 nM 
CDTa-actin 
attempt 3 49 nM 64 nM 64 nM 64 nM 
CDTa-actin 
attempt 4a 15 µM 23 µM 30 µM 30 µM 
CDTa-actin 
attempt 4b 15 µM 18 µM 100 µM 48 µM 
Table 4.1.2a- Different ratios of complex components used during attempts at 
forming a CDTa-actin complex. 
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similar molecular weights, we would expect to see a single peak from a gel-
filtration column if no complex had formed, and potentially two peaks, one slightly 
shifted left than the other, if there was complex formation.  The complex mixture 
was concentrated to 1 ml and was loaded onto a Superdex-200 10/300 gel-
filtration column using a 2 ml loop.  The flow rate was set to 0.2 ml/min and 0.5 
ml fractions were collected.  Analysis of complex formation by SDS-PAGE also 
proved difficult due to the similarity in molecular weights of CDTa and actin, and 
also because the complex would break apart during sample preparation for the 
gel.   
  
Attempt 3- Alternative Ratio of Components and Method of Combining 
 
 For the third attempt at CDTa-actin complex formation an alternative ratio 
of components was trialled, see Table 4.1.2a.  In this attempt, the β-TAD was 
directly added to CDTa and was incubated at room temperature for 30 min.  Actin 
was dissolved in the complex buffer: 2mM Tris pH 8.0, 0.2 mM ATP, 0.5 mM 
DTT, 0.2 mM CaCl2 and 0.02% NaN3, and laγA was immediately added to 
prevent polymerisation.  Actin and laγA were incubated at room temperature for 
30 min.  After the incubation period, all of the components were mixed together 
and were incubated overnight at 4 °C, with gentle shaking.  The sample was 
concentrated down to 1 ml and loaded onto a Superdex-200 10/300 GL column 
(GE Healthcare) using a 2 ml loop.  The flow rate was set to 0.2 ml/min and 0.5 
ml fractions were collected.  The fractions were analysed by SDS-PAGE.       
 
Attempt 4a- Try Complex Formation on Column 
 
 As the previous three attempts have been unsuccessful, an alternative 
method of complex formation has been implemented.  The CDTa-GST protein 
was taken after the first step of the optimised purification protocol and was 
applied to GST-resin using batch binding: CDTa-GST was mixed with unpacked 
resin and incubated overnight at 4 °C, with gentle shaking.  The following day the 
mixture was applied to a gravity column and the any unbound protein was 
washed off the resin using complex buffer (as above).  The following components 
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were mixed together; 5 mg actin, 30 nM β-TAD and 30 nM laγA in complex buffer 
and were then applied to the GST-resin containing bound CDTa-GST, by 
resuspension of the resin with gentle rocking.  The mixture was incubated for 1 
hour at 4 °C, with gentle shaking.  As the GST-tag is fused at the N-terminus, 
there should be no effect on actin binding.  The resin containing the complex 
mixture was then reapplied to a gravity column and any actin that did not bind 
CDTa was washed off using complex buffer.  The resin was then resuspended in 
complex buffer, and sufficient amount of PreScission Protease (70 µl of 2U/µl 
stock) was added to the resin to remove the GST-tag.  The cleaved mixture was 
reapplied to a gravity column and any CDTa-actin complex was collected in the 
flow through.  The bound GST-tag was eluted using complex buffer containing 20 
mM reduced glutathione.  Samples were taken throughout the procedure and 
were analysed by SDS-PAGE, see Figure 4.1.3i.   
 
Attempt 4b- Try Complex Formation on Column 
 
Attempt 4a was repeated with some minor alterations: a slightly different 
ratio was used, see Table 4.1.2a and the incubation period with all components 
was extended to overnight at 4 °C rather than 1 hour. Samples were taken 
throughout the procedure and were analysed by SDS-PAGE, see Figure 4.1.3j.   
 
Formation of a CDTa-CDTb Complex 
Attempt 1 
 
 CDTa was purified using the optimised protocol from this chapter and 
CDTb’’ was purified using the optimised protocol from Chapter 3.  The first 
attempt made at formation of CDTa-CDTb complex was performed using a 
simple method of combining the two proteins in a 1:1.2 (CDTa:CDTb’’) molar 
ratio, incubating overnight at 4 °C, then performing a gel-filtration step.  The 
details of the experiment are as follows: 15 µM of CDTa was combined with 18 
µM CDTb’’ in a total reaction volume of 250 µl.  The mixture was left to incubate 
overnight at 4 °C with gentle rocking.  A superdex-200 10/300 (GE Healthcare) 
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was pre-equilibrated with complex buffer: 50 mM Tris-HCl pH 7.5, 50 mM NaCl, 2 
mM DTT and 10 % glycerol.  The sample was loaded onto the superdex-200 
10/300 column using a 1 ml loop and was left to run at 0.2 ml/min collecting 500 
µl fractions.  The fractions were analysed by SDS-PAGE, Figure 4.1.3k.       
 
Attempts 2 and 3 
 
 In the second attempt, the same protocol was followed except alternative 
ratios of the two components were trialled: 1:3.5 molar ratio of CDTa:CDTb’’ 
(specifically 13 µM CDTa + 46 µM CDTb’’).  In addition, 45 mM beta-octyl-
glucoside (β-OG) was added with the intention of stabilising the CDTb’’ oligomer 
with this detergent.  In this second attempt, the components were incubated for 1 
hour at 4 °C prior to the gel-filtration step.  In the third attempt, a 1:1 molar ratio 
was trialled (specifically 23 µM + 23 µM) in the presence of 45 mM β-OG again, 
but was left to incubate overnight at 4 °C.    
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4.1.3 Results 
Expression and Purification of CDTa Using Established Protocols 
Expression of CDTa from pMAL-p2x-cdtA 
 
The previously established protocol (Sundriyal et al., 2010) for the 
expression of CDTa was used to obtain enough protein for later use in the 
formation of a CDTa-actin complex.  E.coli BL21 (DE3) codon plus cells were 
transformed with pMAL-p2x-cdtA, which were then grown in LB medium 
supplemented with ampicillin, at 37 °C until they reached an OD600 = 0.6-0.8.  
Expression was induced using 1 mM IPTG at 20 °C.  Cells were then harvested 
after 4 hours.  Pre-induction and post-induction samples were taken for analysis 












 As seen in Figure 4.1.3a, the post-induction sample shows good levels of 
expression of CDTa-MBP in comparison to the pre-induction sample.  Therefore, 
purification of CDTa-MBP was performed. 
Figure 4.1.3a- Expression of CDTa-MBP in E.coli BL21 (DE3) codon plus cells.  
Lane 1 on the 10 % Tris-Glycine SDS-PAGE displays the pre-stained ladder, lane 2 
displays the pre-induced cell sample and lane 3 displays the post-induction 
expression sample.  The recombinantly expressed soluble CDTa-MBP can be 
seen as indicated by the arrow at approximately 86 kDa. 
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Purification of CDTa Using Anion Exchange Chromatography 
 
 The previously established purification protocol (Sundriyal et al., 2010) 
was followed to obtain a high quality of purity for use in formation of a CDTa-actin 
complex.  In brief, BL21 (DE3) codon plus cells containing CDTa-MBP were 
lysed using a French press and centrifuged to remove remaining cell debris.  The 
cell lysate was loaded onto Q-sepharose resin and bound CDTa-MBP was eluted 
using increased salt concentration.  The MBP-tag was cleaved using Factor Xa, 
and the protein was dialysed against a large volume of buffer to remove the salt.  
The cleaved protein was then loaded back onto Q-sepharose resin, to which the 










As displayed in Figure 4.1.3b, the purification protocol works effectively to 
produce pure CDTa.  However, the CDTa yield is poor, with only 0.2 mg of CDTa 
obtained from a 1 L culture.  Therefore, a number of adjustments were made to 
attempt to improve the final yield of pure CDTa.   
Figure 4.1.3b- 10 % Tris-Glycine SDS-PAGE displaying the steps taken in the 
purification of CDTa.  The first gel (left) displays the pre-stained ladder in the first 
lane (M), the pre-induced expression sample in the second lane (To) and the 
expressed CDTa-MBP in the third lane (Tf).  The fourth and fifth lane displays the 
loaded cell supernatant (L) and the non-bound protein flow through (FT), 
respectively.  The sixth lane displays the wash step (W), whereby the resin is 
washed until the absorbance 280 nm reading reached a steady flat base line.  
Finally the last lane on the first gel (left) shows the elution step in 10 % elution 
buffer (10%).  The second gel (right) displays the pre-stained protein ladder in the 
first lane (M), the cleaved protein loaded onto the resin (L) and the pure CDTa in 
the third lane (FT) indicated by the arrow.   
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Optimisation of Expression and Purification of CDTa 
Expression of CDTa from pGEX-6p1-cdtA 
 
 The following table displays the alterations that were made to the 
expression and purification protocols in attempts to optimise the production of 
CDTa, with the corresponding results. 
 
Modification to Protocol Result 
MBPTrap column used instead of Q-
sepharose resin 
CDTa-MBP did not bind the MBPTrap 
column 
Source-Q resin used instead of Q-
sepharose resin No significant improvement in yield 
1 mM EDTA and 1 mM DTT additives No effect on yield 
Bead beating cell lysis instead of 
French press 
Some improvement in yield, but not 
significant 
Batch-binding to Q-sepharose resin 
instead of flowing through pre-packed 
column 
Some improvement in yield, but not 
significant 
Clone DNA into alternative expression 
vector 
Significant improvement in quality and 
quantity of CDTa yield, detailed below 
 
The final details of the optimised CDTa expression and purification 
protocols will be given below.  
Cloning of CDTa DNA into Alternative Expression Vector 
 
The plasmid pMAL-p2x-cdtA was digested using BamH1 and Sal1 
restriction enzymes, and was then ligated into the new expression vector pGEX-
6p1, which had also been digested with the same restriction enzymes.  The 
Table 4.1.3a- Optimisation of CDTa expression and purification.  The table displays 
modifications made to protocols in attempts to improve CDTa yield. 
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ligation was repeated twelve times, to ensure success of at least one ligation.  
After ligation, each reaction mixture was digested again to check for the insert 





The successfully ligated DNA was transformed into Top10 cells, cultured 
and the DNA was extracted using the miniprep kit (Wizard ® plus Minipreps DNA 
Purification System, Promega).  After sequencing to confirm the CDTa DNA was 
in frame, BL21 (DE3) codon plus cells were transformed ready for expression. 
Optimised Expression of CDTa Using a New Expression Vector 
 
 The CDTa DNA was cloned into an alternative expression vector, 
pGEX-6p1 and a new optimised expression protocol was established.  In brief, E. 
coli BL21 (DE3) codon plus cells were transformed with the pGEX-6p1-cdtA 
expression construct and soluble CDTa expression was obtained using LB 
Figure 4.1.3c- 0.8 % agarose gel displaying the quick digest for ligation results.  
Lanes 1, 7, 8, 10-12 show the dropout CDTa DNA at approx. 1.5 kbp and the vector 
at approx 5 kbp, indicating successful cloning of CDTa DNA into pGEX-6p1. 
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medium supplemented with 100 µg/ml ampicillin. The expression host was grown 
at 37 °C until the culture reached OD600 = 0.8-1.0, the temperature was reduced 
to 20 °C and expression of CDTa was induced using IPTG.  The cultures were 
harvested after 4 hours by centrifugation at 8,500 rpm for 10 min at 4 °C and cell 
pellets were re-suspended in lysis buffer, followed by rapid freezing in liquid 
nitrogen. 












As demonstrated in Figure 4.1.3d, the expression protocol is successful 
as a clear protein band can be observed at 77 kDa in the post-induced sample 
(Tf), that is not present in the pre-induced sample (To).  Due to the expression 
success, the cell pellets containing CDTa-GST were lysed ready for purification 
of CDTa. 
 
Optimised Purification of CDTa Using New Method 
 
 As CDTa was expressed with a GST-tag instead of an MBP-tag, 






kDa        M    To   Tf 
CDTa-GST 
Figure 4.1.3d- 10 % Tris-glycine SDS-PAGE displaying expressed CDTa-GST.  
Lane 1 displays the prestained protein ladder (M), lane 2 displays the pre-
induced culture sample (To) and lane 3 displays the post-induction sample (Tf) 
with CDTa-GST at 77 kDa. !!
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performed using a 5 ml GSTrap-FF column at low flow rate to ensure complete 
binding of the CDTa-GST to the resin.   
 
In brief, cell pellets stored at -80 °C from the batches of expressed 
protein, were thawed and diluted in lysis buffer (50 mM Tris-HCl pH 8.0, 20 mM 
NaCl and 1 mM EDTA) until a total volume of 10 ml/g of pellet was reached.  The 
cell lysate was then lysed and centrifuged to remove cell debris, and the resultant 
supernatant was filtered prior to loading the GSTrap-FF column pre-equilibrated 
with lysis buffer.  The column was then washed and bound protein was eluted 
using reduced glutathione in lysis buffer. PreScission protease was added to 
ensure complete cleavage of the GST tag and the protein was dialyzed to 
remove the reduced glutathione.  Cleaved protein was then re-loaded back onto 
the GSTrap-FF column, pre-equilibrated in lysis buffer, collecting the pure CDTa 
in the flow through.  The bound GST tag was eluted using reduced glutathione in 
lysis buffer and after washing the column and pre-equilibrating the column again, 
the above step was repeated to ensure complete separation of the cleaved GST 
tag, see Figure 4.1.3e for results. 
 
Figure 4.1.3e- Purification steps of CDTa displayed using 10 % Tris-Glycine SDS-
PAGE.  Lanes 1 and 2 represent cell lysate load and flow through respectively.  
Lanes 3 and 4 represent CDTa-GST elution from column and the overnight cleavage 
of GST-tag using PreScission Protease.  Lanes 5 and 6 represent the ‘pure’ CDTa 
flow through and GST-tag elution respectively.  Lanes 7 and 8 represent the 
repetition of the previous step to ensure complete removal of GST.  Lane 9 
represents the final concentrated CDTa. 
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Figure 4.1.3f- Chromatogram for step 1 GST-affinity chromatography.  The first broad peak (Peak 1) represents non-specific flow through (>1600 
mAu), and the second sharp peak (Peak 2) represents the eluted CDTa-GST protein (1500 mAu) using reduced glutathione elution.  The blue line 
represents the absorbance at 280nm and the red line represents conductivity. 


















Figure 4.1.3g- Chromatogram for step 2 GST-affinity chromatography.  Peak 1 represents the CDTa that has had the GST-tag removed, which does 
not bind to the column.  Peak 2 represents GST-tag that has bound to the column and has been eluted using 20 mM reduced glutathione.  Peak 3 
represents the pure CDTa that has been passed back through the column to ensure complete removal of the GST-tag.  Peak 4 represents the 




The chromatogram in Figure 4.1.3f is an example of the first step from the 
CDTa-GST purification using a GSTrap-FF column.  The first broad peak 
represents the flow through of proteins that have no affinity for the GSTrap resin.  
The column is then washed in buffer and the baseline is reached, at this point all 
of the non-specific proteins will have been washed off the column leaving only 
CDTa-GST bound to the column.  The second peak represents the CDTa-GST 
elution peak, whereby reduced glutathione was applied to the column, which 
competes for GSTrap binding, allowing CDTa-GST to be eluted.  The 
chromatogram in Figure 4.1.3g represents the second stage in the purification 
protocol whereby CDTa with GST-tag removed is passed back through the 
GSTrap-FF column to remove the GST-tag. 
 
Formation of CDTa-actin Complex 
Attempt 1 
 
For the first attempt at forming a CDTa-actin complex, the protocol 
established for the Ia-actin complex was followed (Tsuge et al., 2008).  In brief: 
actin was mixed with laγA, and both were then mixed CDTa and β-TAD.  After an 
overnight incubation at 4 °C, the following five crystallisation screens were 
performed: Morpheus HT-96, JCSG-plus HT-96, PACT premier HT-96, ProPlex 
HT-96 and Structure screen I + II HT-96.  In addition, a control crystallisation 
plate was set up using 5 mg/ml CDTa and the crystallisation condition that was 
used to grow crystals for which data were collected and the structure was solved 
(Sundriyal et al., 2009).  A number of crystallisation hits were observed which 
had different morphologies to the standard CDTa crystal morphology, see Figure 
4.1.3h.  The crystals were taken to Diamond Light Source, mounted in 
LithoLoops (Hampton Research) and one at a time, the LithoLoops were 
mounted on a goniometer and were rotated whilst being exposed to a beam of X-
rays.  Needle-like crystals of CDTa, Figure 4.1.3h-A, diffract to 2 Å resolution and 
have the same cell dimensions as the previously reported CDTa structure 
(Sundriyal et al., 2009), see Table 4.1.3b. Hexagonal plate-like crystals of a 
possible CDTa-actin complex, displayed in Figure 4.1.3h-B also diffracted to high 
resolution, but show similar cell dimensions to that of the native CDTa, which 































CDTa and CDTa-actin cell dimensions and space groups 
 a b c α β γ Space Group 
CDTa crystal A 62.2 46.7 77.6 90.0 97.8 90.0 P21 (monoclinic) 
CDTa-actin 
crystal B 57.4 45.0 77.3 90.0 101.8 90.0 P21 
Table 4.1.3b- Cell dimensions calculated from the diffraction images collected 
during test shots for crystals A and B from Figure 4.2.3h.  Both sets of cell 




Figure 4.1.3h- CDTa crystals and possible CDTa-actin crystals.  A: Standard CDTa 
crystals with needle-like morphology, grown in crystallisation condition 0.1 M MIB 
pH 9.0 and 20% PEG.  B: Possible CDTa-actin hexagonal plate-like crystals, grown 
in condition 0.1 M Morpheus Buffer 1 pH 6.5, 0.12 M Ethylene glycols and 20 % 
PEG 550 MME and PEG 20k.  C: Possible CDTa-actin small fragment crystals, 
grown in condition 0.1 M Morpheus Buffer 1 pH 6.5, 0.12 M Ethylene glycols and 
30 % PEG 550 MME and PEG 20k.  D: Possible CDTa-actin crystal clusters, grown 
in crystallisation condition 0.1 M Morpheus Buffer 1 pH 6.5, 0.12 M Ethylene 






For the second attempt at CDTa-actin complex formation, the same ratio 
of components were added in a similar manner, however the mixture was 
incubated overnight at 16 °C instead of 4 °C, as this is the temperature at which 
crystallisation plates would be set up.  A gel-filtration step was added to 
determine whether or not a complex had formed.  This attempt was also 
unsuccessful at full complex formation, as only a large single peak was observed 
on the gel-filtration chromatogram at the predicted size of 40 kDa, which 
contained a mixture of CDTa and monomeric actin.  
Attempt 3 
 
 For the third attempt at complex formation, an alternative ratio of 
components was trialled; see Table 4.1.2a.  In order to saturate CDTa with β-
TAD and actin, a high concentration of both components were added.  Again, the 
mixture of components was concentrated and was passed through a gel filtration 
column to determine whether or not a complex had been formed.  A shift in the 
peak towards the y-axis should be noted on complex formation, but unfortunately 
the same pattern was observed as with the previous attempt: a single sharp peak 
at approximately 40 kDa.   
Attempt 4a 
 
As the previous three attempts were unsuccessful, an alternative method 
of complex formation was implemented whereby attempts were made at forming 
an ‘on column’ complex.  CDTa with a GST-tag was applied to a GSTrap column 
and was washed to ensure CDTa purity bound to the column.  The GSTrap resin 
was re-suspended in a solution containing the remaining complex components 
and were incubated together overnight.  As the GST-tag is fused at the N-
terminus, there should be no effect of complex formation as actin is proposed to 
interact with the C-terminal domain.  The resin was washed to ensure that 
anything bound to the resin was either CDTa-GST alone or a complex of CDTa-
GST with actin.  The components were then treated with PreScission Protease to 
cleave off the GST-tag allowing release of the potential complex from the resin 
and any excess CDTa.  The reaction was then passed back through a GSTrap 
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column to remove any excess GST-tag.  The results were analysed by 10 % Tris-













Figure 4.1.3i displays the ‘on column’ batch binding method used to form 
the CDTa-actin complex.  Up until now there has been no success in complex 
formation, however, these experiments show indications of small quantities of 
complex that are highly promising for future work.  The 10 % Tris-glycine SDS-
PAGE gel picture displayed in Figure 4.1.3i-A shows the steps taken to form a 
CDTa-actin complex, starting with CDTa-GST binding to the column, with the 
protein band apparent at approximately 77 kDa (lanes 1 and 2).  Lane 3 indicates 
the concoction of excess actin containing laγA and β-TAD and once it was 
applied to the resin containing CDTa-GST bound is indicated by lane 4.  After the 
resin was washed to remove any unbound protein, a large quantity of actin was 
observed, see lane 5.  However, surprisingly once the PreScission Protease was 
added to cleave off the GST-tag, equal volumes of proteins of approximately 45 
!
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Figure 4.1.3i- Attempt 4a of CDTa-actin Complex Formation.  A: The steps taken 
towards complex formation; lanes 1 and 2 represent CDTa-GST binding to the 
GST-resin, lane 3 represents the concoction of actin, laγA and β-TAD, and lane 4 
is the same concoction diluted by GST resin.  Lane 5 represents the non-bound 
protein wash and lane 6 contains the PreScission Protease cleavage and 
therefore elution of any potential complex, and finally lane 7 is the remaining 
GST-tag elution from the column.  B: 4-16 % Native Bis-Tris gel picture displaying 
lane 6 from gel A.  Three clear bands of approximately 120 kDa (band 1), 80 kDa 
(band 2) and 40 kDa (band 3) are apparent on the gel.     
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kDa and 43 kDa were eluted from the resin.  As they are in a ratio of 
approximately 1:1 this is a strong indicated that a CDTa-actin complex was 
formed.  They may appear on this gel picture as two separate bands rather than 
one higher band because it is a reducing gel.  To confirm the presence of the 
complex, the sample was analysed using a 4-16 % native gel, for which the 
results are displayed in Figure 4.1.2i-B.  The key thing to note from this gel 
picture is the presence of a strong band of approximately 40 kDa (band 3) which 
could represent any excess CDTa or actin that have not formed a complex.  
Secondly there is a band of approximately 80 kDa (band 2), which is the correct 
size for a CDTa-actin complex, which is highly promising.  Finally there is a band 
of approximately 120 kDa, which is not present on the 10 % reduced SDS-PAGE 
gel picture, but is present on the native gel (band 1).  This size could mean we 
have a trimer of either CDTa or of actin.             
Attempt 4b 
 
In a second attempt using the ‘on column’ batch binding method, it was 
decided that in order to obtain a better yield of complex, a number of factors 






















  97 
  66 
  56 
  43 
  34 
  27 














Figure 4.1.3j- Complex formation attempt 4b results.  A: 10 % Tris-glycine SDS-
PAGE displaying the steps to complex formation:  Lanes 1 and 2 represent the 
CDTa-GST load and flow through.  Lanes 3 and 4 represent the actin + laγA + β-TAD 
load and flow through respectively.  Finally lane 5 represents the final elution step.  
B: 4-16 % Tris-glycine Native gel displaying the final elution step in lane 1.       
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Firstly, the CDTa must be completely saturated with β-TAD and secondly, 
actin should be 100 % in its monomeric G-actin form, because the trimer could 
be either actin or CDTa based on the molecular weight of the trimer band, 
therefore laγA was also increased to prevent polymerisation.  In addition, the 
incubation period was extended to overnight rather than 1 hour, to ensure that all 
of the CDTa-GST bound to the column is saturated with actin for a long period to 
encourage complex formation.   
 
Figure 4.1.3j-A displays the initial steps towards complex formation, which 
is significantly different from the previous attempt in a number of ways.  Firstly, 
this time we have complete binding of CDTa-GST (lane 1) to the GST resin with 
no protein in the flow through (lane 2).  Secondly, the amount of actin + laγA + β-
TAD (lane 3) washed off the resin (lane 4) is completely diminished suggesting 
all of the actin has bound CDTa thereby forming a complex.  The final complex 
eluted from the column is displayed in lane 5, and the double band shares the 
same pattern as the previous attempt, except there is some CDTa-GST and GST 
contamination.  Again to confirm the presence of a complex, the sample was 
analysed using a 4-16 % Native gel, with results displayed in Figure 4.1.3j-B.  
There is a clear band at approximately 80 kDa, which is a clear indication that a 
CDTa-actin complex has formed, however there is still the CDTa-GST band at 
approximately 70 kDa and some GST contaminant too at approximately 30 kDa.  
So it appears there has been some preliminary success in terms of CDTa-actin 
complex formation, however some refinement of the protocol is required to gain a 
higher yield for crystallisation trials, in addition to removal of some of the 
contaminants.   
 
Formation of a CDTa-CDTb Complex 
 
In attempts to form a CDTa-CDTb’’ complex, a variety of ratios were tried 
to find the optimum for complex formation.  In addition, the presence of a 
detergent (β-OG) was trialled in the hope that this would help to stabilise the 
CDTb’’ oligomer.  After combining all of the complex components and incubating 
for the set time length, the samples were all passed through a gel-filtration 
column.  Each of the three attempts yielded the same chromatogram profile of 
















The two peaks were analysed by 10 % Tris-glycine SDS-PAGE and 
unfortunately the first large peak contained only CDTb’’ for all of the attempts and 
the second peak contained only CDTa for all of the attempts.  This is a clear 
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Figure 4.1.3k.  CDTa-CDTb’’ size-exclusion chromatography results.  A: The 
chromatogram for the size-exclusion run clearly showing two distinct peaks in 
the blue Absorbance at 280nm trace, (brown is conductance).  B: Fractions A2, 
A3, A5, B15, B13 and B11 were analysed by 10 % Tris-glycine SDS-PAGE. 
! ! Chapter!4.2!
! 188!
4.2 CDTa Mechanism 
4.2.1 Introduction 













Figure 4.2.1a- The crystal structure and active site view of CDTa.  A: Overall 
structure of CDTa displayed as surface (grey), with NAD bound displayed as sticks 
(magenta).  B: Close up image of the active site cleft.  C: Active site interactions 
displayed in stereo with the various ADPRT structural motifs coloured as follows: 
ExE-motif and ARTT-loop in blue, STS-motif in green, PN-loop in orange, Arg-motif 
in yellow and other residues involved in NAD binding in teal (Sundriyal et al., 2009).  
Images rendered using PyMOL (Version 1.5.0.4 Schrödinger, LLC). 
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 The structure of CDTa was solved both with and without NAD bound at 
pH 9.0, in addition to pH 4.0 and 8.5 without NAD bound (Sundriyal et al., 2009).  
The structure of CDTa with NAD bound can be viewed in Figure 1.2.2b, and the 












The structure of CDTa shows that the NAD substrate binds tightly in the 
active site cleft with a number of key residues and ADPRT structural motifs 
contributing to its binding and stability.  These interactions can be viewed in 








Figure 4.2.1b- Schematic representation of NAD binding in CDTa active site.  
Residues are colour coordinated with those in the previous active site figures and 
are not orientated as in active site but are placed for easy viewing of specific 
interactions.   
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The structural motifs that are characteristic of the ADPRT family are 
observed in the active site of CDTa including the ExE-motif and ARTT-loop 
(displayed in blue) which are key for ADPRT activity, the PN-loop and Arg-motif 
(displayed in orange and yellow respectively) and the STS-motif (displayed in 
green), which due to its interaction with NAD and the ExE-motif, may be involved 
in both ligand binding and catalysis (Sundriyal et al., 2009).  The ExE-motif has 
been shown to be directly involved in ligand binding and catalysis in other 
ADPRT family members such as the Ia toxin, however in this structure the ExE-
motif is out of range for NAD binding, which is unexpected.  This particular 
arrangement of Glu-385 and Glu-387 in the active site could be due to the 









Figure 4.2.1c- Predicted mechanism for ADP-ribosylation of actin by CDTa.  A: H-
bond formation between E387 (blue) and 2 OH’ of ribose (black).  B: Loss of the 
nicotinamide group.  C: E385 (blue) brings R177 (green) into active site and the 
ribose group oxocarbenium ion is susceptible to nucleophilic attack.  D: R177 
(green) is ADP-ribosylated by CDTa.  Figure adapted from Davies et al. (Davies et al., 





Mechanism of ADP-Ribosylation 
 
Using both the structural aspects of the CDTa active site along with 
mutagenesis studies on homologous ADPRT family members, the mechanism by 
which CDTa ADP-ribosylates monomeric actin can be predicted.  The proposed 
mechanism is the SN1 mechanism via two intermediates; firstly an oxocarbenium 
ion intermediate and secondly a cationic intermediate.  This is commonly thought 
to be the mechanism observed amongst the ADPRT family of toxins.   
 
In the above SN1 mechanism, the catalytic glutamate Glu-387 in CDTa 
forms a H-bond with the 2’OH of ribose forming an oxocarbenium intermediate 
and rendering the ribose group vulnerable to nucleophilic attack.  Following 
cleavage of NAD and formation of an oxocarbenium ion, it is thought that the 
ARTT-loop is rearranged to bring the Glu-385 residue to the reaction centre to 




The aims of this part of this subchapter were to perform mutagenesis 
studies on some of the key active site residues of CDTa and determine their 
importance in the activity of CDTa, thereby testing the hypothesis of the SN1 
mechanism.  This should help resolve the issue of the importance of the ExE-
motif in the catalytic activity of CDTa from the current contradicting evidence of 






4.2.2 Materials and Methods 
Site Directed Mutagenesis of Active Site Residues 
Initial Attempts at Site Directed Mutagenesis !
 Mutagenesis of active site residues was performed at the DNA level 
using the pMAL-p2x-cdtA plasmid as a template and the respective 
oligonucleotides as displayed in Table 4.2.2a.  For each mutant, two 
complementary synthetic oligonucleotides were required for the desired mutation.  
The mutated plasmids were transformed into E.coli Top 10 cells and the 
respective mutations were confirmed by DNA sequencing (Eurofins Genomics 
MWG Operon), resultant sequences were aligned with the native CDTa using T-



















The successfully mutated plasmids were then transformed into E.coli 
BL21 (DE3) codon plus cells for expression trials.  Expression was carried out as 
described in Chapter 4.1.2 under ‘Pre-existing Protocols’.  In brief, cells were 
grown in TB medium at 37 °C until they reached an OD600= 0.6-0.8 whereby the 
temperature was then reduced to 20 °C and protein expression was induced with 
1 mM IPTG and was harvested after 4 hours.  
Mutation Primers 
S345A 5' - CCGAACTTTATTGCAACTAGT – 3' 5' - ACTAGTTGCAATAAAGTTCGG – 3' 
S345F 5' - CCGAACTTTATTTTCACCAGC – 3' 5' - GCTGGTGAAAATAAAGTTCGG – 3' 
S345R 5' - CCGAACTTTATTCGTACCAGC - 3' 5' - GCTGGTACGAATAAAGTTCGG – 3' 
S345Y 5' - CCGAACTTTATTTACACCAGC – 3' 5' - GCTGGTGTAAATAAAGTTCGG – 3' 
E385Q 5' - GTTATGCAGGTCAATATGAAGTG - 3' 5' - CACTTCATATTGACCTGCATAAC - 3' 
E387Q 5' - AGGTGAATATCAAGTGCTTTTA – 3' 5' - TAAAAGCACTTGATATTCACCT – 3' 
E387R 5' - GTGAATATCGTGTGCTTTTA – 3' 5' - TAAAAGCACACGATATTCAC - 3' 
Table 4.2.2a- The synthetic oligonucleotides designed for specific mutations 
highlighted in yellow.   
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Optimised Mutation Production 
 
As discussed in Chapter 4.1.3, the yield of pure CDTa obtained was 
increased by using the pGEX-6p1-cdtA plasmid to express the protein which 
enabled purification by GST-affinity chromatography.  This alteration in the 
protocol improved the final yield of CDTa significantly.  Therefore, to improve the 
yield of the mutants, the same technique was applied: individually the pMAL-p2x 
plasmids containing the mutated CDTa DNA were digested using BamH1 and 
Sal1 and were ligated into the pGEX-6p1 vector using T4 DNA ligase.  DNA was 
sequenced to ensure successful ligation of mutants into the pGEX-6p1 vector. 
 
Expression and Purification of CDTa Mutants 
Expression of CDTa Mutants 
 
Expression of CDTa mutants was performed using the optimised protocol 
from Chapter 4.1.2.  E. coli BL21 (DE3) codon plus cells were transformed with 
the mutant pGEX-6p1-cdtA expression constructs.  Overexpression of soluble 
mutants was obtained using 2 L baffled flasks containing 1 L of LB medium 
supplemented with 100 µg/ml ampicillin.  The medium was inoculated with 10 ml 
overnight culture of the expression host, grown at 37 °C in LB supplemented with 
100 µg/ml ampicillin.  Once the culture reached OD600 = 0.8-1.0, the temperature 
was reduced to 20 °C.  After the temperature reached 20 °C, 1 mM IPTG was 
added to induce expression of CDTa.  The cultures were harvested after 4 hours, 
using 500 ml centrifuge tubes in a 10:500 rotor, spinning at 8,500 rpm for 10 min 
at 4 °C.  The cell pellets were re-suspended in 2 ml/g of pellet of lysis buffer; 50 
mM Tris-HCl pH 8.0 and 20 mM NaCl.  The re-suspended pellets were then rapid 
frozen in liquid nitrogen and stored at -80 °C until further use. 
Purification of CDTa Mutants 
 
Purification of CDTa mutants was performed using the optimised protocol 
from Chapter 4.1.2.  In brief: the mutants were purified using GST-tagged affinity 
chromatography in step 1.  The GST-tag was then removed during dialysis (to 
remove reduced glutathione) using PreScission Protease (GE Healthcare) and 
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non-tagged protein was passed back through the GSTrap column (GE 
Healthcare) and was collected in the flow through.  This was repeated to ensure 
complete removal of the cleaved GST-tag.  The final pure mutants were then 
concentrated to 0.5 mg/ml using 10 kDa cut-off concentrators (Amicon Ultra 15, 
Millipore), and were rapid frozen in liquid nitrogen and stored at -80 °C, until 
further use. 
 
Effect of Active Site Mutations on Catalytic Activity of CDTa 
Vero Cell Assays 
 
To assess the cytotoxicity of the mutated CDTa, Vero cell assays were 
performed using a previously established protocol with some modifications 
(Sundriyal et al., 2010).  The cells chosen were African green monkey kidney 
epithelial cells (Vero cells) as they have previously shown cell death in the 
presence of CDTa and CDTb’ combined, as well as Toxin A and B.  Vero cells 
were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10 % 
fetal calf serum (FCS) and 2 mM glutamine at 37 °C in the presence of 5 % CO2.  
Cells were routinely trypsinized and used to coat 96 well plates in a volume of 
200 µl (104 cells/well) of complete DMEM (supplemented with 10 % FCS and 2 
mM glutamine) and were incubated for 24 hours to allow formation of a confluent 
monolayer.  Prior to any assays, the medium was carefully removed and the cells 
were washed twice with Dulbecco’s phosphate buffered saline (DPBS) and the 
cells were incubated for an hour in 100 µl DMEM (supplemented with 10 % FCS 
and 2 mM glutamine).  A series of negative control assays were performed 
whereby Vero cells were incubated for 24 hours with 100 µl volumes of serum 
free DMEM, CDTa buffer and CDTb’ buffer (separately), 250 ng CDTa and 250 
ng trypsin activated CDTb’ (separately) to ensure no cell death under ‘non-
cytotoxic’ conditions.  In addition Toxin A and Toxin B positive controls were 
performed to ensure that the Vero cells were responsive to the standard 
cytotoxicity assay (established by PHE).  Cells were incubated for 24 hours in 
100 µl of 50 ng/ml Toxin A and 0.5 ng/ml Toxin B, at 37 °C in the presence of 5 
% CO2.  All of the assays were performed in triplicate.  Alongside the control 
experiments, 250 ng of both CDTa and trypsin activated CDTb’ were added to 
the cells in 100 µl to confirm the cytotoxic activity of CDTa and CDTb’ combined.  
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Then 250 ng of each mutant was combined with 250 ng of trypsin activated 
CDTb’ individually (in 100 µl) and were incubated alongside the CDTa+CDTb’ 
control for 24 hours at 37 °C in the presence of 5 % CO2.  The cells were 
examined after 24 hour for evidence of cytotoxic effects.  Assays were performed 
with the help of Dr Joanna McGlashan and Dr April Roberts at Public Health 
England, Porton Down.   
Western Blot Assays 
 
In order to confirm whether or not the mutations were affecting the binding 
of NAD or the transfer of ADP-ribose to actin, a western blot was performed 
using biotinylated-NAD (biotin-NAD) as the substrate.  Samples were subjected 
to 10 % Tris-glycine SDS-PAGE and streptavidin horseradish peroxidase (strep-
HRP) conjugate was used to detect biotin-NAD.  Preliminary attempts were made 
at optimising the assay by using a range of CDTa concentrations, biotinylated-
NAD concentrations and varying ratios of strep-HRP conjugate to develop the 
blot.  Negative controls were performed including CDTa positive, biotinylated-
NAD negative, and biotinylated-NAD positive, CDTa negative, to confirm that 
neither biotinylated-NAD nor CDTa individually alone would be detected in the 
blot.   
 
The final protocol for the Western blot assay is as follows: CDTa and 
biotin-NAD were mixed in equal molar ratio, whilst actin was mixed in equal molar 
ratio with laγA, which is a small molecule that maintains actin in its monomeric 
form, preventing polymerization.  Actin was then added to the CDTa-biotin-NAD 
mix in a 1:1 molar ratio.  The reaction was incubated at room temperature with 
gentle rocking for 1 hour.  The same was repeated for each of the seven purified 
mutants.  The samples were treated with SDS-PAGE sample loading dye and 
were immediately loaded onto a 10 % Tris-glycine SDS-PAGE, without heating 
the samples.  The SDS-PAGE was run at 200 V for 1 hour, after which the 
samples were transferred to nitrocellulose membrane using standard techniques 
for 1 hour at 50 V.  The membrane was blocked overnight in 1 % bovine serum 
albumin (BSA) in phosphate buffered saline pH 7.4 containing 0.05 % Tween-20 
(PBST).  The membrane was then washed for 5 min twice in PBST, after which 
the membrane was incubated with 1:1000 strep-HRP in PBST for 1 hour.  The 
membrane was then washed for 5 min, 6 times before the developing solution 
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was added: 50 mM Tris-HCl pH 7.5, 0.03 % H2O2 and 0.1 % 3, 3’- 
Diaminobenzidine (DAB).  Developing solution was removed immediately after 
bands appeared on the gel to prevent over exposure.   
 
Structure of CDTa Mutants 
 
 To complement the assay work, the plan was to solve the structure of the 
mutants in order to visualize exactly what effect the mutants have on the 
structural arrangements in the active site.  The CDTa native structure is available 
already; therefore this could be used as a model for molecular replacement to 
solve the phase problem.  Therefore the mutants were concentrated to 4 mg/ml 
which is the concentration used for crystallisation of the native, and 24-well 
hanging drop plates were performed using the following crystallisation condition: 
0.1 M malonate imidazole boric acid buffer (MIB) pH 9.0 and 20 % PEG 1500 
(Sundriyal et al., 2009).  The crystallisation screens were set up in triplicate for 
each mutant and the plates were incubated at 16 °C, and monitored weekly for 
crystal growth.  Until date there are no signs of crystal growth for any of the 
mutants, however crystallisation screens were performed towards the end of the 
project and are still regularly checked for signs of crystal growth. 
 
As the original protocol used to solve the CDTa structure involved 
expression of protein from the pMAL-p2x-cdtA construct, the protein was purified 
using a different technique to that which was used for the mutants.  The mutants 
were purified using GST-affinity chromatography and were expressed from a 
pGEX-6p1 construct.  Therefore in an attempt to more accurately replicate the 
original CDTa crystallisation conditions, the individual mutants were buffer 
exchanged into the final CDTa buffer used in the original purification protocol: 50 
mM Tris-HCl pH 8.0 and 20 mM NaCl.  Buffer exchange was performed using 
small volume dialyzing tubes (D-tube dialyzer midi MWCO 6-8 kDa, Millipore) 
overnight at 4 °C to ensure complete transfer into the CDTa buffer.  The above 
crystallisation trials were then repeated using the original crystallisation condition, 
concentration and temperature, with the hanging drop vapour diffusion method.  




Site Directed Mutagenesis of Active Site Residues 
 
As discussed in the materials and methods section (Chapter 4.2.2), the 
original protocol used to obtain pure CDTa was significantly altered to improve 
the final yield.  The initial and most key change in protocol was that the original 
CDTa DNA was cloned into an alternative vector (pGEX-6p1).  As the mutants 
were created prior to this change in protocol, the mutants were also cloned into 
pGEX-6p1 so that they could be expressed and purified in an identical manner to 
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Figure 4.2.3a- 0.8 % agarose gels showing examples of the various stages of 
cloning for the various CDTa mutants.  The upper gel shows the first step in 
cloning whereby the pMAL-p2x vector containing the mutated DNA was digested 
with BamH1 and Sal1, alongside digestion of the pGEX-6p1 vector with the same 
restriction enzymes. The lower gel shows the quick digest checks performed after 
ligation to ensure the presence of the CDTa mutant dropouts from the pGEX-6p1 
vector.  The ticks indicate successful digests.  The pMAL-p2x vector is 
approximately 6.7 kbp long as indicated in the upper gel and pGEX-6p1 is 4.98 
kbp as indicated by the shift downward in the vector band.    
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The mutant plasmids (pMAL-p2x-mutant) were digested alongside the 
new vector pGEX-6p1 using BamH1 and Sal1 restriction enzymes, see Figure 
4.2.3a upper gel for an example.  The CDTa mutant DNA dropouts were 
extracted from the gels and ligated into the digested pGEX-6p1 vector using T4 
DNA ligase.  A quick digest of the ligated mutants was performed, with an 
example of some of the results in Figure 4.2.3a, lower gel, to show the dropout in 
the new vector, indicating successful cloning. 
Expression and Purification of CDTa Mutants 
Expression of CDTa Mutants 
 
The CDTa mutants were expressed using the optimised protocol from 




There is a notable increase in the intensity of the bands at 77 kDa 
following induction of expression with 1 mM IPTG.  This suggests the mutants 
are being expressed in a similar manner to CDTa.  There are notable differences 
in the expression levels across the various mutants, but there are often batch-to-
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Figure 4.2.3b- Soluble expression of CDTa mutants.  A: 12 % Tris-glycine SDS-
PAGE displaying mutant expression: lanes 1, 4 and 7 are pre-induced samples, 
lanes 2 and 3 are S345R post-induction samples (duplicate), lanes 5 and 6 are 
S345Y post-induction samples (duplicate) and finally lanes 8 and 9 are E385Q post-
induction samples (duplicate).  B: 10 % Tris-glycine SDS-PAGE displaying mutant 
expression:  lanes 1-4 are pre-induced samples and lanes 5, 6, 7 and 8 are post-
induction samples of S345A, S345F, E387Q and E387R respectively.  




batch variations in expression levels for the same protein as a result of variation 
in OD600 or temperature fluctuations during cell growth. 
Purification of CDTa Mutants 
 
The CDTa mutants were purified using the optimised protocol designed 
for the native CDTa.  After an initial GST-affinity chromatography step, the GST-
tag was cleaved off using PreScission Protease.  The cleaved protein was then 
passed back through the GSTrap column multiple times collecting the mutant 
protein in the flow through.  This allowed removal of the GST-tag by allowing it to 































  70 
  55 
  35 
  25 







 Figure 4.2.3c- Purification of CDTa mutants with each step analysed by 10 % Tris-
glycine SDS-PAGE.  A: Lanes 1 and 2 represent the protein loaded onto the 
column and the flow through respectively.  Lanes 3 and 4 represent the eluted 
protein and the cleaved protein respectively.  Lanes 5 and 6 represent the ‘pure’ 
protein flow through and the eluted GST tag as indicated.  Lanes 7 and 8 
represent the second purification step where 7 is the pure CDTa flow through and 
8 is the remaining GST and uncleaved protein eluted from the column.  B: Lanes 
1-7 represent the final purified mutants S345A, S345F, S345R, S345Y, E385Q, 








































Figure 4.2.3d- Example of Purification of CDTa Mutants by GST-affinity 
Chromatography.  The blue lines represent the absorbance at 280 nm and the red line 
represents conductivity. A:  First step, cell lysate is applied to GSTrap column 
allowing CDTa-GST to bind and non-specific proteins flow through.  Bound CDTa-
GST is then eluted using reduced glutathione.  B: After cleavage of GST-tag, the 
second step involved, passing cleaved protein back through GSTrap column 
collecting the ‘pure’ CDTa mutant in flow through, whilst the GST-tag binds column.  
This is repeated twice to ensure complete removal of GST-tag. 
A 
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Effect of Active Site Mutations on Catalytic Activity of CDTa 
Vero Cell Assays 
 
To assess the cytotoxicity of the CDTa mutants, Vero cell assays were 
performed.  Vero cells were grown in DMEM containing 10 % FCS and 2 mM 
glutamine at 37 °C in the presence of 5 % CO2.  Cells were routinely trypsinized 
and used to coat 96 well plates.  A series of negative control assays were 
performed whereby Vero cells were incubated for 24 hours with serum free 
DMEM, CDTa buffer and CDTb’ buffer, 250 ng CDTa and 250 ng trypsin 
activated CDTb’ (separately) to ensure no cell death under ‘non-cytotoxic’ 
conditions.  These results are displayed in Figure 4.2.3e A-E respectively.  As 
shown in these images, there is no cell death observed, confirming the Vero cells 
are not sensitive to either of the protein buffers or CDTa and trypsin activated 
CDTb’ individually.   
 
In addition Toxin A and Toxin B positive controls were performed to 
ensure that the Vero cells were responsive to the standard cytotoxicity assay 
(established by PHE).  Figure 4.2.3e F and G display the Toxin A and Toxin B 
positive controls respectively.  It is clear that there is complete cell death in the 
presence of both Toxin A and B individually (cell death indicated by rounding of 
cells).  Cells were then incubated for 24 hours in the presence 250 ng of both 
CDTa and trypsin activated CDTb’ to test the effect of the combination of both 
binary components.  The results are displayed in Figure 4.2.3e H, where it is 
clear there is some cell death, but not to the same extent as Toxin A and B, but 
this is to be expected as these are known to have a clear cytotoxic impact on 
Vero cells.  These results are consistent with those previously reported 
(Sundriyal et al., 2010).   
 
The Vero cells were then incubated in the presence of 250 ng of each 
mutant combined with 250 ng of trypsin activated CDTb’ individually.  The results 
for the S345A mutation are displayed in Figure 4.2.3e I, which shows a significant 
decrease in cytotoxicity but there is still noticeable cell death indicating the 
S345A mutation does not diminish the cytotoxic effect of CDTa.  Images J-O in 
Figure 4.2.3e represent the remaining six mutants: S345F, S345R, S345Y, 
E385Q, E387Q and E387R, respectively. These remaining images show no signs 
of Vero cell death, which indicates that these active site mutations completely 






































Figure 4.2.3e- Vero cell assay results.  A: Media control.  B: CDTa buffer control.  C: 
CDTb control.  D: 250 ng CDTa.  E: 250 ng CDTb’.  F: 50 ng/ml Toxin A.  G: 0.5 ng/ml 
Toxin B.  H: 250 ng CDTa + 250 ng CDTb’.  I: 250 ng S345A + 250 ng CDTb’.  J: 250 
ng S345F + 250 ng CDTb’.  K: 250 ng S345R + 250 ng CDTb’.  L: 250 ng S345F + 250 
ng CDTb’.  M: 250 ng E385Q + 250 ng CDTb’.  N: 250 ng E387Q + 250 ng CDTb’.  O: 
250 ng E387R + 250 ng CDTb’.  The scale bar in each image represents 400 µm. 





















Western Blot Assays 
 
 
 Cell based assays were performed to assess the effect of the mutants 
using Vero cells.  In addition, Western blots were performed to show more 
specifically how the mutations affect the activity of CDTa in terms of either 
















































Figure 4.2.3f- Western blot assay results for CDTa and CDTa mutants.  A: 10 % 
Tris-glycine SDS-PAGE gel picture displaying the protein bands transferred to 
the cellulose membrane for blotting.  Lane 1 represents CDTa + biotin-NAD and 
lane 2 represents CDTa + actin + biotin-NAD.  The remaining lanes 3-9 represent 
the mutations + actin +biotin-NAD in the order of S345A, S345F, S345R, S345Y, 
E385Q, E387Q and E387R respectively.  B: The western blot developed with 
DAB displaying strep-HRP bound to biotin-NAD where present on the 





Displayed in Figure 4.2.3f are the 10 % Tris-glycine SDS-PAGE results 
(A) alongside the Western blot results (B), which correspond to each other 
directly in terms of samples loaded.  The first two lanes represent the control 
samples, CDTa + biotin-NAD, and CDTa + actin + biotin-NAD, which will confirm 
that the native binds NAD and also transfers the ADP-ribose group to actin.  To 
confirm, the NAD is biotinylated at the ADP-ribose end and so can be detected 
after ADP-ribosylation.  There is a faint band in the first lane which shows that 
CDTa has bound biotin-NAD and also in the second lane there is a much 
stronger band and a secondary band below which clearly indicates that biotin-
NAD is present in both CDTa and actin, confirming the activity of the native 
protein.  There is one slightly unusual point to note on both the SDS-PAGE gel 
picture and the Western blot picture and that is the presence of a faint lower 
molecular weight band.  The close proximity stronger double band is 
characteristic of CDTa and actin when loaded on a gel together as they have 
similar molecular weights.  It is possible that the lower molecular weight band is a 
truncated version of actin as it is not present in the first lane, which is the only 
lane that does not contain actin.  The other evidence that points towards this 
theory is the very strong band of CDTa in lane 2 compared with lane 1.  Both 
lanes contain an equal quantity of CDTa, yet in lane 1 there is a very faint 
Western blot band, but lane 2 is very strong.  As there is no substrate for CDTa 
to transfer ADP-ribose to in lane 1, the biotin-NAD could possibly have been 
released, where as in lane 2 it is transferred to actin, which is why the band 
remains so strong.  There is no biotin-NAD wasted in lane 2, hence the stronger 
band.  As the lower molecular weight ‘unknown’ band appears highlighted in the 
Western blot in lane 2, this suggests that it is a substrate for biotin-NAD.  The 
lower band is only present in the lanes containing actin, and this molecular 
weight band is not present in the SDS-PAGE analysis of the purified mutants, 
therefore, it may be a truncated or degraded actin band.   
 
 The following lanes 3-9 represent the mutants and the effect they have on 
NAD binding and/or ADP-ribose transfer to actin.  It is clear from the Western blot 
that lane 3 shows the most consistent effect as the native protein, and this 
mutation is S345A.  These results correlate to the Vero cell assays in which 
S345A was the only mutation that causes any cytotoxic effect on the cells.  Lanes 
4 and 5 that represent S345F and S345R respectively show strong CDTa binding 
and potentially a very small fraction of biotin-NAD present in the low molecular 
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weight band proposed to be actin.  Lane 6 represents S345Y, which has very 
little biotin-NAD present either in CDTa or actin, which could mean this mutation 
prevents any biotin-NAD from binding CDTa at all.  Based on the size of the 
residue that has replaced the existing one, it is more likely that the mutation 
caused a significant reduction in binding and cytotoxic efficiency.  Lanes 7-9 
represent E385Q, E387Q and E387R respectively and each displays a similar 
effect.  The clear picture here is the complete lack of ADP-ribosylation of actin, 
but the presence of low volumes of biotin-NAD in the CDTa-mutant themselves, 
which indicates these mutations don’t inhibit NAD binding but do inhibit ADP-
ribosylation of actin.   
 
Crystallisation of CDTa Mutants 
 
Crystallisation trials were performed for all seven CDTa mutants, following 
the exact conditions used to crystallise the native CDTa including concentration, 
temperature and crystallisation solutions.  This protocol had been used 
previously to successfully grow crystals of CDTa which were used to solve the 
structure at high resolution (Sundriyal et al., 2009).  Initially the trials were 
performed with the mutants in their final purification buffer, however after no 
success in crystal growth, the mutants were buffer exchanged into the buffer that 
was used to purify the native protein prior to crystallisation.  Unfortunately, to 














One of the key aims of this chapter was to determine the 3D-structure of 
CDTa in complex with its target, actin.  Theoretically, if the structure of this 
complex is understood, then we would be able to visualize the interactions 
between the two proteins that are necessary for ADP-ribosylation to take place.  
Understanding these interactions is key for prevention of actin ribosylation.  
Once the key interactions are resolved, it may be possible to design highly 
specific small molecules that can prevent this interaction, thereby inhibiting actin 

















Figure 4.3a- The predicted structure of the CDTa-actin complex.  The Ia-Actin structure 
was used for homology modelling, whereby the structure of CDTa was superposed 
onto that of Ia (Tsuge et al., 2008).  CDTa is displayed in cartoon with the N-terminal 
domain in purple and the C-terminal domain in cyan, corresponding to previous 
figures.  The key active site motifs involved in binding NAD are coloured as previously: 
ExE-motif in blue and STS-motif in green.  NAD is displayed as sticks in magenta.  
Actin is displayed in green as cartoon with the Arg-177 residue displayed in red sticks, 
ATP bound in cyan sticks and latrunculin A bound in orange sticks.      
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Multiple attempts were made at CDTa-actin complex formation with 
some small-scale success for attempts 4a and 4b.  A small amount of complex 
was successfully formed, however, optimisation is required.  The main concept 
of the protocol was based on that used for the Ia toxin which is homologous to 
CDTa and is structurally almost identical (Tsuge et al., 2008), see Figure 4.1.1c-
A showing Ia toxin structure superimposed onto the CDTa structure.  This 
protocol established for the Ia-actin complex was performed on a much larger 
scale and was a simple case of adding all of the components together and 
setting up crystallisation plates without any confirmatory step.  However, this 
protocol was not applicable to CDTa, which could be for a number of reasons: 
one explanation could be that the rate of CDTa crystal growth is more rapid than 
that of Ia and CDTa may start forming microcrystals prior to complex formation.  
Alternatively, CDTa may be folded slightly differently when purified using the 
optimised protocol, as the protocol has been significantly adapted from the 
original.  In order to visualise what the structure of the CDTa-actin complex may 
look like the Ia-actin complex was used for homology modelling, see Figure 
4.3a.   
CDTa-Actin Future Work 
 
 In order to obtain the CDTa-actin structure, the next step should be to 
scale up the ‘on column’ complex formation protocol from ‘attempt 4b’ as this 
was the most successful attempt to date.  This could potentially provide enough 
complex to set up crystallisation screens.  In addition to the standard screens, 
the Ia-actin crystallisation condition should be attempted using both the CDTa 
crystallisation condition and the Ia-actin complex crystallisation condition.     
CDTa-CDTb 
 
Another aim of this chapter was to determine the 3D-structure of CDTa 
in complex with the oligomeric transport component.  For similar reasons to that 
of the CDTa-actin complex: the main aim behind structural determination of 
these complexes is to understand their interactions.  If small molecules can 
block the interactions between the complexes, then the cytotoxic effects of 
CDTa can be reduced indirectly.  Toxicity can be eliminated either by inhibiting 
the access to the cells via the interaction with CDTb or by inhibiting the collapse 




 Attempts were made at CDTa-CDTb’’ complex formation, whereby the 
two components were combined, incubated and subjected to size-exclusion 
chromatography.  However, there was no success, which could be due to a 
number of reasons.  There are two key theories behind the lack of success in 
formation of a complex: 
 
• First and foremost, the way in which CDTa and CDTb’’ interact with 
each other, and at what stage they interact is yet to be understood, 
and in addition, the way in which CDTb’’ interacts with the target cell 
surface is not fully understood.  It is thought that CDTb’ must be 
activated by trypsin cleavage after which it either forms oligomers and 
interacts with the cell-surface receptors, or the monomers interact with 
the cell-surface receptors and slowly form oligomers (Barth, 2004).  
Once the CDTb’’ has formed interactions with the target cell surface, it 
is predicted that CDTa will then interact with CDTb monomers or 
oligomers, but not until they are on the cell surface.  This could be one 
reason behind the lack of CDTa-CDTb’’ complex formation.  When 
CDTb interacts with target cell surfaces, regardless of whether or not 
it is in the oligomeric or monomeric form, it may undergo 
conformational changes allowing CDTa to bind.  This mechanism of 
CDTa entry into cells is not fully understood, and the interaction of 
CDTa and CDTb may be key to understanding how entry is initiated.  
 
• Secondly, there is some ambiguity as to the status of CDTb’’ after 
purification, as discussed in detail in Chapter 3.3.  Briefly, the CDTb’’ 
pure protein is eluted from the gel-filtration column at a higher 
molecular weight predicted size than expected (> 500 kDa), which at 
first could be explained as being a slightly larger oligomer than the 
predicted heptamer, or potentially a dimer of heptamers.  However, 
after extensive analysis of CDTb’’ using a variety of structural and 
biochemical techniques, it is possible that CDTb’’ is not in the correct 
state for potential complex formation, see Chapter 3.3.  Even if the 
first point was not applicable, and that CDTa could interact with 
CDTb’’ prior to interaction with the cell-surface receptors, it may not 




CDTa-CDTb Future Work 
 
 In order to form a CDTa-CDTb’’ complex, a number of challenges need 
to be overcome.  The first hindrance that should be addressed is the CDTb’’ 
oligomeric state.  If there is to be a chance at CDTa-CDTb’’ formation it is crucial 
that CDTb’’ is in the correct state to interact with CDTa, see Chapter 3.3 for 
efforts to overcome this problem.  The second option to consider is introducing 
an additional component to the complex that acts as the cell surface.  Recently 
the lipolysis-stimulated lipoprotein receptor (LSR) was identified as the host 
receptor for the binary toxin CDTb component (Papatheodorou et al., 2011).  If 
the theory of CDTb’’ altering conformation on cell-surface binding is correct, 
then incorporating this receptor with CDTb’’ could help with CDTa-CDTb’’-
receptor complex formation.   
 
 
CDTa Mechanism of ADP-ribosylation of G-Actin 
 
 The selected residues Glu-385 and Glu-387 of the ExE-motif were 
mutated, as this motif is known to play a strong role in ligand binding and 
catalysis.  They directly correspond to residues Glu-378 and Glu-380 from the Ia 
toxin which in previous mutagenesis studies were shown to play key roles in the 
cytotoxicity of Ia (Perelle et al., 1996).  In addition the Ser-345 residue was also 
selected for mutagenesis studies due to its key role in binding Glu-387 and 
NAD.  The planned mutations included, removing the residues by mutating to 
alanine, altering the charge of the residue and changing the size of the residue 
to see what effect each of these changes has on the cytotoxicity.  Due to time 
restraints, not all of the mutations were achieved at both the DNA level and the 
expression/purification level.  Those mutants that were taken from DNA through 
to purification and were therefore used in the assays include S345A, S345F, 
S345R, S345Y, E385Q, E387Q and E387R.    
 
 To test the effect of these mutations on the activity of CDTa, both in vitro 
Vero cell assays and Western blot assays were performed.  The Vero cell assay 
is a visual qualitative assay that will provide a yes or no answer as to whether or 
not the mutations affect the cytotoxicity of CDTa.  The Western blot assays were 
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designed to differentiate between CDTa binding of NAD and ADP-ribosylation of 
actin, and therefore will test the effect of the mutations on either binding or 
catalysis or both. 
 
 The Vero cell assay results displayed in Figure 4.2.3e show a series of 
images taken of the various control and experimental assays performed on the 
Vero cells on a 96-well plate.  In the first five images Figure 4.2.3 A-E are the 
negative controls performed using standard DMEM, CDTa and CDTb’ buffers, 
and then CDTa positive, trypsin activated CDTb’ negative and trypsin activated 
CDTb’ positive ,CDTa negative controls.  There is no cell death observed 
amongst the negative controls as expected, which is confirmation that CDTa 
and CDTb’ are non-toxic to Vero cells individually.  The following two images, 
Figure 4.2.3e F and H are positive controls performed using Toxin A and B that 
are known to be toxic to Vero cells in low concentrations.  In these two images 
there is conclusive evidence of complete cell death, confirming the cells are 
responsive to the standard toxicity assay (established by PHE).  The most 
essential assay performed was the combination of CDTa and trypsin activated 
CDTb’, see Figure 4.2.3e-H.  This control is necessary to confirm that when 
CDTa and trypsin activated CDTb’ are combined, there is noticeable cell death, 
confirming that both components of the binary toxin are required to cause Vero 
cell death, which is consistent with the literature (Sundriyal et al., 2010).  Trypsin 
activated CDTb’ was used rather than CDTb’’ as this shows greater cytotoxicity 
when combined with CDTa, as established previously by Sundriyal et al.  The 
amount of cell death observed for the CDTa + CDTb’ control is much less than 
that observed for the LCTs which is to be expected as they are considered to be 
more potent toxins.  As the quintessential CDTa + CDTb’ assay was successful, 
even though the observed cell death is low, it was deemed suitable enough to 
continue with the CDTa mutants.   
 
 Each of the mutants were individually combined with trypsin activated 
CDTb’ at the same concentration and were added to the Vero cells concurrently.  
The results for the mutants are displayed in Figure 4.2.3e images I-O and 
represent S345A, S345F, S345R, S345Y, E385Q, E387Q and E387R.  When 
directly comparing these images to the CDTa + CDTb’ control, it is evident that 
mutants J-O display no indication of cell death at all, suggesting these mutations 
have had a direct inhibitory effect on the cytotoxicity of CDTa.  Image I which 
represents S345A is the only mutant that still shows blatant cell death, albeit 
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less than that of the native, there is still evidence that this mutation hasn’t 
inhibited the activity of CDTa but may have slightly reduced its efficacy.  
        
Displayed in Figure 4.2.3f are the Western blot assay results, which were 
performed in order to elucidate the effect the mutations have directly on binding 
and/or catalysis.  The first two lanes represent the control samples, CDTa + 
biotin-NAD and CDTa + actin + biotin-NAD, which confirms that the native binds 
NAD and also that ADP-ribosylation of actin occurs. The NAD is biotinylated at 
the ADP-ribose end and so can be visible both before and after ADP-
ribosylation.     
 
The Western blot assay confirms that CDTa ADP-ribosylates actin in the 
native form, as biotin is observed in both CDTa and actin bands in lane 2.  This 
assay also shares similar results to the Vero cell assays in that the S345A 
mutant also shows evidence of ADP-ribosylation of actin, as displayed in lane 3.  
In addition, the remaining mutants displayed no evidence of ADP-ribosylation of 
actin; see Figure 4.2.3f lanes 4-9 which again correlate to the results observed 
for the Vero cell assays.   
 
The potential slight design flaw in this assay is that biotin-NAD is 
hydrolysable hence why we can observe ADP-ribosylation of actin.  Therefore, 
the amount of biotin-NAD present in the native CDTa and mutants is not the end 
point amount as the biotin-NAD will be hydrolysed and released from the active 
site.  This will complicate the assay to a certain extent in that it may be more 
difficult to determine whether or not the mutants are affecting NAD binding.  
However, due to the presence of the actin, the assay will be conclusive as to 
whether or not the actin is ADP-ribosylated.  If the actin is not ribosylated this 
could mean the mutants are not binding the NAD in the first instant or if they are 
that they are not able to catalyse the hydrolysis and transfer of ADP-ribose to 
actin.  For the native, it is possible to see trace amounts of biotin-NAD present in 
the control without actin, which shows promise for determination of whether or 
not the mutants affect NAD binding.   
 
 The lanes 4-9 represent the mutants that show no indication of ADP-
ribosylation and so based on the previous statement of the observation for the 
native, the remaining mutants will be directly compared for NAD binding.  Lanes 
4 and 5 that represent S345F and S345R respectively show strong similar NAD 
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binding to the native and potentially a very small fraction of biotin-NAD present 
in the low molecular weight band proposed to be actin.  Lane 6 represents 
S345Y, which displays a very faint band, which could mean this mutation 
prevents NAD binding.  Based on the size of the residue that has replaced the 
existing one, it is likely that the mutation caused a significant reduction in 
binding and cytotoxic efficiency.  Lanes 7-9 represent E385Q, E387Q and 
E387R respectively and each displays a similar effect.  The clear picture is the 
complete lack of ADP-ribosylation of actin, but the presence of low volumes of 
biotin-NAD in the CDTa-mutant themselves, which indicates these mutations 
don’t inhibit NAD binding but may inhibit ADP-ribosylation of actin.   
 
 
 Both the Western blot assay and the Vero cell assay have confirmed that 
S345A is the only mutation that maintains cytotoxicity.  Figure 4.3b displays the 
mutations performed, and it is clear from the diagram that mutating a serine 
residue to alanine, only removes the –OH group, where as the mutations to 
either phenylalanine, arginine and tyrosine are much more significant in terms of 
Figure 4.3b- Successfully performed mutations, expressed, purified and used in 
both Vero cell and Western blot assays.  The Ser-345 residue was mutated to 
alanine, phenylalanine, arginine and tyrosine.  Glutamic acid residues Glu-385 and 



















size and functional group properties.  This would suggest that the functional –
OH group of serine does not play an important role in the active site, but the size 
of serine does play a key role.  As mutating this serine residue to alanine only 
marginally reduced the cytotoxicity but the other three mutations caused 
complete loss of cytotoxicity.  This increase in size of the Ser-345 residue 
causes an adverse effect on cytotoxicity which could be due to a number of 
reasons, firstly it could prevent the residue from interacting with and stabilising 
Glu-387, or it could block the transfer of ADP-ribose to actin.  The enlarging 
effect of the residue doesn’t seem to affect NAD binding as demonstrated by the 
Western blot assay, with the exception of S345Y which could be purely due to 
space issues in the active site, reducing the NAD binding capacity.   
 
 The ExE-motif mutations also show interesting results.  Previously it has 
been suggested that the hydrolysis of NAD and ADP-ribosylation of actin take 
place via an SN1 reaction, with Glu-387 playing a key role in oxocarbenium ion 
formation by interaction with the 2’OH ribose group of NAD.  By creating E387Q, 
the –OH group of Glu-387 is substituted with –NH2, which appears to completely 
abolish ADP-ribosylation of actin.  This suggests that the proposed SN1 reaction 
involving Glu-387 has some validity.  In addition E385Q also completely 
eliminates ADP-ribosylation of actin, which indicates that the –OH functional 
group plays a crucial role in the mechanism.  The theory is that Glu-385 brings 
Arg-177 from actin into the active site via the –OH functional group of Glu-385.  
Again, this mutagenesis study indicates this theory may also be correct.  Having 
already established that substitution of the functional group of Glu-387 to –NH2, 
it confirms the view that increasing the size of this residue and substituting the 
functional group (E387R mutation) also eradicates ADP-ribosylation.   
CDTa ADP-Ribosylation Mechanism Future Work 
 
The purpose of mutating these specific three residues and monitoring 
their affect on cytotoxicity is to determine whether or not these residues are vital 
individually for the activity of CDTa.  Here, the combination of both the Vero cell 
assays and the Western blot assay, have proven that altering these three 
residues can have a significant negative impact on the activity of CDTa.  
Therefore, these three residues should be key in small molecule drug design to 
block CDTa activity.  If the activity of CDTa can be inhibited, then ADP-
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ribosylation of actin can be prevented, which in turn will protect from cell 
rounding and cell death.   
 
Solving the crystal structures of these CDTa mutants may shed some 
light on the orientation of the mutants in the active site, to ensure they are not 
having an adverse affect on cytotoxicity of CDTa based on their position, rather 
than the changes to their properties.  At present the optimised protocol of CDTa 
native production and mutant production differs from that used for the original 
protocol that lead to successful determination of the native structure.  Attempts 
have been made at crystallising the native and mutant proteins using the same 
conditions that were in place for the established protocol.  However, as the 
protein is now expressed from a different construct there may be small changes 
to the terminal residues, and potentially changes to the overall fold of the 
proteins that may cause them to behave differently.  Therefore, in order to grow 
diffraction quality crystals for structural studies, it may be necessary to screen 














5.1 Toxin A 
 
Toxin A is a large multi-modular clostridial toxin with dominant 
hydrophobic properties.  The four domains that make up Toxin A include the 
glucosylating ‘A’ domain, the binding ‘B’ domain, the cysteine protease ‘C’ 
domain and the hydrophobic `D’ domain (Jank and Aktories, 2008).  Each of 
these four domains plays a key role in toxicity (see Figure 1.2.1b in Chapter 1.2 
for an illustration).  The ‘B’ domain interacts with cell surface receptors on target 
cells and the whole toxin is taken up by receptor-mediated endocytosis.  Within 
the endosomal compartment, pH changes stimulate conformational changes 
within Toxin A allowing pore formation of the ‘D’ domain and insertion into the 
endosomal membrane.  The ‘A’ and ‘C’ domains are translocated into the cytosol, 
whereby the ‘C’ domain interacts with InsP6.  The ‘C’ domain catalytically cleaves 
off the ‘A’ domain releasing it into the cytosol whereby it targets Rho GTPases for 
glucosylation (Davies et al., 2011; Jank and Aktories, 2008).  As discussed in 
Chapters 1.2 and 2.2, the crystal structures of the ‘A’ domain, ‘C’ domain and a 
fragment of the ‘B domain for Toxin A have been solved at high resolution.  The 
focal point of the Toxin A Ph.D project was to structurally characterise the full-
length Toxin A using X-ray crystallography. 
 
Although ambitious due to the size and nature of the toxin, attempts were 
made at crystallising Toxin A for use in X-ray crystallography studies.  Toxin A 
contains a high percentage of leucine, isoleucine, phenylalanine and tyrosine 
residues, which gives the protein hydrophobic properties commonly seen in 
membrane proteins.  The majority of the hydrophobic residues are located in the 
‘D’ domain, as this is the membrane insertion domain.  At present the ‘D” domain 
has not been characterised structurally and similarly there are no structural 
homologues for this region.  This hydrophobic element may be one of the 
reasons for the difficulties experienced during crystallisation.  In addition, the ‘B’ 
domain structure reveals a helical region which is thought to increase surface 
area for optimized binding to target cells (Greco et al., 2006).  This region binds 
carbohydrate receptors on target cell surfaces.  It is long, helical and may be 
quite flexible, which may explain why the protein molecules in the crystal are not 




After extensive crystallisation trials and optimisations, diffraction quality 
crystals were obtained, and three datasets were collected, with the best 
resolution being 10 Å.  Although ambitious, attempts were made at solving the 
structure by molecular replacement, however the combination of low-resolution 
data and lack of model for 50 % of the toxin is a challenging combination.  There 
are potentially up to 12 molecules in the asymmetric unit, so if the resolution of 
the crystal diffraction can be improve to at least 5 Å or higher then it may be 
possible to solve the structure by molecular replacement.   
 
Due to the difficulties experienced in high-resolution structural studies for 
Toxin A, low-resolution structural techniques were employed, including small-
angle X-ray scattering (SAXS).  SAXS data collected for Toxin A were used for 
ab initio modelling to produce a low-resolution structure, displayed in Figure 2.3a-
A.  The structure is consistent with the Toxin A reconstruction generated from 
electron microscopy data, Figure 2.3a-B (Pruitt et al., 2010).  The SAXS 
envelope of Toxin A was superimposed onto the model structure of Toxin A 
generated from electron microscopy data, Figure 2.3a-C, which clearly shows 
their similarities.  Both structures have a globular head domain and an extended 
long tail domain.  The SAXS structure of Toxin B, solved by Albesa-Jové et al., 
shows few similarities to that of Toxin A other than that they are both elongated 
and approximately 265-275 Å.  The Toxin B structure lacks the globular head 
domain and instead has a protruding domain mid way along the envelope, see 
Figure 2.2.1d (Albesa-Jové et al., 2010).  There has not been a successful 3D-
reconstructed structure reported for Toxin B from electron microscopy data as 
yet.  Previous attempts found that the electron microscopy images of Toxin B 
provided a more heterogeneous field of particles rather than the significantly 
more homogeneous field of particles reported for Toxin A (Pruitt et al., 2010).  
The characteristic globular head was still present amongst the heterogeneous 
particles, but due to the heterogeneity of the sample, a model was not 
constructed.   
 
Future Work for LCTs 
 
There are numerous avenues in which this project could be taken further 
given more time.  First and foremost, the continued work in crystallisation and X-
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ray crystallography studies for Toxin A.  The research performed during the 
project to date has included identification of a crystallisation condition for full-
length Toxin A.  Now that a condition has been established, further crystallisation 
condition optimisations should be carried out, including the use of alternative 
crystallisation techniques including microdialysis, crystallisation under oil, 
sandwich drop and free interface diffusion.  The next stage in this progression 
should be to try co-crystallising Toxin A with various molecules to stabilise the 
protein.  This could include carbohydrates or cell surface receptors for the ‘B’ 
domain or antibody fragments such as Fab fragments.  In addition, complex 
studies of the ‘A’ domain and Rho GTPases could be performed, which could 
provide insights into the interaction between the glucosylation target and the ‘A’ 
domain.  Highlighting these interactions using X-ray crystallography could provide 
a platform for specific drug design to inhibit glucosylation of Rho GTPases by 
Toxin A.  Finally, as there is no crystallographic data for the full-length Toxin B, 
this structure should also be pursued given it is thought to be the most potent and 




 To conclude, elucidating the 3D-structure of Toxin A proved challenging 
using crystallographic techniques, however success was achieved using low-
resolution structure techniques.  A SAXS structure of Toxin A was obtained, 
which provided our first visualisation of Toxin A from X-ray scattering data.  This 
structure was consistent with the model reconstruction structure obtained by 
electron microscopy.  This achievement has brought this project one step further 
to elucidating the high-resolution full-length structure of Toxin A. !!
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5.2 CDT Binary Toxin !
 
Some more virulent C.difficile strains produce an ADP-ribosylating binary 
toxin; CDT, alongside the two potent exotoxins; Toxin A and B.  The role of the 
binary toxin in pathogenicity is unclear, however some studies have shown that CDT 
causes the formation of microtubule-based protrusions on the cell surface of target 
cells (Schwan et al., 2009).  It is postulated that these protrusions promote 
adherence of C.difficile to the intestinal epithelial cells (Schwan et al., 2009).  As 
discussed in detail in the introductory chapter, the binary toxin is made up of two 
independently produced components: CDTa, the enzymatic component and CDTb, 
the transport component.  The transport component is thought to interact with cell 
surface receptors on target cells.  This component forms oligomers, interacts with the 
enzymatic component, CDTa, and both components are taken up into the cells by 
receptor mediated endocytosis.  Studies have shown that individually CDTa and 
CDTb are non-toxic, however when the components are combined CDT is toxic to 
Vero cells (Sundriyal et al., 2010). 
 
 The objectives for the binary toxin project were firstly to characterise the 
enzymatic mechanism of CDTa by testing the current hypothesis, secondly to solve 
the crystal structures of the CDTb variants and finally to form complexes of CDTa-
CDTb and CDT-actin.  Two of these objectives were achieved: the first being the 
mutagenesis studies performed on CDTa to elucidate the roles of active site residues 
in the ADP-ribosylation mechanism and the second being the formation of a CDTa-
actin complex.   
 
For the CDTa mechanism studies, see Chapter 4.2, both Western blot assays 
and the Vero cell assays were used to test the effect of active site mutations on the 
ribosylation mechanism.  The results show that Ser-345, Glu-385 and Glu-387 all 
individually play essential roles in the mechanism.  Based on the range of mutations 
performed, it was also observed that on removal of the –OH groups from both Glu-
385 and Glu-387, ADP-ribosylation of actin was completely inhibited, which indicates 




Chapter 4.1 describes the steps taken to produce a CDT-actin complex.  
Although success was achieved in formation of the complex, the yield was too low to 
perform crystallisation trials.  In addition, attempts made at forming a CDTa-CDTb 
complex were unsuccessful.  The reasoning behind this lack of complex formation for 
CDTa-CDTb is unknown, however one contributing factor could be the discovery that 
CDTb variants form interchangeable oligomers of high molecular weight when 
concentrated.  The way in which CDTa and CDTb interact is yet to be established.  
However, it is postulated that CDTb’’ interacts with specific carbohydrate receptors 
on target cells and forms heptamers prior to CDTa binding (Barth, 2004; Barth et al., 
2004).  It is unclear whether or not the conformation of CDTb changes upon receptor 
binding, or if receptor binding is required prior to interaction with CDTa.  
 
Extensive crystallisation attempts were made for all three forms of CDTb and 
although diffraction quality crystals were grown for CDTb’ and CDTb’’, the resolution 
was low and the crystals did not survive in the beam long enough to collect data.  
Crystallisation occurs when proteins interact non-covalently to form highly ordered 
lattices.  If proteins are irregular in shape the ‘building blocks’ of the crystal lattice do 
not pack well, which can lead to poor diffracting crystals.  This might be the cause of 
the low-resolution diffraction observed for CDTb crystals.  High concentrations of 
protein are required for crystallisation, however as discovered in Chapter 3.3, CDTb 
forms heterogeneous oligomers when concentrated.  This may prevent tight and 
well-ordered crystal packing, which must be overcome in order to grow improved 
diffraction quality crystals.     
 
 
Future Work for CDTa-actin Complex and CDTa Mechanism  
 
 The preliminary CDTa-actin complex formation has shown promising results 
for future work.  The current ‘on-column’ protocol established in Chapter 4.1 should 
be pursued and performed on large scale, as this could potentially provide enough 
complex for crystallisation trials.  If this complex can be crystallised and data 
collected, the structures of actin and CDTa individually can be used as models for 
molecular replacement.  This structure could provide a platform for small molecular 
drug design to block ADP-ribosylation of actin.  As it has been established in this 
project that the SN1 mechanism is used by CDTa to ADP-ribosylate actin, using Vero 
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cell and Western Blot assays, it would be useful to solve the crystal structures of 
these mutant CDTa constructs to supplement the biochemical assay data.  This is 
required to confirm that the active site mutations are affecting the cytotoxicity of CDT 
based on their functional group alterations rather than the positioning of the mutated 
residues.  High-resolution crystal structures of the mutants would confirm the position 
of these residues in the active site.       
 
Future Work for CDTa-CDTb Complex and CDTb Variants  
 
In terms of solving the structure of CDTb and forming a CDT-CDTb complex, 
future efforts should be focused on inhibition of the sporadic oligomerisation that 
occurs during concentration.  This oligomerisation may prevent protein from forming 
tightly packed crystals, hence the lack of high-resolution diffraction from CDTb 




 Although the specific role of the binary toxin is still unknown, it is understood 
that the more virulent strains of C.difficile produce both of the LCTs and the binary 
toxin, which indicates that this toxin does contribute to pathogenicity.  Studies have 
shown that the binary toxin can cause microtubule based protrusions on the target 
cell surfaces, increasing bacterial adherence to the gut, and that the binary toxin is 
toxic to Vero cells (Schwan et al., 2009; Sundriyal et al., 2010).  The work in this 
thesis is directed towards a greater understanding of the actions of the binary toxin 
inside and outside of the target cells.  Firstly investigating the method of CDTa entry 
into cells, including CDTb processing and oligomerisation and CDTa-CDTb 
interaction, and secondly the action of CDTa once in the cytosol in terms of 
mechanism of action and interactions with the ribosylation target.  The achievements 
of this part of the project include the formation of a CDTa-actin complex which has 
provided a platform for future structural studies of this complex, in addition to 
generating evidence to conclude that the mechanism of ADP-ribosylation of actin by 
CDTa is an SN1 mechanism requiring residues Glu-385 and Glu-387 of the ExE-
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Appendix 2- Recipes for Media 
Lysogeny Broth 
For 1 L of LB medium: 
10 g tryptone 
5 g yeast extract 
10 g sodium chloride 
Terrific Broth 
For 1 L of TB medium: 
12 g tryptone 
24 g yeast extract 
4 ml glycerol 
(make up to 900 ml and add 100 ml of TB salts) 
 
For 100 ml TB salts: 
2.13 g potassium phosphate monobasic 
12.54 g potassium phosphate dibasic !!
Appendix 3- Sequencing of CDTa Mutants 
 
Native      338- LSYPNFISTSIGSVNMSAFA- 357 
S345A      338- LSYPNFIATSIGSVNMSAFA- 357 
                           * * * * * * * : * * * * * *  *  *  * * * * 
 
Native      338- LSYPNFISTSIGSVNMSAFA- 357 
S345F      338- LSYPNFIFTSIGSVNMSAFA- 357 
 * * * * * * *   * * * * * *  *  * * * * * 
 
 
Native      338- LSYPNFISTSIGSVNMSAFA- 357 
S345R      338- LSYPNFIRTSIGSVNMSAFA- 357 
  * * * * * * *   * * * * * *  *  * * * * * 
 
Native      338- LSYPNFISTSIGSVNMSAFA- 357 
S345Y      338- LSYPNFIYTSIGSVNMSAFA- 357 





Native      378- AIPGYAGEYEVLLNHGSKFK- 397 
E385Q     378- AIPGYAGQYEVLLNHGSKFK- 397 
 * **  * * *  *  :  * * * * * * *  * * * * * 
 
Native      378- AIPGYAGEYEVLLNHGSKFK- 397 
E387Q     378- AIPGYAGEYQVLLNHGSKFK- 397 
 * **  * * *  * *  * :  * * * * *  * * * * * 
 
Native      378- AIPGYAGEYEVLLNHGSKFK- 397 
E387R     378- AIPGYAGEYRVLLNHGSKFK- 397 
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Super toxins from a super bug: structure and function of Clostridium difficile
toxins
Abigail H. DAVIES*†, April K. ROBERTS†, Clifford C. SHONE† and K. Ravi ACHARYA*1
*Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, U.K., and †Health Protection Agency, Porton Down, Salisbury SP4 0JG, U.K.
Clostridium difficile, a highly infectious bacterium, is the leading
cause of antibiotic-associated pseudomembranous colitis. In
2009, the number of death certificates mentioning C. difficile
infection in the U.K. was estimated at 3933 with 44% of
certificates recording infection as the underlying cause of death.
A number of virulence factors facilitate its pathogenicity, among
which are two potent exotoxins; Toxins A and B. Both are large
monoglucosyltransferases that catalyse the glucosylation, and
hence inactivation, of Rho-GTPases (small regulatory proteins of
the eukaryote actin cell cytoskeleton), leading to disorganization
of the cytoskeleton and cell death. The roles of Toxins A and B in
the context of C. difficile infection is unknown. In addition to these
exotoxins, some strains of C. difficile produce an unrelated ADP-
ribosylating binary toxin. This toxin consists of two independently
produced components: an enzymatic component (CDTa) and
the other, the transport component (CDTb) which facilitates
translocation of CDTa into target cells. CDTa irreversibly ADP-
ribosylates G-actin in target cells, which disrupts the F-actin:G-
actin equilibrium leading to cell rounding and cell death. In the
present review we provide a summary of the current structural
understanding of these toxins and discuss how it may be used to
identify potential targets for specific drug design.
Key words: large clostridial toxin (LCT), Toxin A (TcdA), Toxin
B (TcdB), ADP-ribosyltransferase (ADPRT), Clostridium difficile
binary toxin (CDT), pseudomembranous colitis (PMC).
INTRODUCTION
Clostridium difficile is an anaerobic Gram-positive spore-forming
bacterium that was first described in 1935. It was given this name
as it grew slowly in culture and was difficult to isolate [1]. C.
difficile was not thought to be a particularly harmful pathogen until
a rise in the number of cases of PMC (pseudomembranous colitis)
in the 1970s. Infection with C. difficile accounts for 90–100% of
antibiotic-associated PMC, with a 6–30%mortality rate [2]. The
majority of patients diagnosed with PMC are treated with broad-
spectrum antibiotics such as metronidazole and vancomycin,
which can be very effective. Metronidazole is the drug of choice
as it is a lower cost drug than vancomycin. Metronidazole and
vancomycin have similar efficacy in mild disease, however there
is growing concern regarding treatment failure with the use of
metronidazole in severe disease. Vancomycin has been shown
to be superior in treatment of severe disease [3]. The use of
broad-spectrum antibiotics to treat other diseases can disturb the
balance of the normal bacterial flora in the gut, resulting in host
susceptibility to colonization or overgrowth of C. difficile [1,4–
6]. It is estimated that over 50% of infants are colonized with C.
difficile. However, these infants are usually asymptomatic and do
not develop PMC. At present there is no clear understanding of
why the infection does not manifest in infants [7]. It is thought
that the infants’ intestinal cells are not fully developed and
so are deficient in toxin-specific carbohydrate surface receptors
[5,8]. Patients infected with C. difficile initially experience mild
diarrhoea, abdominal pains and a fever, and are diagnosed by
the presence of C. difficile toxins in stool samples. In the case
of mild infection, patients are usually advised to discontinue
taking any antibiotics to prevent imbalance of flora in the gut.
However, in extreme cases of C. difficile infection leading to PMC,
metronidazole and vancomycin are the suggested treatments.
Relapse is a common problem associated with antibiotic treatment
(occurring in up to 25% of cases), in which case patients are
required to continue with prolonged courses of these drugs [4].
C. difficile is a highly infectious bacterium, and its spores can
survive on surfaces for long periods of times, therefore it is a
difficult organism to control in hospital environments and so the
majority of infections are contracted nosocomially.
VIRULENCE FACTORS
C. difficile has a number of virulence factors that contribute to its
pathogenicity, but this review will focus on its secreted toxins. The
pathogenic strains of C. difficile produce two potent exotoxins,
Toxin A and Toxin B (often called TcdA and TcdB), which
induce mucosal inflammation and diarrhoea [1,6,9]. In addition
to these exotoxins, some C. difficile strains produce an ADP-
ribosylating binary toxin (CDT), however, the role of this toxin
in disease is unclear [10,11]. In the present review, we focus on
the current structural knowledge of clostridial toxins and relevant
data regarding the roles of these structures within the host will be
discussed in detail.
LARGE CLOSTRIDIAL TOXINS (LCTs)
Biology of LCTs
Bacteria from the genus Clostridium produce a wide range of
toxins, the most well known being the clostridial neurotoxins such
Abbreviations used: CD-grease, α-Gal-(1,3)-β-Gal-(1,4)-β-GlcNAcO(CH2)8CO2CH3; CDT, Clostridium difficile ADP-ribosylating binary toxin; CPD,
cysteine protease ‘C’ domain; GAP, GTPase-activating protein; GDI, guanine-nucleotide-dissociation inhibitor; GEF, guanine-nucleotide-exchange factor;
LCT, large clostridial toxin; PaLoc, pathogenicity locus; PMC, pseudomembranous colitis; SAXS, small-angle X-ray scattering; TNS, 2-(p-toluidinyl)
napthalene-6-sulfonic acid, sodium salt; UDP-Glc, UDP-glucose.
1 To whom correspondence should be addressed (email k.r.acharya@bath.ac.uk).
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Figure 1 Domain organization of C. difficile toxins
(A) The LCTs are composed of four domains, the glucosylating enzymatic domain ‘A’ (dark blue), the autocatalytic processing domain ‘C’ (green), the translocating domain ‘D’ (magenta) and the
binding domain ‘B’ (purple). The current solved crystal structures include the ‘A’ domain of Toxin B (Figure 3), the ‘C’ domain of Toxin A (Figure 5) and the ‘B’ domain of Toxin A (Figure 4). The colour
scheme for the domain organization of the LCTs is maintained throughout all of the Figures. (B) The domain organization of CDT is shown for the two independently produced components, CDTa
and CDTb. The N-terminal signal peptides are displayed in green for both components. The active CDTa’ domain is coloured in accordance with Figure 6, with the N-terminal domain (purple) and
the C-terminal domain (cyan). The CDTb component has an activation domain (yellow) that must be cleaved to give the CDTb’ activated domain (red).
as the BoNTs (Clostridium botulinum neurotoxins) which can
cause flaccid muscular paralysis known as botulism, and the TeNT
(Clostridium tetani neurotoxin) which causes spastic paralysis
[12]. Toxins A and B, however, are part of the LCT group, owing
to their high molecular mass: Toxin A is 308 kDa and Toxin
B is 269.6 kDa [13]. All of the members of the LCT family,
which includes Toxins A and B from C. difficile, lethal toxins
from Clostridium sordellii and α-toxin from Clostridium novyi,
act on target cells by modifying small GTPases [14,15]. Toxins
A and B are encoded by the genes tcdA and tcdB, which are
located in a 19.6 kb locus, known as PaLoc (pathogenicity locus).
There are three other genes in the PaLoc that encode positive and
negative regulators of the production of these toxins, in addition
to a gene encoding a holin-like protein which allows secretion of
the toxins [16,17]. C. difficile strains are grouped on the basis
of the variations in the structure of the PaLoc [16,18]. There
are a number of reports that suggest Toxin B is essential for
pathogenicity, whereas the role of Toxin A is less clear. This
is reflected in the reported outbreaks of C. difficile strains that
are Toxin A negative/Toxin B positive. Universal gene knock-out
systems developed for the genus Clostridium [19,20] were used in
studies that indicate Toxin A is not essential for virulence [21,22].
However, a recent report suggests that Toxin A is able to cause
disease in the absence of Toxin B [23].
Toxins A and B have a multi-modular domain structure
described by Jank and Aktories [13] as the ABCD model. This
comprises: (A) the biologically active N-terminal domain; (B) the
C-terminal binding domain; (C) the cysteine protease domain;
and (D) the hydrophobic domain (for a schematic diagram see
Figure 1A). The C-terminal binding ‘B’ domain, which consists
of polypeptide repeats, is involved in receptor binding to specific
cell-surface carbohydrate receptors, but other domains may also
play a direct or indirect role in binding [24]. The precise
mechanism of toxin uptake into the cells is unclear; however, there
is evidence to suggest that it is a four step procedure, summarized
in Figure 2: (1) highly specific binding of the ‘B’ domain
to receptors on the cell surface followed by receptor-mediated
endocytosis of the toxin into the endosomal compartment; (2)
a decrease in pH within the endosomal compartment causes
conformational changes within the LCTs, allowing pore formation
and the subsequent translocation of part of the toxin into the
cytosol, which has been shown by the use of 86Rb ions [25,26].
The ‘D’ domain is a large hydrophobic region that makes up
almost 50% of the total size of the toxin and is thought to be
involved in pore formation prior to translocation of the ‘A’ domain
into the cytosol [25,26]. (3) The toxins undergo autoproteolysis
allowing only the enzymatic ‘A’ domain to be released into the
cytosol. It is thought that the cysteine protease domain ‘C’ is
involved in this autoprocessing, and requires InsP6 [27–29]; and
finally (4) Rho proteins are targeted for glucosylation by the
biologically active ‘A’ domain in the cytosol. Toxins A and B
target Rho GTPases (Rho, Ras and Cdc42), which are molecular
switches involved in numerous signal processes, in particular, the
regulation of the actin cytoskeleton (Figure 2). Once the toxins
enter the cytosol, they catalyse the addition of UDP-Glc (UDP-
glucose) to Thr37 (monoglucosylation) in Rho GTPase leading to
depolymerization of actin filaments, disruption of the cytoskeleton
and eventually cell rounding and cell death [30–32]. C. difficile
is a harmful pathogen and the main cause of the rise in cases of
PMC in hospitals, therefore it is of great interest to understand
the function of LCTs. Structural studies have given us an insight
into the molecular mechanism of the LCTs, and we will discuss
these below.
Structural aspects of LCTs
Negative stain electron microscopy
Recent studies have shown that Toxins A and B (which share
68% sequence similarity and 47% sequence identity) both
have similar native structures to each other using negative stain
electron microscopy [33]. Toxins A and B both have an elongated
c⃝ The Authors Journal compilation c⃝ 2011 Biochemical Society
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Figure 2 Cartoon representation of the processing machinery of Clostridial toxins
The LCT is displayed using the three-dimensional structures known for the four domains (note: the D domain structure is unknown) from both Toxins A and B, and is colour co-ordinated to the
primary domain structure shown in Figure 1. The toxins bind to the target cells via the B domain (purple) and are taken up by receptor-mediated endocytosis. Following a change in the endosomal
pH, conformational changes occur within the toxin and the D domain (magenta) forms a pore in the endosomal membrane allowing translocation of the A domain (dark blue) into the cytosol. This
then undergoes autocatalytic cleavage via the C domain (green) on binding of InsP6. Upon autocatalytic cleavage, the A domain is released into the cytosol where it glucosylates target Rho GTPases.
In the GDP-bound conformations, Rho GTPases are inactive. GDIs keep GTPases in the cytosol. Rho GTPases are activated by GEFs, enabling interaction with effectors that control a number of
signalling pathways. GAPs facilitate the hydrolysis of GTP to GDP, converting GTPases back to their inactive form. The A domain (dark blue) glucosylates Rho GTPases, which prevents effector
coupling thereby inhibiting specific signalling pathways. In addition, it blocks GEF and GAP activity. GTPases are no longer able to bind GDI and so are found at the plasma membrane. An animated
version of this Figure is available at http://www.BiochemJ.org/bj/436/0517/bj4360517add.htm.
structure containing a ‘head’ domain, a long ‘tail’ domain and
a short inner ‘tail’ domain. As Toxin A was considerably more
homogenous in structure than Toxin B, mapping studies have
focused on Toxin A. The three-dimensional structure of Toxin A
was constructed using the random conical tilt approach where the
modular domains were mapped into the corresponding structure
[33]. After imaging the fragments of the individual domains
using electron microscopy and antibody labelling, Pruitt et al.
[33] concluded that the long ‘tail’ fragment corresponds to the
‘B’ domain, the short ‘tail’ corresponds to the ‘A’ domain
and the ‘head’ corresponds to the ‘D’ domain. The cysteine
protease domain was not located. The same structure was then
reviewed using a lower pH environment and, as predicted,
conformational changes were observed in the ‘head’ shape,
confirming the location of the ‘D’ domain in the structure, and also
in the glucosyltransferase ‘A’ domain, providing a framework for
the molecular mechanism of translocation [33]. Although negative
stain electron microscopy provides images of the overall toxin
shape, it is beneficial to understand the toxins at a molecular
level using X-ray crystallography. Owing to the size and nature
of the LCTs, purification and crystallization of the whole toxins
is difficult and so a significant amount of work by researchers
is focused on structure determination of the four individual
domains.
Small angle X-ray scattering
Recently reported data using SAXS (small-angle X-ray scattering)
have provided an ab initio, low resolution surface model of the
native Toxin B [34]. When combined with the known structural
information obtained and models of the unknown domains, this
information has allowed visualization of the actual organization
of the four individual domains of LCTs for the first time. The
data revealed four distinct domain boundaries, into which
the structural information and model structures can be aligned.
The four domains are organised as demonstrated in Figure 1(A).
The hydrophobic ‘D’ domain contains a highly solvent-exposed
region which protrudes away from the core structure [34]. The
SAXS data were collected at a neutral pH, so the low pH-induced
conformational change that is predicted to occur within this ‘D’
domain has not been shown in this structure.
c⃝ The Authors Journal compilation c⃝ 2011 Biochemical Society
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Figure 3 The glucosyltransferase ‘A’ domain of Toxin B
(A) Crystal structure of the glucosyltransferase domain of C. difficile Toxin B (dark blue), where UDP-Glc (green) is bound to the catalytic cleft via a manganese ion (magenta), with the residues
involved in the active site displayed (teal) (PDB code 2BVL) [34]. (B) Stereo view of the catalytic cleft of Toxin B with water molecules (blue) and manganese ion (magenta). Residues involved in
enzyme activity (teal) and UDP-Glc recognition (raspberry) are displayed, in addition to the DxD motif (orange). Images were created using PyMOL (http://www.pymol.org).
X-ray crystallographic studies of individual LCT domains
‘A’ domain: glucosyltransferase N-terminal domain
The glucosyltransferase domain, which is responsible for
glucosylation of Rho proteins, is located at the N-terminal region
known as the ‘A’ domain. As there is limited structural data
for both Toxins A and B, examples have been taken from the
individual domains, where available, for analysis in the present
review. Figure 3(A) displays the crystal structure of the ‘A’
domain of Toxin B which gives some insights into the mechanistic
implications of Toxin B activity within target cells (PDB code
2BVL) [35]. The structure of the ‘A’ domain of Toxin A is yet to
be determined. This catalytic fragment of the LCT is delivered
to the cytosol where it glucosylates small GTPases. The ‘A’
domain of Toxin B consists of residues 1–543 in the VPI 10463
C. difficile strain and was co-crystallized with UDP-Glc and
c⃝ The Authors Journal compilation c⃝ 2011 Biochemical Society
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manganese ions that are essential for catalysis [36,37]. UDP-
Glc was cleaved during the crystallization process owing to the
hydrolytic activity of the toxin, but the products α-D-glucose
and UDP were identified in the electron density [35]. The
crystal structure shares the same common fold (consisting of
234 residues) seen among the glucosyltransferase type A family.
The remaining 309 residues are arranged predominantly in
α-helices and are thought to contribute to the specificity of the
toxin [35]. As shown in Figure 3(B), the catalytic pocket in this
Toxin B domain is made up of the β2, β5 and β10 strands, in
addition to α12 and α18 helices, and a 510–523 residue loop
[38]. The DXD motif involved in the binding of UDP-Glc and
Mn2+ is composed of Asp286 and Asp288. The Asp288 residue binds
directly to Mn2+ , whereas Asp286 forms a hydrogen bond with a
water molecule of the Mn2+ co-ordination sphere, in addition to
binding to both the 3′-hydroxy group of UDP-ribose and glucose,
making it a key residue for catalysis [35]. Mutational analysis
by alanine scanning revealed five important residues involved
in enzyme activity: Asp270, Arg273, Tyr284, Asn384 and Trp520. In
addition, four residues, Arg455, Asp461, Lys463 and Glu472, were
found to be important for UDP-Glc recognition [39].
The LCTs target and glucosylate the Rho family of GTPase
proteins. These are molecular switches that are predominantly
responsible for regulating the actin cytoskeleton. These Rho
proteins play other roles in cellular functions such as cell polarity,
gene transcription and cell cycle progression. The Rho GTPase
family of proteins consists of the Rho, Rac and Cdc42 subfamilies.
The proteins exist in two forms: the GTP-bound form which is
active and the GDP-bound form which is inactive, as displayed in
Figure 2. These two forms are inter-convertible and are regulated
by GEFs (guanine-nucleotide-exchange factors), GDIs (guanine-
nucleotide-dissociation inhibitors) and GAPs (GTPase-activating
proteins) (Figure 2). GDIs bind to Rho GTPases at a switch I
region, rendering them soluble in the cytosol and in the inactive
form. Activation of GTPases to their GTP-bound form is induced
by GEFs, and this activation allows interaction with numerous
effector molecules that control a number of signalling pathways.
GAPs hydrolyse GTP-bound Rho GTPases into inactive GDP-
bound Rho GTPases [40]. In the GDP-bound conformation,
Rho GTPases have an exposed Thr37 residue which is targeted
by LCTs for glucosylation. Upon glucosylation, actin filaments
depolymerize, leading to disruption of the cytoskeleton and cell
death. The Rho proteins are not glucosylated when bound to GTP
or when their switch I region is complexed with GDIs, as the
Thr37 residue is not exposed. Rho is glucosylated in the GDP-
bound conformation as the Thr37 residue is exposed and allows
an oxygen acceptor atom to be in position for attack from the C1
donor atom of the LCTs [31,32]. Toxin B binds to RhoA in the
Rho-GTP form [41].
Two possible mechanisms have been suggested for the catalytic
activity of the ‘A’ domain; a double displacement reaction (SN2)
and an internal return stereo-specific (SN1-like) reaction. The
double displacement reaction firstly requires a nucleophile in a
position to attack the β-side of the C1 atom in glucose. However,
as this atom is surrounded by non-polar residues, there is no
nucleophile in position to attack the C1 atom, hence a double
displacement reaction is unlikely. An internal return mechanism
SN1 is possible, as the oxocarbenium intermediate would be
stabilized by the surrounding negative phosphate and carboxylate
groups from Asp270, Asp286, Asp288 and Glu515, which are in turn
compensated by the positively charged Arg273 and a Mn2+ ion
[35]. LCTs exhibit high substrate/co-substrate specificity, with
Toxins A and B only binding UDP-Glc. The two residues Ile383
and Glu385, which are located in the active site, are responsible for
this specificity as shown by mutagenesis studies [39,41].
‘B’ domain: binding C-terminal domain
The initial step in the toxication process of C. difficile is the
binding of LCTs to the cell-surface of intestinal epithelial cells,
which is carried out by the ‘B’ domain. The ‘B’ domain of
LCTs interacts with carbohydrate structures such as Gal-α-(1,3)-
Gal-β-(1,4)-GlcNAc on the host epithelial cells [42]. Although
a functional carbohydrate receptor in humans has yet to be
identified, attempts to gain more insights into carbohydrate
binding have been made. The crystal structure of the C-
terminal binding domain of Toxin A has been determined
for two different fragment sizes. The first fragment (127
residues), named TcdA-f1, from strain 48489, toxinotype VI
was obtained by expressing a longer fragment and isolating a
smaller cleaved fragment (PDB code 2F6E) [43]. The second
fragment, TcdA-f2, which is a slightly longer fragment (255
residues), is in complex with a synthetic derivative of a
carbohydrate receptor, CD-grease [α-Gal-(1,3)-β-Gal-(1,4)-β-
GlcNAcO(CH2)8CO2CH3] (Figure 4A) (PDB code 2G7C) [44].
In this complex there are two carbohydrate-binding regions.
However, in the full-length C-terminal fragment there are
seven of these potential binding domains that are highly
conserved, giving it a high binding capacity. Although there
is little information about the binding domain of Toxin B, it is
believed that Toxin B uses different receptors to bind to target
cell surfaces than Toxin A [41]. However, considering Toxins A
and B share 47% sequence identity, the structural information
regarding the Toxin A–carbohydrate interactions may provide
some clues as to how Toxin B might interact with carbohydrate
surface receptors.
Sequence analysis of the Toxin A gene shows that 31.5% of
the gene is in 38 contiguous repeating units and these repeats
are located in the C-terminal region. These repeats can be split
into two categories: class I (long), of which there are seven types,
each repeat being 30 amino acids long; and class II (short), of
which there are 31 types, each consisting of either 20 or 21 amino
acids [45]. TcdA-f2 contains nine small repeats and two long
repeats, whereas TcdA-f1 consists of four short repeats and one
long repeat [43,44]. Each short and long repeat forms β-hairpins
that are connected by loops of 7–10 residues in short repeats and
18 residues in long repeats [41]. The β-hairpins are related to
each other by a 31 screw-axis transformation, meaning that each
β-hairpin is related to the adjacent hairpin by 120 ◦ (Figure 4B)
[44]. This results in a β-solenoid left-handed helix, which is
a common conformation of many bacterial cell-surface-binding
proteins, and is thought to increase surface area for optimized
binding to the target cells (Figure 4B) [44]. These results are
consistent with that of the TcdAC26–39 structure of the ‘B’ domain
from Albesa-Jove´ et al. [34].
‘C’ domain: cysteine protease domain and the ‘D’ domain: hydrophobic region
The CPD (cysteine protease ‘C’ domain) is thought to be located
between residues 543 and 769 in Toxin A and between residues
543 and 767 in Toxin B [27]. The crystal structure of the CPD
(543–809) from Toxin A was determined at 1.6 Å (1 Å= 0.1 nm)
in the presence of InsP6 (Figure 5A) (PDB code 3HO6) [29].
This sits between the enzymatic domain and the delivery domain,
playing a role in proteolytic cleavage of the toxin. Toxins A
and B both undergo auto-catalytic cleavage in the presence of
InsP6. Once the target cell has taken up the LCT via receptor-
mediated endocytosis at the ‘B’ domain, the toxin undergoes
autoproteolysis in order to allow the ‘A’ domain to pass across the
endosomal membrane into the cytosol [46]. The structure reveals
a central nine-stranded β-sheet flanked by five α-helices. The
c⃝ The Authors Journal compilation c⃝ 2011 Biochemical Society
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Figure 4 The binding ‘B’ domain of Toxin A
(A) Ribbon structure of the binding domain of C. difficile Toxin A (purple) with two carbohydrate synthetic derivatives of CD-grease bound, shown as stick models (pink) (PDB code 2G7C) [43].
(B) Cross-section through the binding domain of Toxin B showing the β-hairpin 31 screw axis, where the β-hairpins are related to the adjacent hairpin by 120◦. Images were created using PyMOL
(http://www.pymol.org). Adapted from Jank et al. [30] with permission c⃝ 2007 Oxford University Press.
Figure 5 The cysteine protease ‘C’ domain of C. difficile Toxin A
(A) Ribbon structure of the ‘C’ domain (green) displaying the proposed residues in the active
site (cyan) and the InsP6 (red) bound on the opposite side of the central nine-stranded β-sheet
(PDB code 3HO6) [28]. (B) The InsP6-binding site on the ‘C’ domain displaying the electrostatic
potential of the binding site (blue represents positively charged residues). InsP6 is displayed
as a ball and stick molecule (red). The InsP6-binding site is highly positive as shown by the
abundance of blue colour. Images were created using PyMOL (http://www.pymol.org).
InsP6-binding site and the proposed active site are located on
opposite sides of the central β-sheet and are separated by a
three-stranded β-hairpin, known as the ‘β-flap’. The N-terminal
domain extends around the exterior of the domain from the
InsP6-binding site to the proposed active site [29]. Cys700, His655
and Asp589 have been identified as the catalytic triad. However,
owing to the distances between these residues, hydrogen bond
formation is not possible as with other cysteine proteases.
Therefore the mechanism of catalysis may differ from other
cysteine proteases. Pruitt et al. [29] have shown that the CPD
changed conformation on binding of InsP6 to a more stable form,
which increases resistance to chymotrypsin digestion. InsP6 is
a highly negatively charged ligand and binds to a number of
positively charged residues that span the entire domain including
Arg753, Tyr579 and seven lysine residues: Lys577, Lys602, Lys649,
Lys754, Lys766, Lys777 and Lys794 (see Figure 5B, with these
positively charged residues in blue). The ‘β-flap’ is thought to be
involved in transmitting structural changes from the InsP6-binding
site across to the active site. The CPD uses InsP6 to activate
an intramolecular autoproteolytic cleavage event which allows
the correct processing of the toxins to transfer the enzymatic
domain into the cytosol. Shen et al. [46a] recently solved the
structure of the CPD of Toxin B (PDB code 3PEE) which shares
56% sequence identity with the CPD of Toxin A and a highly
similar structure [rmsd (root mean square deviation) of 1.3 Å].
Comparison of the structures show a completely conserved active
site, an almost identical InsP6-binding site (with the exception
of two residues) and a well-conserved β-flap. Using chemical
probes, Shen et al. [46a] showed that the CPD of Toxin B can
adopt the activated conformation without the presence of InsP6,
and InsP6 in fact shifts the equilibrium in favour of the active
conformation. Through the use of tryptophan fluorescence assays,
mutagenesis and structural analysis. Shen et al. [46a] were able to
show that a conserved group of interconnected residues in the β-
flap region are responsible for communicating the InsP6-binding
signal to the active site.
Following receptor-mediated endocytosis of the LCTs, the
‘A’ domain is translocated into the cytosol. The hydrophobic
‘D’ domain is thought to be involved in the translocation,
although little is known about its structure. LCTs undergo
conformational changes stimulated by a decrease in endosomal
pH. Qa’Dan et al. [26] used bafilomycin A1, which is a potent
inhibitor of the endosomal vacuolar ATPase pump that controls
the acidity of the endosome, to assess the effect of endosomal
acidification. Translocation was measured using TNS [2-(p-
toluidinyl) napthalene-6-sulfonic acid, sodium salt] fluorescence.
For Toxin B, as the acidity of the endosome increased, an increase
in TNS fluorescence was seen, suggesting a conformational
change within Toxin B and exposure of the hydrophobic ‘D’
domain, thereby confirming its role in translocation [26]. Owing
to the hydrophobic nature of the ‘D’ domain, purification and
crystallization are difficult, which may explain why the structure
has not yet been determined.
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CLOSTRIDIUM DIFFICILE BINARY TOXIN
Biology of the binary toxin
In addition to the LCTs, some C. difficile strains can produce
an additional toxin called the ADP-ribosyltransferase binary
toxin, CDT, which is a member of the ADPRT family [11]. The
ADPRT family is divided into four classes on the basis of domain
organization and their targets [47]. The first group is the AB5
group that includes cholera toxin. Within this group, the toxins
are composed of one A subunit and five B subunits, and they
target small regulatory G-proteins. The second group is the AB
three domain group which includes diphtheria toxin. Toxins of
this group ribosylate a diphthamide residue on elongation factor
2, and have a binding domain, a transmembrane domain and
a catalytic domain. The third group is the single polypeptide
group, which includes C3 toxin from C. botulinum, and have
unknown roles in pathogenesis. The final group is the AB binary
toxin group, which are made up of two subunits and target actin.
This group includes the C2 toxin from C. botulinum and Iota
toxin from Clostridium perfringens [47]. CDT is a member of
the AB binary toxin group and is made up of two independently
produced components: the enzymatic component, CDTa (mature
length 48 kDa), and the transport component, CDTb
(mature length 74 kDa); see Figure 1(B) for a schematic
representation of the domain organization [10,48].
In one study of CDT genes in the United States, 15.5%
of C. difficile strains tested had both the genes for the CDT
components (cdtB and cdtA), 8.7% of which did not have the
LCT genes [49]. The precise pathogenesis of CDT is yet to be
established due to the dominant production of LCTs in most
virulent strains of C. difficile and lack of CDT [10]. However,
it has been shown that a CDTa–CDTb (CDT) complex is toxic
to Vero cells [50]. A recent study has suggested a role for
CDT in increasing adherence of bacteria to target cells, by
the formation of microtubule protrusions. Using time-lapse and
immunofluorescence microscopy, Schwan et al. [51], have shown
that CDT forms dynamic microtubule protrusions on the surface of
human colon carcinoma cells (Caco-2) concomitantly with ADP-
ribosylation of actin and depolymerization of microfilaments. In
addition to protrusion formation, cellular microtubule structures
were also altered to increase bundling of microtubules. The CDT-
induced formation of protrusions caused a ∼5-fold increase in
adherence of C. difficile in anaerobic conditions. The protrusions
were shown to form a dense mesh-work in which the bacteria were
caught, contributing to the colonization of C. difficile. Similar
results were also demonstrated for the homologues C. botulinum
toxin C2 and C. perfringens Iota toxin [51].
The transport component, CDTb, is essential for entry of
CDTa (enzymatic component) into the cytosol [52]. The proposed
mechanism of uptake of CDTa is similar to other members of
the ADPRT family such as C. botulinum C2 toxin and Iota
toxin from C. perfringens [48]. The CDTb component must be
activated via cleavage, after which it then can form heptamers
at the cell surface and bind to specific cell-surface receptors.
Subsequently, CDTa binds to CDTb and is taken up into the
cell by receptor-mediated endocytosis. In a similar mechanism
to the LCTs, low pH-induced conformational changes occur
leading to potential heptameric pore formation and translocation
of CDTa into the cytosol [48,52]. The N-terminus of CDTa is
responsible for interaction with CDTb, whereas the C-terminus
harbours the enzymatic activity (Figure 1B) [53]. We can predict
that CDTa will irreversibly ADP-ribosylate monomeric G-actin
at the Arg177 residue from the structural evidence of Iota toxin
(closest homologue of CDTa). This ADP-ribosylation will block
polymerization of G-actin to F-actin and subsequently disrupt
the F-actin:G-actin equilibrium [54,55]. Disruption of the actin
equilibrium results in cell rounding and cell death.
Structural aspects of CDT
The crystal structure of CDTa was solved at three different
pH values, 4.0, 8.5 and 9.0 (PDB codes 2WN8, 2WN4 and
2WN5 respectively) [56]. In addition, the structure was solved
in complex with ADP ribose donors NADPH and NAD at pH 9.0
(PDB codes 2WN6 and 2WN7) [56]. The structure in complex
with NAD was determined at 2.25 Å and detailed mechanistic
implications of CDTa have been proposed on the basis of this
structural data [56]. It is known that CDTa transfers the ADP
ribose group of NAD/NADPH to monomeric G-actin at Arg177,
blocking polymerization of actin and therefore leading to the
collapse of the cell cytoskeleton. This prediction was made on
the basis of the mechanism of C. perfringens Iota toxin, of which
CDTa shares 84% sequence identity [54,55].
The structure of CDTa in complex with NAD is displayed
in Figure 6(A). We can observe the N-terminal domain, which
consists of five α-helices and eight β-strands, extending from
residues 1 to 215, and the C-terminal domain, which extends
from residues 224 to 240, also consisting of five α-helices and
eight β-strands. These domains are linked by a loop extending
from residues 216 to 223, shown in red in Figure 6(A) [56].
The C-terminal domain harbours the enzymatic activity, whereas
the N-terminal domain is predicted to interact with the CDTb
domain. Both NAD and NADPH bind to the catalytic cleft of
CDTa via the interacting residues Arg302, Arg303, Gln307, Asn342
and Ser345 [56]. Figure 6(B) displays these catalytic residues in
addition to a number of other defining features of the ADPRT
family of toxins, for example the PN loop (orange) and the Arg-
motif (yellow). The highly flexible ARTT loop can be seen in
blue, which is an ADP-ribosyl turn-turn loop that is important for
substrate binding, along with the catalytic residues of the EXE
motif, which has been shown to be crucial for activity in ADPRTs.
In CDTa, the EXE motif is composed of the residues Glu385 and
Glu387, which is thought to be involved in stabilizing the substrate–
enzyme complex as seen with the corresponding residues Glu378
and Glu380 in Iota toxin. However, in this structure both of these
residues are not in direct contact with NAD or NADPH, which
might suggest that the EXE motif in CDTa is not necessary for
ligand binding and stabilization of this complex, although there
is no experimental evidence to support this [56]. However, this
could be due to the location of both Glu385 and Glu387 on the
flexible ARTT loop. The final feature shown in Figure 6(B) is
the STS motif, which includes the residues Ser345 and Ser347. Ser345
forms a strong hydrogen bond with Glu387, and also directly with
NAD and NADPH, therefore suggesting a role for the STS motif
in ligand binding and catalysis [56].
The proposed mechanism of ADP-ribosylation of actin in
Iota toxin was suggested to be an SN1 reaction after formation
of an actin–Iota complex and also by the use of site-directed
mutagenesis [57]. The SN1 reaction occurs via two intermediates:
first an oxocarbenium ion intermediate and secondly a cationic
intermediate. This mechanism is thought to be a common
mechanism amongst the ADPRT family of toxins [47]. As Iota
toxin is the closest homologue to CDTa, a similar SN1 reaction has
been proposed [56]. In following the SN1 mechanism, the catalytic
glutamate Glu387 in CDTa should form a H-bond with the 2′-OH
of ribose forming an oxocarbenium intermediate and rendering
the ribose group vulnerable to nucleophilic attack (Figure 7).
Following cleavage of NAD and formation of an oxocarbenium
ion, it is thought the ARTT loop is rearranged to bring the
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Figure 6 The active CDTa component of CDT from C. difficile
(A) Ribbon structure displaying the N-terminal domain (purple), the C-terminal domain (cyan) and the connecting loop between the C-terminal and N-terminal domains (red), and the active site is
shown within the black box (PDB code 2WN7) [55]. (B) Stereo view of the active site of CDTa with key residues involved in NAD binding: STS-motif (green), the PN-loop (orange), the EXE motif
and ARTT loop (blue), the Arg-Arg residues (yellow), and any remaining residues involved in binding are shown in light blue and the NAD molecule is in pink. Images were created using PyMOL
(http://www.pymol.org).
Glu385 residue to the reaction centre to stabilize the transfer of
ADP-ribose to the Arg177 of actin [56]. Further structural and
experimental evidence is required to validate this hypothesis, such
as site-directed mutagenesis of catalytic residues in addition to
solving the structure of a CDTa–actin complex.
CONCLUDING REMARKS AND PERSPECTIVES
Some of the more dominant and pathogenic strains of C. difficile
produce two large glucosylating toxins (Toxin A and Toxin B) and
an ADPRT toxin (CDT) such as that from the CD196 strain [10].
However, there are strains of C. difficile that have variations in
their ability to produce these toxins, and there is a great uncertainty
over the roles of each of these toxins individually in pathogenesis
[21–23]. As some of the most pathogenic strains of C. difficile
produce CDT in addition to the LCTs, it is tempting to question
whether or not CDT plays an adjunctive role to the LCTs in
pathogenesis.
In the present review we have summarised the research into
clostridial toxin structures. The full-length structures of the LCTs
are yet to be determined, but the structures of some of the indi-
vidual domains of these toxins have been solved. From the current
structures we now have a better understanding of the binding,
the autoproteolysis and their mechanism of action once the
enzymatic domain has entered the cytosol. These findings have
opened up a number of avenues that are of great value for use in
drug therapeutics. These structures have provided multiple targets
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Figure 7 Predicted mechanism of ADP-ribosylation in CDT
The catalytic glutamate residue (blue) forms a hydrogen bond with the 2’-OH of the ribose
group in NAD (black). This stabilizes the oxocarbenium intermediate leaving the glycosidic
bond susceptible to nucleophilic attack from the target arginine residue from actin (green).
for drug design such as the binding domain to prevent uptake of
the toxins, the cysteine protease domain to prevent cleavage
of the toxin, or targeting the enzymatic domain to inhibit its
activity. Determination of the crystal structures of the remaining
unsolved domains is highly desirable, in addition to solving the
structure of an enzyme–substrate complex. This will provide
an understanding of how the toxins function as a whole. The
crystal structure of CDT has provided a great insight into
the active site of the toxin and its mechanistic implications. Further
work using mutational analysis and enzyme–substrate complex
formation will improve our understanding of the mechanism of
ADP-ribosylation and help provide more specific drug targets for
therapeutic design.
OUTSTANDING QUESTIONS
(1) What renders Toxin B more cytotoxic than Toxin A?
(2) How do the LCTs bind to cell surfaces, do their specificities
differ and does this affect their differences in pathogenicity?
(3) How does the cysteine protease ‘C’ domain cleave the
toxin and why does it require InsP6?
(4) By what mechanism do the LCTs glucosylate Rho
GTPases?
(5) What is the precise role of CDT in pathogenesis?
(6) Could CDT play an adjunctive role to the LCTs in
pathogenesis?
(7) By what mechanism does CDT ADP-ribosylate actin?
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